{
  "positives": [
    {
      "sentence": "A total of 178 participants were randomized in the SAD/MAD cohorts of both studies (mean age: 36.7 years; 94.9% male).",
      "entity": "Age (years)"
    },
    {
      "sentence": "African populations harbor the highest genetic diversity globally, shaped by over 300 000 years of adaptation to the continent's diverse ecology.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Twenty children with SRNS received CsA therapy for 2 years between February 2001 and October 2006 in the Department of Nephrology.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The mean age of children at initiation of CsA therapy was 5.5 years (30 months to 12 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Renal fibrosis was rare in patients treated with a low dose of CsA for 2 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Adult patients (≥18y old) will be recruited at specialized COVID-19 units and ICUs at 9 Belgian hospitals.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Twenty patients, 2 to 15 years of age, were studied.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The follow up was carried out according to WHO-IWGE guidelines for 5 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Of the 43 patients fourteen were ≤ 15 years of age and had a differentiated pre-surgical treatment.",
      "entity": "Age (years)"
    },
    {
      "sentence": "From the ≥ 16 years of age, 36 completed the treatments and the 5 years follow up.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A follow-up of at least 5 years would be recommended to assure remission and control of the transmission.",
      "entity": "Age (years)"
    },
    {
      "sentence": "There were 928 people (70.3%) followed up at 12 months (61.2% female, 52% ≥55 yrs).",
      "entity": "Age (years)"
    },
    {
      "sentence": "22 women, 35-68 years old with breast cancer, suitable for neoadjuvant chemotherapy were included onto this study.",
      "entity": "Age (years)"
    },
    {
      "sentence": "This is a cross-sectional study on 65 adolescents and adults older than 16 years old (55 females and 10 males) with moderate to severe degrees of acne vulgaris under a fixed low dose of 20 mg/day Isotretinoin treatment for 120 days.",
      "entity": "Age (years)"
    },
    {
      "sentence": "In this study, 65 records of patients with a mean age of 22.21±6.25 years were assessed.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 6-year-old domestic shorthair male castrated cat was evaluated for sudden onset of vomiting and anorexia.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The mean age was 73.0 years (MD 74.0 and LD 72.5).",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 56-year-old woman had fever, weakness and clinical findings of a nephrotic syndrome with normal renal function.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Ninety-seven patients were male (46.19%) and 113 were female (53.81%) with age ranging from three months to 18 years (mean 10.51 ± 3.81 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 68-year-old man presented with nephrotic syndrome.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The records of 5398 consecutive native renal biopsies performed in adults (>or=14 years of age) in our centre between 1993 and 2007 were retrospectively analysed.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Then they were divided into four groups according to age for stratified analysis: 14-24 years, 25-44 years, 45-59 years and the elderly (>or=60 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "The spectrum of primary glomerulonephritis has changed within the last 15 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Long-term patient survival rates were: 29.5% at 14 years for heart, 19.4% at 9 years for lung and 26.2% at 11 years for heart-lung recipients.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The most important risk factor for mortality of US heart recipients at one month, one year and conditionally at 5 years after transplantation was receipt of a previous heart transplant.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Before and after 18 +/- 2 months of NIPPV, we measured during the daytime arterial blood gases, lung mechanics, and respiratory muscle strength in 8 patients (51 +/- 5 years; mean +/- SEM).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Half of patients evolve to end-stage renal disease within 5 years, and are additionally exposed to complications secondary to persistent NS and to the adverse effects of immunosuppressive therapy.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Subjects were 150 adult patients (mean age 56.79 years, SD 15.69 years) referred to the Balance Disorders Clinic at Vanderbilt University Medical Center.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The median age was 16 years (range 2-52) at time of lead placement.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Mean age of the patients was 28.5 +/- 7.2 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Cross-sectional multicenter data analysis of 60 patients (53 families) with Selenoprotein N-related myopathy and single-center retrospective longitudinal analysis of 25 patients (21 families) over a median period of 5.3 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The majority of patients (46/60, 77%) presented before age 2 years with hypotonia, poor head/neck control, and developmental delay.",
      "entity": "Age (years)"
    },
    {
      "sentence": "At last assessment (median age 14 years; range 2.5 to 36 years), 10/60 patients had minimal or no ambulation.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Ventilatory support was initiated in 50/60 patients at a mean Forced Vital Capacity (FVC) of 38% and at a median age of 13 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Forty-five/60 patients developed scoliosis (at median age 12.1 years) and 18 had scoliosis surgery at a median age of 13.6 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "We describe a case of a 24-year-old female renal transplant recipient who, 10 years after receiving a deceased-donor kidney, presented with acute and massive increases in serum creatinine and proteinuria levels of 13 g over 24 hours.",
      "entity": "Age (years)"
    },
    {
      "sentence": "US food and drug administration has recently approved deflazacort for Duchenne muscular dystrophy (DMD) and recommended the dosage of 0.9 mg/kg/d for patients aged ≥5years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Newly diagnosed patient aged 5-15 years with genetic or muscle biopsy confirmed DMD and baseline 6-min walk distance (6MWD) > 150 m were screened.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Patients were randomly assigned (1:1), stratified to prespecified subgroups by age (≤7years and >7years), and baseline 6MWD (≤350 m and >350 m), to receive either 0.45 mg/kg/d or 0.9 mg/kg/d regimens.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The mean difference in change in 6MWD in the subgroups of boys ≤7 years of age was 21.8 m (95% CI -0.82, 44.5, p = 0.059), with baseline 6MWD of >350 m was 19.9 m (95% CI -2.4, 42.4; p = 0.08).",
      "entity": "Age (years)"
    },
    {
      "sentence": "The low dose deflazacort was non-inferior in subgroup of patients with age ≤7 years and baseline 6MWD of >350 m. Clinical Trial Registry-India Identifier: CTRI/2019/02/017388.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 76-year-old Japanese man with nephrotic syndrome was admitted to our department for treatment.",
      "entity": "Age (years)"
    },
    {
      "sentence": "HRQOL was assessed at enrollment and follow-up visits 1 to 3 times annually for up to 5 years with the Patient-Reported Outcomes Measurement Information System (PROMIS).",
      "entity": "Age (years)"
    },
    {
      "sentence": "This cohort study included 84 adults (median age, 65 years; males, 57%) with primary nephrotic syndrome (excluding minimal change disease) not receiving RASis during enrollment in the Japanese Nephrotic Syndrome Cohort Study from January 2009 to December 2010, and were followed up for 5 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "In all but one of these cases, MCNS occurred after HIV diagnosis (mean of 9.5 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Fifty-six patients have documented follow-up for 2 years or more, and 21 have 4 years or more of follow-up.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The patients followed 2 to 4 years had 86% vertigo class A and B results.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Those followed 4 years or more show 76% with a vertigo class A or B result.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Seventy-eight patients were identified with a median age of 9.9 years [interquartile range [IQR): 7-12].",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 72-year-old man visited the clinic for generalized edema 20 days after starting GJD.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Retrospective chart review of all cases of adult PNS extracted from a database of 1388 cases for the last 10 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Lipoid nephrosis was identified by light, immunofluorescence and electron microscopy in 34 children aged 1 month to 10 years (23 males).",
      "entity": "Age (years)"
    },
    {
      "sentence": "These patients were followed up for a mean of 6.8 years (range 2.2 to 14 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "At 5 years follow up 94% of patients were in remission.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The mean age was 6.9 years (standard deviation ±3.51) with a male-to-female ratio of 1.8:1.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The clinical courses of these patients both prebiopsy and for a minimum of 2 years after completion of cyclophosphamide therapy were analyzed using retrospective case note analyses.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Using a standard 20-electrode configuration, the P300 was measured during an \"oddball\" task in 14 young normal individuals (YN: 21-41 years), 11 elderly normal individuals (EN: 61-80 years), and 23 probable AD patients (AD: 63-93 years; NINCDS-ADRDA criteria).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Administration of 30 mg/kg per day methylprednisolone with heparin for 3 days was taken as one course, and this was given 14 times over 2 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "An 80-year-old woman was referred to the Division of Nephrology at Ehime University Hospital because of leg edema in December 2010.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Pediatric patients (4-12 years of age) with minimal change nephropathy were consecutively assigned to receive prednisone monotherapy (1-2 mg/kg/d; maximal total dose, ≤60 mg) or prednisone at the same dosage plus fluvastatin (5 mg/d if aged <5 years; 10 mg/d if aged ≥5 years), for 6 weeks.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Sixty evaluable patients were assigned active treatment (monotherapy: 16 male, 14 female; mean age, 7.6 [3.6] years [range, 6-12 years]; combination therapy: 15 male, 15 female; mean age, 7.1 [4.9] years [range, 4-12 years]); the control group comprised 50 healthy children (26 male, 24 female).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Mean age was 41 years, and mean length of stay was 14 days.",
      "entity": "Age (years)"
    },
    {
      "sentence": "FVC, TLC, and DLCO did not change significantly in either mycophenolate (from 79.0 ± 12.5 to 80.2 ± 8.1 to 81.2 ± 11.4, from 71.5 ± 16.1 to 74.3 ± 10.8 to 71.8 ± 13.0, from 56.8 ± 12.0 to 55.2 ± 9.9 to 50.6 ± 8.5, respectively) or cyclophosphamide group (from 77.3 ± 12.5 to 79.7 ± 10.3 to 82.5 ± 12.9, from 64.7 ± 14.9 to 68.6 ± 16.0 to 66.1 ± 15.5, from 53.1 ± 14.3 to 56.4 ± 13.5 to 56.3 ± 6.7, respectively), after 1 or 2 years of treatment.",
      "entity": "Age (years)"
    },
    {
      "sentence": "However, and despite the fact that patients in the cyclophosphamide group had more extended ILD at baseline, a deterioration of lung HRCT findings at 2 years was noticed after mycophenolate (from 10.0 ± 8.9 to 12.7 ± 8.2, p = 0.039) but not after cyclophosphamide.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Standardized %MBD change (per 2 years), categorized as stable/any increase (≥ 0%), minimal decrease of less than 5% or a decrease greater than or equal to 5%, was determined from baseline and follow-up mammograms.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Associations were stronger among women ≥ 50 years at BBD diagnosis (OR 0.48; 95% CI 0.25, 0.92) and with proliferative BBD (OR 0.32; 95% CI 0.11, 0.99).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Glomerular disease occurred after the diagnosis of sarcoidosis in 11 of 26 cases (42%) (mean delay of 9.7 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "In six patients (23%), the glomerulopathy preceded the sarcoidosis diagnosis (mean delay 8 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "At the end of the follow-up (mean of 8.4 years), six patients had reached end-stage renal disease and three patients had died.",
      "entity": "Age (years)"
    },
    {
      "sentence": "In total 451 patients were included (57.9 ± 6.6 years, 65% male, 50/39/11% GOLD II/III/IV), of which 309 completed follow-up.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Although the nephropathy is commonest in the 26-35 year age group, 11% of the IgA nephritic patients were children below 16 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Several risk factors have been identified, including advanced age (>60 years), corticosteroid use, renal failure or dialysis, female sex, and nonobesity.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A total of 1246 renal biopsies were performed over 15 years, on 1096 patients.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The mean age of the patients at the time of biopsy was 9.2±3.7 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Randomised controlled trials and cluster-randomised controlled trials comparing fluoride toothpaste with placebo or fluoride toothpaste of a different concentration in children up to 16 years of age with a follow-up period of at least 1 year.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The decision of what fluoride levels to use for children under 6 years should be balanced with the risk of fluorosis.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Children ages 4-21 years with sickle cell disease admitted to the hospital for an acute painful vaso-oclusive crisis were eligible.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The size of the collagen band did not change for 2 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Observational study in patients ≥18 years old receiving usual care for CSU (daily or almost daily occurrence of generalized hives or angioedema for ≥6 weeks).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Patients were included consecutively and completed the UAS, EQ-5D, and the Chronic Urticaria Quality of Life scale (CU-Q Data from 166 patients was available for analysis (mean age 49 years, 65.7% female).",
      "entity": "Age (years)"
    },
    {
      "sentence": "We report, in a 24 years old male, the occurrence of an apparently idiopathic nephrotic syndrome with minimal change glomerular lesions.",
      "entity": "Age (years)"
    },
    {
      "sentence": "In this open label, non-inferiority trial, 160 patients, 2 to 18-years-old with frequent relapses, were randomly assigned to receive either prednisolone (0.5-0.7 mg/kg/alternate-day, given daily during infections), or levamisole (2-2.5 mg/kg/alternate-days) for one-year.",
      "entity": "Age (years)"
    },
    {
      "sentence": "We retrospectively reviewed long-term outcomes (> 3 years; median follow-up, 9.1 years) of 21 children with initial SRNS (FSGS, N = 9; MCD, N = 12) who achieved complete remission with immunosuppressive agents, including cyclosporine.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Fifty-three children from age one to 15 years admitted with steroid-sensitive nephrotic syndrome diagnosed as per the International Study of Kidney Disease in Children (ISKDC) criteria were enrolled in the study.",
      "entity": "Age (years)"
    },
    {
      "sentence": "In the relapse category, 88% were male, and 67% were between one and 5.5 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Mean disease duration was 11.4 ± 10.0 years; 62.5% had diffuse cutaneous systemic sclerosis.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The mean age of the children was 11.4 years (range 3.5-18.1 years) with a mean age at diagnosis of 5.6 years (range 1.6-13.3 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "The average time from the diagnosis to initiation of tacrolimus was 5.3 years (range 0.3-13.3 years, median 6 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "In two cases the onset of the nephrotic syndrome antedated the recognition of lymphoma by 4 and 7 years respectively, while in the other two the nephrotic syndrome manifested 5.5 years and 13 months respectively after lymphoma.",
      "entity": "Age (years)"
    },
    {
      "sentence": "In as a cross sectional study, the medical records of all children with INS aged 1 to 15 years who were referred to our referral hospital was reviewed.",
      "entity": "Age (years)"
    },
    {
      "sentence": "We report the successful use of phenobarbital for proportionate EoL sedation in a 57-year-old man with opioid use disorder (heroin) and metastatic urothelial carcinoma presenting to an acute care hospital with intractable back pain related to bone metastases.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Children from 3 to 15 years of age, having renal disease and indications for biopsy, underwent ultrasound guided percutaneous renal biopsy.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Fifty-five patients (forty males, fifteen females) with a median age of 40 years (range, 8-85 years), who underwent endovascular embolization of iatrogenic renal arterial lesions between March 2003 and December 2013 were included in this retrospective study.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Three patients with mild to moderate PD (all male; aged 52, 54, and 70 years; Hoehn & Yahr stages I-III) completed a 4-week LSVT BIG training program (16 individual 1-hour sessions) and an intensive home training program in accordance with the LSVT BIG protocol.",
      "entity": "Age (years)"
    },
    {
      "sentence": "For the age group between 18 and 50 years, LN, FSGS and IgAN predominated; for patients aged between 51 and 65 years, the proportion of DKD and 2nd FSGS increased, and SV was more common in patients > 65 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "All patients were female with an average age of 39.4 ± 6.6 years at diagnosis.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Two hundred three consecutive outpatients diagnosed with HOA were followed for 2 years (183 women, median age 69 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "After 2 years, all radiographic scores deteriorated significantly in the study population (p <  0.05), and the number of proximal and distal interphalangeal nodes was significantly higher (p <  0.01).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Evidence of radiological progression over 2 years was observed in patients with HOA in the LIHOC population even without clinical worsening of disease.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Reported was an aged woman (80-year-old) of minimal change nephrotic syndrome which was complicated with reversible oliguric acute renal failure.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The previously reported cases older than 80-year-old which remitted from minimal change nephrotic syndrome complicated with reversible acute renal failure, were very rare.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Mean age at enrolment was 22.77 ± 7.45 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A total of 16 patients met inclusion criteria with a mean follow-up of 6.6 years (range 0.6-17.6 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Renal survival rates were 87, 71, and 57% at 2, 5, and 10 years, respectively.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Total body fat, visceral adipose tissue (VAT) and subcutaneous abdominal adipose tissue (SAT) volumes, intrahepatic and intramyocellular lipid contents, insulin sensitivity (hyperinsulinemic-euglycemic clamp), glucose tolerance, and postprandial insulin secretion and clearance rates (mixed meal with minimal modeling) were measured before and after 4.8% ± 0.5% weight loss in 11 MONW Asians (48 ± 3 years old, six men and five women, BMI 22.7 ± 0.4 kg/m Weight loss decreased total fat mass by ∼9%, VAT and SAT volumes by ∼11% and ∼17%, respectively, and intrahepatic fat by ∼50% (all P < 0.05).",
      "entity": "Age (years)"
    },
    {
      "sentence": "16 participants (13 male), mean age 75 (SD 6.7) mean duration since diagnosis 7.1 years (±2.8).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Baseline and follow-up (2.8 years) angiographic data were analyzed among 320 women.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 76-year-old woman with a history of lumbar fracture and marked proteinuria, bilateral pitting edema, malaise and pruritus was referred for an evaluation of an impaired renal function.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A Japanese boy developed nephrotic syndrome (NS) and had microscopic hematuria at 8 years old.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Cyclosporine A (CyA) was introduced at 10 years old, and there were no relapses between then and when it was discontinued at 12 years old.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Microscopic hematuria appeared at 13 years old, however, with gross hematuria appearing at the time of infection.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Currently (14 years old), CyA treatment has been discontinued and the patient is undergoing lisinopril therapy for IgA nephropathy, but there are still relapses of NS.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Three women aged 89 to 95 years with moderate AD who resided in an assisted living facility participated in physical therapy to address their mobility limitations.",
      "entity": "Age (years)"
    },
    {
      "sentence": "No new safety risks were identified with exposure to UPA through 2 years (week 104).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Between January 1976 and December 1985, renal biopsy was indicated in 663 adults (greater than 15 yrs) patients who were born and lived in a rural area of 400,000 inhabitants.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Primary GN was diagnosed in 418 pts (63%) corresponding to a prevalence (P) for 10 yrs of 1/1000.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Sixteen patients (nine women and seven men; mean age, 38 years; range, 18-55 years) without structural heart disease who had ventricular tachycardia underwent radiofrequency catheter ablation to eliminate the ventricular tachycardia.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Mean duration of symptoms was 6.7 years (range, 0.5-20 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 32-year-old woman with KL grade 4 right ankle OA subsequent to a clubfoot repair in childhood performed 12 weeks of BFR-training.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Median postoperative follow-up was 1.6 years with, on average, 3.4 MRI examinations per patient.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The average age was 7.2 ± 2.65 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The average age of participants was 58.47 years old, 48.21% of whom only attended primary school or below.",
      "entity": "Age (years)"
    },
    {
      "sentence": "During a median 6.8 years of follow-up, 212 patients (11.1%) experienced the CVD outcome (10-year risk, 14.7% [95% CI, 12.8%-16.8%]).",
      "entity": "Age (years)"
    },
    {
      "sentence": "The mother revealed a persistent nephrotic syndrome for more than 20 years despite treatment with various immunosuppressive drugs.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 28 years old woman, G4P3, was admitted to our hospital in the sixth month of pregnancy because of epigastralgia and vomiting for 10 days and respiratory distress for one day.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Here, we report a 51-year-old woman with latent tuberculosis infection who developed nephrotic syndrome during treatment with rifampicin and isoniazid for 25 days.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The analysis included 253 patients (median age, 61.0 years; females, 76%).",
      "entity": "Age (years)"
    },
    {
      "sentence": "A statistically significant improvement occurred in ODI, SF-36 Physical Component Summary, and NRS leg pain scores from preoperatively to 2 years postoperatively (P<.0001) within all groups; and a statistically significant improvement occurred in back pain scores in the moderate and severe back pain groups.",
      "entity": "Age (years)"
    },
    {
      "sentence": "No statistically significant change occurred in back pain from preoperatively to 2 years postoperatively (P=.528) in the minimal back pain group.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 80-year-old woman visited our hospital complaining of generalized edema that had started 4 weeks prior.",
      "entity": "Age (years)"
    },
    {
      "sentence": "She reported a sense of thirst and dry eye for the last 5 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The median age of patients was 66 years old, with 63% female and 37% male (Table 1).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Table 1 Patient demographics and clinical characteristics of 16 patients with EDP induced by EGFRi Case no Demographics: age, race, and sex Fitzpatrick skin type Cancer type EGFR therapy Concomitant photosensitive drug(s) Time to EDP (months) Clinical features Distribution Symptoms Treatments and clinical course EDP status from most recent follow up 1 47 y/o Asian male III Stage IV NSCLC Erlotinib None Unknown Brown-blue-gray hyperpigmented patches Bilateral shins Left thigh Xerosis Pruritus Triamcinolone 0.1% ointment for 4 months, improvement of blue discoloration Tacrolimus 0.1% BID for 9 months, improvement but no resolution Ongoing 2 62 y/o Asian female IV Stage IV NSCLC Osimertinib None 4 Gray-brown hyperpigmented patches Bilateral arms Back Forehead Neck Right shin None Tacrolimus 0.1% ointment for 1 year with minor improvement Ongoing 3 69 y/o Asian female IV Stage IV NSCLC Osimertinib None 4 Gray-brown macules and patches Chest Face Forehead Bilateral legs None Tacrolimus 0.1% ointment for 10 months, no improvement Ongoing 4 79 y/o White male II Stage IV NSCLC Osimertinib None 15 Mottled grey-blue hyperpigmented patches and plaques with mild scaling Bilateral arms Back Forehead Neck None Photoprotection, no improvement Ongoing 5 69 y/o Asian female III Stage IV NSCLC Osimertinib Ibuprofen 4 Blue-grey hyperpigmented macules and patches Abdomen Bilateral arms None Tacrolimus 0.1% ointment for 7 months, no improvement Ongoing 6 65 y/o Asian male III Stage IV NSCLC Osimertinib None 20 Hyperpigmented blue gray macules and patches Helix Bilateral shins None Photoprotection, no improvement Ongoing 7 66 y/o Asian female IV Stage IV NSCLC Erlotinib TMP-SMX 6 Ashy grey-brown thin plaques Back Forehead None 2.5% hydrocortisone ointment for 8 months, resolved Resolved 8 82 y/o Asian male III Stage III NSCLC Erlotinib Simvastatin 20 Ash-grey hyperpigmented patches Dorsal feet Forehead Scalp None Photoprotection Ongoing 9 57 y/o Asian female III Stage II NSCLC Erlotinib None 1 Bue-grey discoloration Tongue None No intervention Ongoing 10 51 y/o Asian female III Stage IV NSCLC Osimertinib None 9 Blue-grey hyperpigmented macules and patches Bilateral arms Axillae Groin Neck Trunk None 2.5% hydrocortisone ointment, triamcinolone 0.1% ointment, photoprotection with mild improvement Ongoing 11 67 y/o Asian male III Stage IV NSCLC Osimertinib None 7 Gray-blue macules and patches with mild background erythema and scaling Bilateral arms Ears Face Bilateral shins None Triamcinolone 0.1% ointment, protection for 6 months with mild improvement Ongoing 12 75 y/o Asian female IV Stage III NSCLC Osimertinib TMP-SMX 3 Gray-blue hyperpigmented patches Bilateral arms Abdomen Back Face Bilateral shins Pruritus Triamcinolone 0.1% and betamethasone 0.01% with relief of pruritus, lesions unchanged Triluma cream 6 months, mild improvement Ongoing 13 42 y/o Asian male IV Stage IV NSCLC Afatinib TMP-SMX 24 Grey-brown hyperpigmented patches Back Face None Hydroquinone 4% cream for 2 years with mild improvement Ongoing 14 74 y/o White female III Stage II NSCLC Osimertinib Atorvastatin 4 Grey-brown hyperpigmented patches Bilateral legs Trunk None Photoprotection Ongoing 15 64 y/o Asian female IV Stage IV NSCLC Osimertinib None 3 Gray-brown hyperpigmentation Abdomen Bilateral arms Back Bilateral legs Pruritus Triamcinolone 0.1% cream; No change, minimal concern to patient Ongoing 16 52 y/o Asian female IV Stage IV NSCLC Osimertinib None 42 Gray hyperpigmented patches with digitate shape Abdomen Bilateral flanks None Triamcinolone 0.1% cream Ongoing NSCLC, non-small cell lung cancer, TMP-SMX, Trimethoprim/Sulfamethoxazole CONCLUSIONS: We highlight the largest case series describing EDP from EGFR inhibitors, which mostly affected Asian patients with lung malignancy and on EGFR tyrosine kinase inhibitors.",
      "entity": "Age (years)"
    },
    {
      "sentence": "We report on two brothers (the product of first-degree consanguineous marriage; aged 15 and 12 years) who presented with severe hypotonia at birth, proximal muscle weakness associated with delayed motor milestones but normal cognitive function.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Investigations (at 4 years of age) revealed mildly elevated serum creatine kinase (CK) levels (300 and 824 IU/l; N < or = 210).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Clinical examination at 12 and 9 years, respectively, showed mild facial weakness and high-arched palate in both patients.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A repeat muscle biopsy showed advanced dystrophic changes in the younger patient at the age of 10 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The study included 21 self-reported healthy adults, aged 65-84 years (mean 73.5; SD 6.4 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 41-year-old woman presented with a nephrotic syndrome and ARF.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 15-year-old boy developed minimal change nephrotic syndrome (MCNS) during remission of Hodgkin's disease.",
      "entity": "Age (years)"
    },
    {
      "sentence": "To describe cognitive and academic outcomes in survivors after pediatric stem-cell transplantation (SCT) through 5-years post-SCT.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A battery of neurocognitive measures were administered before admission and at 1, 3, and 5 years post-SCT for 268 patients who underwent SCT; the study sample is comprised of 158 patients who survived and were evaluated at 1-year post-SCT.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Of the 92 patients, 79 (85.8%) were adults (> or = 19 years) and 13 (14%) were children (< 19 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "The mean age of adults was 36.44 +/- 11.55 (range 19-69 years) and that of the children was 10.54 +/- 3.85 years (range 4-18 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Corticosteroid resistance in pediatric INS patients was independently associated with the black race, older age at presentation (>8 years), and female sex.",
      "entity": "Age (years)"
    },
    {
      "sentence": "In a prospective study of 50 consecutive patients over a 10 yr period with this syndrome, clinical and neuropsychological features, pathogenesis and outcome were studied to provide information concerning management and prognosis.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Stroke or vascular death rate was 2.7% per yr during a mean follow-up period of 2.25 yrs.",
      "entity": "Age (years)"
    },
    {
      "sentence": "From June 1994 to June 1997, 28 consecutive patients 16 to 65 years old (mean age 45) selected for corporoplasty underwent a total of 29 operative procedures for disabling penile curvature.",
      "entity": "Age (years)"
    },
    {
      "sentence": "He had a history of thymectomy and radiotherapy because of invasive thymoma 4 years before the development of NS.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 37-year-old woman presented to the nephrology department with a 6-year history of MCD.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 47-year-old woman with type 1 diabetes mellitus was presented for evaluation of progressive oedema, fatigue and weight gain.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A retrospective cross-sectional study was carried out among adult patients (>18 years) with a histological diagnosis of GN at the University Professorial Unit over a period of six months.",
      "entity": "Age (years)"
    },
    {
      "sentence": "There were 109 patients (females = 90) with a mean age of 40.32 ± 15.24 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The LA datasets in TAPVC patients were analyzed before surgery (n = 28) and follow-ups at 1-2 (n = 24) and 5-7 years of age (n = 13) and compared with those of age-matched healthy controls (January 2009-2022).",
      "entity": "Age (years)"
    },
    {
      "sentence": "All 2DSTE-determined LA strains showed significant reductions at all time points in the TAPVC group compared to those in the control (median εR, εCD, and εCT; before surgery: 17.0% vs. 26.0%, 12.9% vs. 15.9%, and 6.3% vs. 10.4%; follow-up at 1-2 years: 30.0% vs. 45.7%, 23.2% vs. 29.6%, and 6.1% vs. 16.3%; follow-up at 5-7 years: 31.2% vs. 43.1%, 25.0% vs. 31.2%, and 5.2% vs. 10.8%, respectively; p < 0.05).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Nephrotic syndrome developed in an 80-year-old woman taking naproxen, and remitted after discontinuation of the drug.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 73-year-old woman with Graves' disease underwent total thyroidectomy and was being treated with levothyroxine.",
      "entity": "Age (years)"
    },
    {
      "sentence": "This study included patients aged 1 to 18 years with SSNS.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Seventy-eight patients-median age, 3.2 years (interquartile range [IQR], 2.65) and median follow-up of 4.37 (IQR, 5.6)-were evaluated.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Participants (aged 8-18 years) all initiated tumor necrosis factor inhibitor (TNFi) therapy and completed questionnaires, examinations, and magnetic resonance imaging (MRI) at baseline and 12 weeks.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Of the evaluable cohort (N = 57), 68.4% were male, and the median age was 15.3 years; 70.2% of youth treated with TNFi had clinical response (change ≥2 in patient global assessment).",
      "entity": "Age (years)"
    },
    {
      "sentence": "MesPGN was seen mostly in young adults with mean age of 28.63 years for males and 26.3 years for females.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The present systematic review and meta-analysis aimed to explore the efficacy and safety of nusinersen in patients older than 12 years of age with 5q-SMA.",
      "entity": "Age (years)"
    },
    {
      "sentence": "We report the analysis of 30 years of native renal biopsies and the temporal pattern of primary glomerular disease in a single United Kingdom (UK) region.",
      "entity": "Age (years)"
    },
    {
      "sentence": "All 1844 adult native kidney biopsies for 30 years (1976-2005 inclusive) were analysed.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Biopsy rates increased significantly from 2.02 to 7.08 per hundred thousand population per year (php/year) (chi(2) = 55.9, P < 0.001), and the mean patient age at biopsy rose from 33 to 49 years over the study period (F = 58, P < 0.001).",
      "entity": "Age (years)"
    },
    {
      "sentence": "The patient is a 25-year-old Syrian male, previously in good health, presenting with severe abdominal pain and vomiting that had persisted for 6 days.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The mean follow- up period was 3.4 years (range, 1-7 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "In this report, we presented a case of a 69-year-old male patient with CLL who developed nephrotic syndrome.",
      "entity": "Age (years)"
    },
    {
      "sentence": "It collects data about 143 patients admitted during 10 years at the hospital, between January 1989 and December 2000, to have renal biopsy for suspicion of glomerulopathy.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A total of 309 postmenopausal women entered the Estrogen Replacement and Atherosclerosis trial, of whom 248 underwent baseline angiography and completed follow-up angiography after an average of 3.2 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "We herein report a 75-year-old woman with minimal change disease who developed pains in the right back, groin, and thigh because of retroperitoneal bleeding during prophylactic anticoagulation with unfractionated heparin.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The KDIGO criteria do not rely on changes in GFR for staging except in children under the age of 18 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "One hundred native kidney biopsies were performed on 95 patients with a mean age of 40.8+/-18 years, and a glomerular filtration rate of 57+/-42 ml/min/1.73 m2.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Seventy-five patients with COPD (44 men) in a stable clinical state with mean age 70 years (SD 9 y), forced expiratory volume in one second 52% (SD 21%) predicted and baseline walking distance 359 meters (SD 104 m).",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 52-year-old male with pulmonary hypertension secondary to partial anomalous pulmonary venous return unassociated with atrial septal defect was given thoracic epidural anaesthesia for elective cholecystectomy.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Included in the study were 69 non-smoking Canadian women 19-29 years of age with no history of obesity, diabetes, or alcohol misuse.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Twenty adults (5 men, 15 women; age = 24.35 ± 6.95 years, height = 169.29 ± 10.10 cm, mass = 70.58 ± 12.90 kg) with self-reported CAI participated.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A 45-year-old Turk had a year ago noticed a submandibular and a retroauricular node-like swelling, about 2 cm in diameter each, firm and freely mobile.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The ECGs and Echos were recorded at baseline, 3 months, and annually for 4 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "CAD was quantified by angiography at baseline and after a minimum of 3 years of therapy with fenofibrate or placebo.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The elucidation of podocyte biology during the last 15 years has significantly improved our understanding of the pathophysiologic processes of proteinuria and glomerulosclerosis.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Subjects with a linear dose-response pattern had been exposed to isocyanates at work for a significantly shorter interval (7.2 +/- 6.7 yr) than subjects with a nonlinear pattern (20.0 +/- 13.1 yr).",
      "entity": "Age (years)"
    },
    {
      "sentence": "The patient was an 18-year-old man who developed nephrotic syndrome after a 'wheat spider' bite (",
      "entity": "Age (years)"
    },
    {
      "sentence": "The mean age of the patients was 31.48 ± 13.46 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Eight Tanner stage I adolescents with Crohn's disease, mean age 14 yr 5 mo, had a mean weight gain of 0.38 kg and height gain of 1.4 cm for the year before initiation of nasogastric feedings.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The mean age of the patients was 37.41±15.78 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "We report the case of a 50-year-old male who had classical ECG signs of inferior wall myocardial infarction.",
      "entity": "Age (years)"
    },
    {
      "sentence": "A case of nephrosis in a 10 year-old boy treated with chlormethine (cumulative dose: 0.8 mg/kg) and chlorambucil (cumulative dose: 10 mg/kg) is reported.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Demographic factors, physiological metrics, performance metrics, symptoms, and ratings of perceived exertion were collected from 55 participants (age, 16.5 ± 2.3 years, 31.5% female) initially evaluated within 14 days of SRC who completed EXiT at medical clearance for RTS.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The study includes 423 patients, mean age was 10.48 ± 4.58 years, males 245 (57.9%) were more than females 178 (42.1%).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Patients had a mean age of 48.6 years, mean plaque volume 256 mm IFN-α2b, as minimal invasive (intralesional) options for the treatment of PD, demonstrated significant improvement in plaque volume, penile curvature with minimal complications.",
      "entity": "Age (years)"
    },
    {
      "sentence": "The Control of Allergic Rhinitis and Asthma Test for Children (CARATKids) assesses asthma and allergic rhinitis control in children younger than 12 years.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Children aged 6 to 12 years with asthma and allergic rhinitis were studied (n = 102).",
      "entity": "Age (years)"
    },
    {
      "sentence": "The outcome set will aim to serve individuals 2 years of age and older with primary NS conditions (specifically focal segmental glomerulosclerosis, minimal change disease, IgM nephropathy, membranous nephropathy, and childhood-onset NS not biopsied).",
      "entity": "Age (years)"
    },
    {
      "sentence": "Altogether 4004 biopsies in 3874 patients were performed (males 57.9%, children < or = 15 years 17.7%, elderly >60 years 14.3%).",
      "entity": "Age (years)"
    },
    {
      "sentence": "The most common in patients with nephrotic proteinuria were MCD (50.5%) among children, but IgAN (24.6%) in adults aged 16-60 years and MGN (16.8%) among the elderly.",
      "entity": "Age (years)"
    },
    {
      "sentence": "Mean age was 74.0 ± 8.8 years, and 86% of patients were male; 74% had hypertension, 79% had hyperlipidemia, and 59% had a concomitant aortic aneurysm.",
      "entity": "Age (years)"
    },
    {
      "sentence": "There were 45 PAU vessels with >1 CTA (total of 167 CTAs) with a median follow-up of 4.0 years (interquartile range: 2.0-6.2 years).",
      "entity": "Age (years)"
    },
    {
      "sentence": "There was minimal growth noted in a median follow-up of 4 years, and no PAUs required intervention for symptoms or progression.",
      "entity": "Age (years)"
    },
    {
      "sentence": "At 1 year after transplantation, there were 42% of recipients that had an absolute GFR decrease greater than 20 mL/min per 1.73 m, and 39% that decreased greater than 25% from their transplant baseline.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Only 22% had an absolute improvement in GFR greater than 5 mL/min per 1.73 m. Sixty-four percent of liver transplant recipients overall experience a decrease in GFR 1 year after transplantation.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "To assess the ability of TNFR2 to predict persistent decline in estimated glomerular filtration rate (eGFR < 30 mL/min/1.73m Serum and urine TNFR2 levels were significantly elevated in patients compared to controls.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Patients with relapses on alternate day prednisolone at over 1 mg/kg, prior use of potent steroid-sparing therapies, eGFR under 60 ml/min/1.73 m",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Compared with controls, suPAR levels were significantly higher in patients with focal segmental glomerulosclerosis (FSGS) and estimated glomerular filtration rate (eGFR) under 30 ml/min per 1.73 m(2) (6365 pg/ml), congenital nephrotic syndrome (4398 pg/ml), and other proteinuric diseases with or without eGFR under 30 ml/min per 1.73 m(2) (5052 and 3875 pg/ml, respectively; both significant).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Chronic kidney disease (CKD) was defined as estimated glomerular filtration rate of <60 mL/min/1.73 m Chronic kidney disease prevalence ranged from 2.9% to 8.8% in women and 3.2% to 8.6% in men.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "One patient had eGFR ≤90 mL/min/1.73 m Patients who had frequent relapses had more measurements available for serum creatinine and height, creating a sampling bias.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Un seul patient a présenté une valeur de DFGe de plus de 90 ml/min/1,73 m Un biais d’échantillonnage est introduit par le fait qu’un nombre plus élevé de mesures de taille et de DFGe étaient disponibles pour les patients ayant fait plusieurs rechutes.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Following the intervention, peak oxygen uptake increased by 0.18+/-0.14 l/min in the exercise training group, which was significantly higher (P<0.0001) than that in the usual activity group (0.02+/-0.14 l/min).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The mean glomerular filtration rate values at the end of the study were similar to those prior to starting TAC (97.9 +/- 21.2 ml/min/1.73 m(2) vs. 96.4 +/- 18.4 ml/min/1.73 m(2), p = 0.30).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Forty-two nephrotic patients (M/F 21/21), with well-preserved renal function (creatinine clearance 87+/-20 ml/min) were included in the study.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Both groups will be categorized into one of 3 levels of baseline eGFR (≥60, 45-59, and <45 mL/min per 1.73 m The primary outcome, progressive kidney disease, will be defined as a composite of a persistent ≥40% drop in eGFR from the baseline value, a new persistent eGFR <15 mL/min per 1.73 m We will test for statistical interaction to determine whether the baseline category of eGFR modifies the rate of long-term progressive kidney disease after pregnancy.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "This includes at least 395 000 pregnant females with baseline eGFR ≥60 mL/min/1.73 m Measures of kidney function will be obtained as part of routine care (not according to a research schedule).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Measures of baseline proteinuria are frequently missing from routine care data, even in up to 15% of those with an eGFR <45 mL/min per 1.73 m This study will investigate whether the level of baseline eGFR modifies the rate of progressive kidney disease after pregnancy and will estimate the cumulative incidence of progressive kidney disease in pregnant and non-pregnant females across 3 categories of baseline eGFR.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Les deux groupes seront classés selon trois niveaux de DFGe initial (≥60, 45 à 59 et <45 ml/min par 1,73 m²).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Le principal critère d’évaluation, l’insuffisance rénale progressive, a été défini comme un composite des éléments suivants : réduction persistante d’au moins 40 % du DFGe par rapport à la valeur initiale, DFGe nouvellement établi à < 15 ml/min/1,73 m² de façon persistante, dialyse d’entretien ou transplantation rénale.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "La cohorte des femmes enceintes comprendra au moins 395 000 femmes avec un DFGe initial ≥60 ml/min/1,73 m², 300 avec un DFGe de 45 à 59 ml/min/1,73 m² et 110 avec un DFGe < 45 ml/min/1,73 m².",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Les mesures initiales de protéinurie sont souvent absentes des données des soins courants, et ce, même pour jusqu’à 15 % des personnes présentant un DFGe < 45 ml/min/1,73 m².",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Lower eGFR, higher urinary protein-creatinine ratio (UPCR), and lower serum albumin levels at enrollment were associated with higher risk of first CV and TE event (eGFR per 10 mL/min/1.73 m Age of cohort, duration of follow-up.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "At multivariate Cox analysis, proteinuria >1.0 g/day, hypertension, eGFR <60 ml/min/1.73 m(2), hypoproteinemia and hyperuricemia were independent risk factors of renal survival for Non-MCD-IgAN patients [hazard ratio (HR) 3.43, p < 0.001; HR 1.65, p < 0.05; HR 2.61, p < 0.001; HR 2.40, p < 0.001; HR 2.27, p < 0.001, respectively), but not for patients with MCD-IgAN.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Delta Ccr was - 4.2 +/- 9.4 mL/min in subjects with minimal early immunoreactivity for CC and - 20.5 +/- 5.9 mL/min in subjects with strong reactivity (p < 0.05).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Delta Ccr was - 14.5 +/- 18.6 mL/min in subjects with minimal early immunoreactivity for LC and - 11.7 +/- 12.8 mL/min in those with strong reactivity.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Estimated creatinine clearance before CYA therapy was unchanged at the end of the observation period, 133+/-10 vs. 131+/-8 ml/min per 1.73m2, respectively.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Patients with estimated glomerular filtration (eGFR) rate <15 ml/min/1.73 m The network will allow accurate ascertainment of disease burden of glomerular diseases across study sites, establishment of the treatment pattern of common glomerular diseases, investigation of medium- and long-term outcomes (remission, relapse, rate of eGFR decline), and building a suitable infrastructure to carry out clinical trials in primary glomerular disease.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "However, serum creatinine increased from 121.8 +/- 60.5 to 150.4 +/- 64.6 mol/l (p less than 0.01) and glomerular filtration rate as estimated by 24-hour creatinine clearance fell from 85.5 +/- 33.7 to 72.1 +/- 37.2 ml/min (p less than 0.05).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "No significant change was observed in the mean estimated GFR value as compared to the pretreatment value (183.1 +/- 35.4 ml/min/1.73 m2vs.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "185.4 +/- 39.3 ml/min/1.73 m2).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Two hundred and sixty-five consecutive CKD patients attending our renal clinic, with estimated glomerular filtration rate (eGFR) of 20-70 ml/min/1.73m(2) at baseline and a minimal follow-up of 1 year, were studied retrospectively.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The rate of ΔeGFR was -1.5 ± 5.0 ml/min/1.73 m(2) per year in patients who received RASB (N=168) and -6.0 ± 5.4 in those who did not (N=97) (P<0.001).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "In the response group, CCr was 37.0 +/- 5.0 ml/min before LDL-A, and increased significantly to 55.7 +/- 12.0 ml/min after LDL-A (p = 0.038).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Patients had an estimated glomerular filtration rate of 64.6 mL/min/1.73 m Retrospective design and sampling bias of needle biopsy.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Changes in creatinine clearance were more decreased in group I than in group II (-39.4±8.2 vs 2.7±4.3 ml/min per 1.73m(2), p<0.0001).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "However, uVDBP was still markedly elevated in patients with SRNS with eGFR >100 mL/minute/1.73 m(2).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "In the group who had both TBMD and GN, heavy proteinuria (6.1 +/- 5.2 g/day), hypoalbuminaemia (26 +/- 12 g/L) and renal insufficiency (76 +/- 25 mL/min) might develop.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Twenty-seven subjects with estimated glomerular filtration rate (eGFR) ranging from 70 to <10 ml/min per 1.73 m2 (median eGFR = 48) underwent a frequently sampled intravenous glucose tolerance test (FSIVGTT) on a single occasion.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Median serum creatinine was 0.7 (0.6-1.0) mg/dl, mean eGFR was 104 ± 33 ml/min/1.73 m Our data are generally compatible with the literature.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The focal and segmental glomerulosclerosis group displayed the highest incidence of ESRD (25.8%) and the fastest decline of estimated GFR (4.6 ml/min per 1.73 m(2) per year).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "After PIL training, one adult asthma patient and one COPD patient inhaled <30 L/min through the Spiromax compared to one adult asthma patient and five COPD patients with the Turbuhaler.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "All patients achieved PIF values of at least 30 L/min after enhanced training.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The degree of proteinuria at presentation was similar (4.5 +/- 0.7 vs 3.9 +/- 0.6 g/d, older vs younger, p = NS), but older patients had higher creatinine levels (1.7 +/- 0.2 vs 1.2 +/- 0.07 mg/dl, p <.01), lower creatinine clearances (64 +/- 7 vs 111 +/- 7 ml/min., p <.05), and higher systolic blood pressure (164 +/- 8/88 +/- 2 vs 145 +/- 4/94 +/- 2 mm Hg, p <.01).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "For both individual descriptors and clusters, we used Cox regression models to assess associations with time from biopsy to proteinuria remission and time to a composite progression outcome (≥40% decline in eGFR, with eGFR<60 ml/min per 1.73 m Intrarater and interrater reproducibility was >0.60 for 12 out of 12 and seven out of 12 descriptors, respectively.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "At diagnosis, patients in the HR group without other mutations were more often adults [35 (53.8%) versus 19 (27.1%); P = 0.003] and had a lower estimated glomerular filtration rate (78.9 versus 98.8 mL/min/1.73 m2; P = 0.02).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Patients with FSGS or TR-MCD, eGFR >30 ml/min per 1.73 m Seven participants were enrolled, with median baseline urine protein:creatinine ratio 12.1 mg/mg (interquartile range [IQR], 2.2–18.6), serum albumin 2.4 g/dl (IQR, 2.0–2.8), and eGFR 57 ml/min per 1.73 m Precision medicine trials are feasible in rare glomerular disorders.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Thirty-seven (35.2%) of the 105 patients had CKD, as defined by an eGFR of 60 ml/min/1.73 m2 and/or proteinuria.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The serum creatinine and creatinine clearance before and three months after the operation were 2.4 mg/dl and 2.6 mg/dl, 36.7 ml/min and 32.5 ml/min, respectively.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "In the tests in vitro, fresh blood was infused at flow rates up to 120 ml/min.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Hemolysis was minimal at flow rates of 60 ml/min or less (less than or equal to 0.92 +/- 0.18%), but increased exponentially at higher rates (13.64 +/- 2.37% at 120 ml/min, p less than .002).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "A randomized, crossover clinical trial was next performed by delivery of blood perfusion at 60 ml/min to 15 patients undergoing coronary angioplasty.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Thus, myocardial protection with oxygenated autologous blood perfusion at rates of 60 ml/min appears to be a safe and effective technique that may permit increased inflation time and extend the range of coronary angioplasty to include individuals at high risk for the procedure.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Baseline estimated glomerular filtration rate (eGFR) was 87 ml/min (interquartile range 66-100).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Four years later, the patient was in good general health, the glomerular filtration rate was 30 ml/min/1.73m² and there was non-nephrotic proteinuria.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The estimated glomerular filtration rate did not change significantly at 24 month follow-up with a mean decrease of 6.4 mL/minute/1.73 m(2) (-7.5%, P = .22).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "In a randomly assigned, crossover design, the effectiveness of the endoscopically (e) inserted ITO catheter was assessed by measuring the capillary blood gases, respiratory rate (RR), tidal volume (Vt) and minute ventilation (MV) after 1 h breathing room air without eITO and 1 h after eITO (flow: 3 l/min).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "A higher eGFR was associated with an increased risk of relapse (hazard ratio 1.18 [1.03-1.36] per 10 mL/min increase in eGFR), and females were significantly more likely than males to have an early relapse.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Compared to prebiotics, it is uncertain whether synbiotics improve estimated glomerular filtration rate (eGFR) at four weeks (1 study, 34 participants: MD -3.80 mL/min/1.73 m², 95% CI -17.98 to 10.38), indoxyl sulfate at four weeks (1 study, 42 participants: MD 128.30 ng/mL, 95% CI -242.77 to 499.37), change in gastrointestinal (GI) upset (borborymgi) at four weeks (1 study, 34 participants: RR 15.26, 95% CI 0.99 to 236.23), or change in GI upset (Gastrointestinal Symptom Rating Scale) at 12 months (1 study, 56 participants: MD 0.00, 95% CI -0.27 to 0.27), because the certainty of the evidence was very low.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Compared to certain strains of prebiotics, it is uncertain whether a different strain of prebiotics improves eGFR at 12 weeks (1 study, 50 participants: MD 0.00 mL/min, 95% CI -1.73 to 1.73), indoxyl sulfate at six weeks (2 studies, 64 participants: MD -0.20 μg/mL, 95% CI -1.01 to 0.61; I² = 0%) or change in any GI upset, intolerance or microbiota composition, because the certainty of the evidence was very low.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Compared to certain strains of probiotics, it is uncertain whether a different strain of probiotic improves eGFR at eight weeks (1 study, 30 participants: MD -0.64 mL/min, 95% CI -9.51 to 8.23; very low certainty evidence).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Compared to placebo or no treatment, it is uncertain whether synbiotics improve eGFR at six or 12 weeks (2 studies, 98 participants: MD 1.42 mL/min, 95% CI 0.65 to 2.2) or change in any GI upset or intolerance at 12 weeks because the certainty of the evidence was very low.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Compared to placebo or no treatment, it is uncertain whether probiotics improve eGFR at eight, 12 or 15 weeks (3 studies, 128 participants: MD 2.73 mL/min, 95% CI -2.28 to 7.75; I² = 78%), proteinuria at 12 or 24 weeks (1 study, 60 participants: MD -15.60 mg/dL, 95% CI -34.30 to 3.10), indoxyl sulfate at 12 or 24 weeks (2 studies, 83 participants: MD -4.42 mg/dL, 95% CI -9.83 to 1.35; I² = 0%), or any change in GI upset or intolerance because the certainty of the evidence was very low.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "To assess the minimum effective duration of remission preventing damage accrual (Systemic Lupus International Collaborating Clinics damage index [SDI]) and impaired kidney function (IKF: estimated glomerular filtration rate of <60 mL/min/1.73 m Patients with biopsy-proven LN followed up at least twice yearly were enrolled; clinical variables were collected regularly.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Sustained clinical remission (sCR) was defined as estimated glomerular filtration rate of >60 mL/min/1.73 m In total, 293 patients with LN were included (median follow-up: 15.7 [10.4-22.9] years) of whom 84.3% achieved sCR lasting 8.7 (5.4-13.1) years.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Cardiac index fell significantly (3.4 plus or minus 0.2 [SEM] to 2.6 plus or minus 0.1 L/min/m-2) with the higher dose only.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Participants (T2DM [HbA1c 7-10.5%], eGFR ≥60 mL/min/1.73m2, not taking metformin for ≥2 months) were randomized to QD placebo (PBO); QD Metformin DR 600, 900, 1200, or 1500 mg; or to single-blind BID Metformin immediate-release (IR) 1000 mg.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "eGFR slightly increased (62.1 +/- 31.8 to 65.3 +/- 31.8 ml/min, p = n.s.)",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Serum albumin concentration was significantly associated with remission (multivariable-adjusted hazard ratio [95% confidence interval] per 1.0 g/dL, 0.57 [0.37, 0.87]), along with eGFR (per 30 mL/min/1.73 m",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Maximal clearance approached 2 ml/min per kilogram at ANCs > 17.0 x 10(9)/L; minimal clearance was 0.29 ml/min per kilogram at ANCs of 0.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "CKD patients (eGFR < 30 ml/min.1.73m 207 patients were included; 186 (90%) completed the follow-up.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Maintenance cyclosporin therapy to prevent relapse was not associated with any adverse effects, and there was no significant difference between the creatinine clearance before and after 30 days of therapy (86.9 +/- 19.3 and 81.7 +/- 23.5 ml/min respectively, P greater than 0.1).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The eGFR slope before COVID-19 infection was-1.40mL/min/1.73m Infrequent or short follow-up.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Group B showed a higher GFR than groups A and C (group B = 133.9 +/- 16.26 ml/min/1.73 m2, group A = 107.91 +/- 18.19 ml/min/1.73m2; p = 0.014, group C = 113.89 +/- 13.17 ml/min/1.73m2, p = 0.015).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "RR was significantly lower (absolute and relative) in group B than in group C (group B = 10.9 +/- 15.46 ml/min/1.73m2, group C = 38.58 +/- 21.47 ml/min/1.73m2, p = 0.016 and group B = 8.56 +/- 11.75%, group C = 34.35 +/- 21.43%, p = 0.016, respectively).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The microsphere blood flow technique revealed that blood flow was less than 0.05 ml/min per g in all layers of the ischemic zone, i.e., inner, middle, and outer thirds.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "All patients experienced some impairment in renal function with mean creatinine clearance decreasing from 129 +/- 19 to 91 +/- 13 ml/min/1.73m2 (p less than 0.05).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Mean serum creatinine at diagnosis was 0.8 mg/dL (±2.5) and estimated GFR (eGFR) was 87 mL/min/1.73 m In this series of patients, almost 46% of adult-onset nephrotic MCD patients experienced a relapse, although their renal progression was rare.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Evidence from laboratory and field studies indicates that it is advisable for marathoners to consume 800 to 1000 L/h of sports drink providing 45 to 60 g/h of carbohydrate.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Median eGFR improved significantly from 34 mL/min/1.73 m2 at the time of conversion to 43 mL/min/1.73 m2 at the last follow-up (27% increase in eGFR; P = 001).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Median monthly change in eGFR was from -0.25 mL/min/1.73 m2 pre-sirolimus therapy to +1.28 mL/min/1.73 m2 post-sirolimus therapy (P =.09).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The reduction in GFR was 5.8 and 11.7 ml/min/1.73 m2 during these periods.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Median GFR (measured by creatinine clearance) did not change significantly (55 ml/min vs 59 ml/min, p = 0.345) although there was a significant decrease in the protein excretion rate (1700 mg/day vs 900 mg/day, p = 0.001) at 6 months.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Flow study demonstrated favorable increase in flow (up to 3.0 L/min) in proportion to change in pump speed.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "At referral, median creatinine clearance was 50 mL/min (0.83 mL/s) (range, 18 to 117 mL/min [0.30 to 1.95 mL/s]).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Patients had an eGFR of 71.0 ml/min per 1.73 m This study revealed that eC",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Estimated glomerular filtration rate remained stable during the entire study period in the patients given losartan (44.8 ± 8.1 to 44.1 ± 7.7 mL/min per 1.73 m; P = 0.120) but were significantly reduced in the placebo group (44.5 ± 8.5 to 39.1 ± 7.4 mL/min per 1.73 m, P < 0.001).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The glomerular filtration rate was different between the groups (78.1 ± 37.0, 58.0 ± 43.6 ml/min/1.73 m2, p = 0.006), but the urine protein/creatinine ratio was not (3.21 ± 4.01, 5.38 ± 7.47 g/gCr, p = 0.172).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Among 25 children (18 males and 7 females), three patients had proteinuria indicating nephrotic syndrome (24-hour urinary total protein/weight > 50 mg/kg/d), nine patients had severely reduced estimated glomerular filtration rate (eGFR < 30 ml/min/1.73 m This study evaluates histomorphologic findings from kidney biopsies of pediatric recipients following allo-HSCT.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Although the percent gamma globulin excretion was inversely related to GFR in children with FSGS, this measurement exceeded a 4.3% cutoff in 9 of these patients while their GFR was normal (less than or equal to 80 ml/min/1.73M2).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "59 ml/min.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Cases in which there were tubulointerstitial changes of the cortical area or arteriosclerosis in biopsy specimens and cases that included hypertension (greater than 140/90 mm Hg) or decreased renal function (glomerular filtration rate, less than 70 ml/min) were clearly associated with an unfavorable outcome in delivery.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Ten healthy adults underwent polygraphic monitoring, consisting of electromyography of the masseter muscle and electrocardiography during intra-oesophageal acid infusion (10 mL/min, 10 min).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The mean volumetric blood flow in EC-IC bypass was 34.2±5.7 mL/min.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Although patients without left ventricular failure (Group I) showed a decline in cardiac output (5.7 to 4.7 l/min), this parameter remained unchanged in Group 2.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "One study comparing vildagliptin to placebo showed no significant change in estimated glomerular filtration rate from baseline (1.9 ± 10.3 mL/min/1.73 m Evidence concerning the efficacy and safety of glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients is limited.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "In the patients with renal diseases, fractional excretion of lithium (FELi) and fractional proximal reabsorption of sodium (FPRNa) were not changed in patients whose glomerular filtration rate (GFR), was over 30 mL/min, but FELi was increased and FPRNa was decreased when the GFR was lower than 30 mL/min.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Moreover, fractional distal reabsorption of sodium (FDRNa) was decreased in patients whose GFR was under 40 mL/min.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The median eGFR decline was 1.0 mL/min per 1.73 m Our findings from a real-world clinical environment revealed significant differences in eGFR decline and ESRD risk among patients with 5 glomerulonephropathies.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Furthermore, the mean estimated GFR increased from 111.3±25.7 to 121.8±29.2 ml/min per 1.73 m(2) (P=0.01), with the largest increases in children and in FSGS subgroups.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "After 24 hours of diuresis and a 2.2-kg weight loss, maximal flow increased from 19.9 to 26.1 ml/min X 100 ml (p less than 0.05).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Despite a further 1.4-kg weight loss between 24 and 48 hours, maximal blood flow increased no more (26.1 to 25.8 ml/min X 100 ml).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Significant improvement was noted in GFR (75.4 ± 21.2 vs. 80.9 ± 22.4 mL/min/1.73 m2; p = 0.012) in addition to improvement in right atrial pressure (RAP; 9.1 ± 4.1 to 5.0 ± 2.2 mm Hg; p < 0.001), mean pulmonary artery pressure (49.1 ± 10.7 to 29.8 ± 8.3 mm Hg; p < 0.001), cardiac index (CI; 2.42 ± 0.6 to 2.70 ± 0.6 L/min/m2; p = 0.004), and pulmonary vascular resistance (9.42 ± 3.6 to 4.4 ± 2.3 Wood units; p < 0.001).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Adult patients with chronic kidney disease and an estimated glomerular filtration rate under 30 mL/min/1.73 m2 who were not receiving dialysis treatment completed seven PROMIS CATs (assessing physical function, pain interference, fatigue, sleep disturbance, anxiety, depression, and the ability to participate in social roles and activities), the SF-12, and the PROMIS Pain Intensity single item and Dialysis Symptom Index at inclusion and 2 weeks.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "When divided by the median value of U-FABP4 at baseline in 33 of the 81 patients who could be followed up, the yearly change (post-pre) in eGFR in the low U-FABP4 group was significantly greater than that in the high U-FABP4 group (median: 11.0 vs. -5.0 mL/min/1.73m U-FABP4 level is independently associated with proteinuria and renal dysfunction in patients with glomerular kidney disease.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Morphologic changes were evaluated by quantitative coronary angiography (automated edge-detection) and theoretical pressure drop across the dilated and stented stenosis was calculated from the Poiseuille formula, with turbulent resistances assuming a coronary blood flow of 1 or 3 ml/s.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "In the patients investigated GFR ranged between 40 and 127 ml/min/1.73 m2 body surface area, the filtration fraction between 6.9 and 22.5%, and the serum albumin concentration between 14 and 46 g/liter.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The baseline UPC was 4.1 g/g (IQR, 1.9, 7.7) and the eGFR was 81 ml/min per 1.73 m(2) (IQR, 50, 105).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Tertiary-care hospital; 41 consecutive patients with idiopathic SRNS, estimated glomerular filtration rate greater than 60 mL/min/1.73 m(2), and histological characteristics showing minimal change disease, focal segmental glomerulosclerosis, or mesangioproliferative glomerulonephritis were randomly assigned to treatment with tacrolimus (n = 21) or CsA (n = 20).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "We compared 30 control subjects to 30 patients with glomerular disease, proteinuria, and glomerular filtration rate > 30 ml/min/1.73 m(2) : membranous glomerulonephritis (n = 13), minimal change disease (n = 2), focal and segmental glomerulosclerosis (n = 3), IgA nephropathy (n = 5), lupus nephritis (n = 5), antiphospholipid antibody nephropathy (n = 1), cryoglobulinemic glomerulonephritis (n = 1).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Isc MBF-rest decreased in patients receiving dipyridamole (0.10 mL/minute/g; P = 0.03) and increased in the placebo group (0.16 mL/minute/g; P = 0.01) during the 24-week study.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "There was a significant reduction in GFR after 3 months of CyA therapy [118 +/- 33 (SD) to 93 +/- 24 ml/min per 1.73 m2] but no further fall thereafter, although the reduction in GFR was sustained for the duration of CyA therapy.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "We monitored progression of chronic kidney disease (CKD), assessed as a glomerular filtration rate of < 90 ml/min/1.73 m During a mean follow-up period of 4.8 ± 0.6 (range 3.5-6.0) years, 13 children (20%) evolved to at least CKD stage 2.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "This study aimed to characterize the single-dose pharmacokinetic (PK) and pharmacodynamic (PD) profile of rivaroxaban 15 mg administered before and after dialysis in subjects with end-stage renal disease (ESRD), and to compare this profile in subjects with ESRD to that in healthy control subjects (creatinine clearance ≥80 ml/min).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "From preoperation to 12 months postoperation, eGFR decreased by 2.8 and 1.1 mL/min/1.73 m RPN is a reasonable treatment option in patients with CKD, as it did not lead to a greater decline in renal function contributed by the surgical kidney.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Multivariable Cox proportional hazards models were fit for time to composite outcome (kidney failure or 40% decline in eGFR and eGFR <60 ml/min per 1.73 m 2 ) and proteinuria remission (urine protein-to-creatinine ratio [UPCR] <0.3 mg/mg).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The post-ART rollout patients were older (p = 0.007), had higher eGFR at presentation (p = 0.016) and fewer presented with eGFR of less than 15ml/min/1.73m2 (p = 0.0008).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "A total of 17 patients had renal dysfunction (estimated glomerular filtration rate < 60 ml/min/1.73m",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "GFR (C (In)) increased significantly after withdrawal of CsA from 54 +/- 7.3 to 64 +/- 8.5 ml/min (p < 0.01).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Measurements were made after a 5-min period of minimal speed (T0) of the HP to avoid retrograde regurgitation through the turbine; during the increase from minimum to maximal speed (T1); after a 5-min period of maximal HP flow (3l/min) (T2) and after HP was pulled back (T3).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "From T0 to T2, cardiac index rose from 1.93 +/- 0.38 to 3.26 +/- 0.35 l/min/m2 and capillary wedge pressure decreased from 18 +/- 6 to 13 +/- 5 mmHg (p less than 0.05); from T2 to T3, cardiac index decreased to 2.4 +/- 0.4 while capillary wedge pressure increased to 17 +/- 5 (p less than 0.05).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "During invasive ventilation, external flow jet nebulization results in increases in displayed exhaled tidal volumes (V Ventilators with internal and external flow sensors were tested by using a variety of volume and pressure control modes (the target V Results are reported as percentage change from baseline after addition of 3.5 or 8 L/min external flow.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "A multivariable model showed that FSGS (versus MCD: hazard ratio [HR], 0.28; 95% confidence interval [CI], 0.20 to 0.41), systolic BP (per 10 mm Hg: HR, 0.93; 95% CI, 0.86 to 0.99), and eGFR (per 10 ml/min per 1.73 m The North American cohort had more FSGS and more frequent family history.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The clearance of solute-free water (CH2O) was 0.9 +/- 0.8 ml/min during relapse, compared with 3.6 +/- 0.6 ml/min during remission (P less than 0.005).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Patients with CKD3b-5 (eGFR <45 mL/min/1.73m One hundred patients were included in the study.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The median baseline eGFR was 21.5 mL/min/1.73m In patients with advanced CKD, ultra-low contrast PCI is feasible and safe with minimal need for peri-procedural RRT.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Blinatumomab pharmacokinetics were described by a one-compartment linear model with first-order elimination, a clearance (CL) of 2.22 L/h, and a central volume of 5.98 L. A statistically significant effect of body surface area (BSA) on CL was observed.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Renal biopsy was mainly performed in patients with GFR >60 ml/min and asymptomatic urinary abnormalities suggesting concern on the part of clinicians regarding glomerular diseases.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The overall goal for treating Fabry nephropathy is to reduce the rate of loss of GFR to -1 ml/min per 1.73 m(2)/yr, which is that seen in the normal adult population.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "A total of 29 patients with non-STEMI and CKD (estimated glomerular filtration rate [eGFR] of ≤60 ml/min/1.73 m The median creatinine level was 2.1 (inter-quartile range 1.8-3.3), and mean eGFR was 48 ± 8 ml/min/1.73 m In non-STEMI patients with high-risk CKD who require revascularization, QFR and no contrast OCT-guided ultra-low contrast PCI may be performed safely without major adverse events.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Compared with placebo, budesonide/formoterol significantly increased resting oxygen uptake (mean change from baseline: 1.25 vs 11.37 mL/min; P = 0.007) as well as tidal volume and minute ventilation.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "BAFF on podocytes and III was associated with worst renal function at follow-up; those patients had 25% probability of having GFR >90 mL/min/1.73m2, versus 84.9% when absent (p = 0.0067).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Patients with BAFF in III had 42.9% probability of having GFR>90 mL/min/1.73 m2, versus 94.1% when absent (p = 0.0063).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Renal events were defined as a >50% decrease in estimated glomerular filtration rate (eGFR), eGFR of <15 mL/min/1.73 m2, or end-stage renal disease development.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "All hemodynamic variables showed no significant change before and after pericardiotomy, including heart rate (76 +/- 16 versus 75 +/- 15 beats per minute), mean pulmonary arterial pressure (46.3 +/- 11.1 versus 45.5 +/- 11.7 mm Hg), cardiac index (1.8 +/- 0.5 versus 2.0 +/- 0.6 l/min/m2), left ventricular end-diastolic pressure (5.9 +/- 5.7 versus 7.1 +/- 5.0 mm Hg), and right ventricular end-diastolic pressure (7.9 +/- 6.6 versus 8.0 +/- 6.7 mm Hg).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "GFR in the nephrotic stage was significantly lower than in remission and in controls, and was lowest at onset of the disease (84 +/- 6, 111 +/- 4, and 119 +/- 2 ml/min per 1.73 m2).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Halving of uEGF/Cr was associated with a decrease in eGFR slope of 2.0 ml/min per 1.73 m uEGF/Cr may be a useful noninvasive biomarker that can assist in predicting the long-term course of kidney function in children with incident nephrotic syndrome.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Children showed relatively preserved mean kidney function at disease onset (eGFR >100 ml/min per 1.73 m Kidney outcomes were poor in genetic nephrotic syndrome; in FSGS, outcomes were strongly associated with the proteinuria level.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "After acute occlusion of the left anterior descending coronary artery (LAD) in 26 anesthetized open-chest pigs, minimal collateral blood flow was indicated by retrograde flow (0.2 +/- 0.1 ml/min) and microsphere-myocardial blood flow (0.005 +/- 0.001 ml X min-1g-1).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "In an open-label, randomized clinical trial, we included patients aged 18-80 on maximal tolerated ACE inhibitor or angiotensin receptor blocker with eGFR 25-45 mL/min/1,73 m Twenty patients (10 per group) with a mean mGFR of 34 mL/min/1,73 m The combination of finerenone and dapagliflozin was safe and significantly reduced albuminuria.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "CO was 12.06 ± 4.05 ml/min in juveniles vs 29.71 ± 10.13 ml/min in adults, ρ < 0.001.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "With far-advanced chronic renal failure (creatinine clearance [CCr] < 15 to 20 ml/min), when many of these patients are seen by nephrologists, the use of diets very low in protein, and hence also very low in phosphorus content, combined with calcium-containing phosphate binders, have been shown to lower serum intact PTH levels and improve the osseous pathology.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "In less-advanced renal insufficiency (CCr, 25 to 60 ml/min), the active vitamin D sterols calcitriol or alfacalcidol [1 alpha-hydroxyvitamin D3] have been shown to ameliorate the skeletal lesions of renal osteodystrophy.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Other data support the greater likelihood of having normal bone if treatment is initiated when CCr exceeds 25 ml/min.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The optimal benefits may be obtained if this treatment is started early in the course of renal insufficiency (CCr in the range of 25 to 60 ml/min).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "LN patients had a mean initial estimated glomerular filtration rate (eGFR) of 69 mL/min.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The mean initial eGFR for 1o FSGS was 33 mL/min, and it did not improve, and only 2 of 5 had partial resolution of proteinuria.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "In the study group, GFR decreased within 12 months from 136 +/- 19 to 120 +/- 31, to 114 +/- 14 ml/min per 1.73 m(2) at latest follow-up (p < 0.0001).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "In the control group, GFR dropped within 3 months, from 137 +/- 27 to 130 +/- 24, to 126 +/- 19 ml/min per 1.73 m(2) at latest follow-up (p = 0.1).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "A randomised controlled multicentre non-inferior unblinded trial including 96 adult, incident patients with biopsy-proven MCN, albuminuria > 3 g/day, and an estimated glomerular filtration rate (eGFR) > 30 ml/min from renal departments in Denmark.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "A hyperfiltration subgroup (n=11) with creatinine clearance (Ccr) of > 150 mL/min/1.73 m2 was formed.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "This discrepancy was particularly evident in subjects with Ccr below 120 mL/min/1.73 m2.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Distal (poststenotic) coronary blood flow at baseline was 47 +/- 23 ml/min and 57 +/- 38 ml/min during hyperemia.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "After PTCRA, coronary blood flow increased to 104 +/- 59 ml/min and to 132 +/- 73 ml/min with hyperemia.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "After adjunctive angioplasty, coronary blood flow was 84 +/- 40 ml/min (p=not significant [NS] vs PTCRA) and increased to 143 +/- 81 ml/min with hyperemia (p=NS vs PTCRA).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The poststenotic coronary flow reserve increased from an initial value of 1.1 +/- 0.2 ml/min to 1.3 +/- 0.3 ml/min after PTCRA (p=NS vs baseline) and to 1.6 +/- 0.3 ml/min after adjunctive balloon angioplasty (p<0.01 vs p=NS vs PTCRA).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Oral cysteamine lowered leukocyte cystine over 80%, and in patients before transplant, improved growth and preserved renal function (mean creatinine clearance [+/- SE], 0.64 +/- 0.04 mL/s.1.73 m2 [38.5 +/- 2.5 mL/min.1.73 m2] in the cysteamine group compared with 0.50 +/- 0.03 mL/s.1.73 m2 [29.7 +/- 2.0 mL/min.1.73 m2] in controls; 95% CI for the difference, 1.8 to 15.8).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "CIT clearance correlated well with GFR above 50 ml/min/1.73 m2.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "At lower levels, percent tubular reabsorption of CIT decreased rapidly, reaching levels between 17% and 41% at GFR less than 10 ml/min/1.73 m2; this disproportionate fall might be related to reduced renal CIT utilization at a relatively early stage of renal insufficiency.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Mean eGFR values remained stable with a median of 67 ml/min/1.73 m In this single-center cohort, the switch from IR- to ER-cysteamine was safe and effective over the short term and provided advantages in terms of frequency of administration and less halitosis/bad breath.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Eras 2 and 3 had lower risk of acute rejection (aHR 2 vs 1:0.45; P < .001) (aHR 3 vs 1:0.26; P < .001) and higher 5-year mean GFR (difference 2 vs 1:9.2 mL/min/1.73 m",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Additionally, estimated glomerular filtration rate increased from 55.93 ± 22.43 ml/min/1.73 m",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Median creatinine clearance was 48 ml/min/1.73 m2 (range 21 - 61).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Creatinine clearance decreased from median 48 - 45 ml/min/1.73 m2 (p < 0.05) and returned to previous values after discontinuation of enalapril.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "After pregnancy, one patient reached end-stage renal disease, but she already had advanced CKD before pregnancy (creatinine 239 μmol/L, eGFR 23 ml/min/1.73 m",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "In terms of renal function at T0 and T1, serum creatinine levels (1.1 ± 0.5 vs. 0.9 ± 0.5 mg/dL, respectively; p < 0.0001), creatinine clearance (69.7 ± 32.2 vs. T1 = 78.5 ± 33.9 mL/min/1.73 m(2), respectively; p = 0.006), and cystatin c level (1.33 ± 0.53 vs. 1.15 ± 0.54 mg/l, respectively; p = 0.0057) were all significantly different at these two time points.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Urinary volume, protein excretion, and coagulation markers were collected to determine the glomerular filtration rate (GFR) >50 ml/min/1.73 m2, <20 ml/min/1.73 m2, before and after starting dialysis.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Sixteen (32%) developed an eGFR <90 ml/min/1.73 m Primary tubulopathies are a heterogeneous group of diseases that cause growth impairment, largely reversible with treatment, risk of eGFR reduction and significant extrarenal complications derived or associated.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Prepubertal growth rates were stable in a range between -2 and -3 height velocity SDS as long as glomerular filtration rate was above 20ml/min per 1.73m2.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The patient's estimated glomerular filtration rate was 66.8 mL/min/1.73 m Even if no ophthalmological abnormalities are present, nephropathic juvenile cystinosis should be suspected in children with Fanconi syndrome.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Children whose estimated or measured glomerular filtration rate (GFR) was less than 30 mL/min/1.73 m2 or who had received a kidney transplant were excluded.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The mean estimated glomerular filtration rate (eGFR) was 82.31 ± 37.45 ml/min/1.73m Glomerulonephritis may be a frequent finding in addition to the well-known tubular dysfunction in patients with cystinosis.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The mean creatinine clearance declined over the years from 76 to 45 ml/min/1.73 m2, and the incidence of hypertension increased to more than 80% of the patients.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "GFR ranged between 4-95 mL/min/1.73 m².",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Second, a generalized additive mixed model (GAMM) was applied showing that patients with initiation of treatment before 2 months of age are expected to have a 34 ml/min/1.73 m",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "For the non-transplanted patients, the mean estimated glomerular filtration rate (eGFR) change/year was more pronounced during ER-treatment (- 3.39 versus - 6.80 ml/min/1.73 m The results from this long-term retrospective study indicate that switching from IR- to ER-cysteamine was feasible and well tolerated under routine clinical practice.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "At the last follow-up (median 46.5 months; IQR, 23.2-98.2), 5 patients had persistent mild proteinuria; no patients had estimated glomerular filtration rate < 90 mL/min/1.73 m Japanese childhood HSPN cases with moderate severity had good outcomes without need for corticosteroids or immunosuppressants, when prescribed RAS inhibitor treatment.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Renal function on admission was decreased: serum creatinine was 1.5 mg/dl and creatinine clearance, 21 ml/min.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Following recent experimental data suggesting an aggravating effect of circulating proinflammatory cytokines on the histological lesions of IgAN, we studied changes in serum proinflammatory cytokines and their soluble receptors and antagonists in patients treated with polyvalent immunoglobulins (15 with severe nephropathy who had indicators of poor prognosis: heavy proteinuria, hypertension, altered renal function and Lee's histological grade III or IV; and 14 with moderate forms of IgAN who had permanent albuminuria > 300 mg/day and < 2000 mg/day, Lee's histological grade II and a glomerular filtration rate > 70 ml/min) in comparison with healthy controls (n = 20) and patients with non-IgA nephritides (n = 50).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Initial clinical features included: oedema (24/30), hypertension (19/30), gross haematuria (15/30), oliguria (15/30) and a decreased glomerular filtration rate (GFR less than 30 ml/min per 1.73 m2) (22/30).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "On follow-up, 3 patients were dead, 1 was lost to follow-up, 12 were on dialysis/transplant programmes, 4 had a GFR of less than 30 and 10 a GFR of more than 30 ml/min per 1.73 m2.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "We assessed independence and interactions using general linear models and repeated measures analyses and compared levels with subjects with active focal and segmental glomerulosclerosis, ANCA-associated vasculitis, and membranous and IgA nephropathies ( The diabetic cohort had an initial GFR of 25 ± 9 ml/min per 1.73 m Urinary MAC is present in patients with overt DN at levels comparable to autoimmune glomerulonephritis and correlates with the GFR decline, supporting that complement activation and its measurement are clinically relevant in DN.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The decrease in glomerular filtration rate was greatly slowed or stopped (median rate of decline in glomerular filtration before, -3.78 mL/min per month; after, 0 mL/min per month).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Glomerulonephritis was more severe at baseline in males than in females, with a lower median estimated glomerular filtration rate (eGFR) [90 (IQR 59-105) vs 97 ml/min/1.73 m2 (76-116), P = 0.015] and increased median proteinuria (0.84 vs 0.58 g/day, P = 0.01).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "One treated patient, not biopsied due to extreme obesity, had a creatinine clearance of 49 ml/min/1.73 m2 and proteinuria of 21.3 g/24 h. These 21 patients were initially treated with azathioprine and daily oral prednisone (13 patients) or i.v.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Over the course of follow-up, 19 treated patients showed a decline in hematuria (> 5 red blood cells/high power field) from 100% to 16% (p < 0.01), a fall in the serum creatinine from 1.71 +/- 2.20 to 0.78 +/- 0.25 mg/dl (p < 0.01), an increase in creatinine clearance from 76 +/- 43 to 122 +/- 26 ml/min/1.73 m2 (p < 0.01), and a reduction in proteinuria from 8.8 +/- 7.5 to 0.47 +/- 0.39 g/24 h (p < 0.01).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "All patients had nephrotic-range proteinuria (4.9 +/- 2.5 g/m2/d, mean +/- SD) and decreased glomerular filtration rate (GFR) (46.5 +/- 9.5 mL/min/1.73 m2) at the time of the initiation of PP.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "All five patients treated promptly with high-dose immunosuppressant had normal estimated glomerular filtration rate (eGFR) (median 159 ml/min/1.73 m(2)) at follow-up.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The average predicted time to eGFR <15 ml/min per 1.73 m Proteinuria trajectory is a major predictor of disease progression in patients with IgA nephropathy.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Median initial proteinuria was 330 mg/mmol, albuminemia 32 g/l, and eGFR 110 ml/min/1.73 m Of children with IgAVN, 30% present a persistent renal disease at the end of a 3-year follow-up.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Renal insufficiency was defined as an estimated glomerular filtration rate <60 ml/minute.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Children had better kidney function than adults at diagnosis (estimated glomerular filtration rate of 90-128 vs 50-88 ml/min/1.73 m Most studies were retrospective and observational, with limited data on children and disease mechanisms.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Les enfants avaient une meilleure fonction rénale que les adultes au moment du diagnostic (DFGe: 90 à 128 ml/min/1,73 m La plupart des études examinées étaient rétrospectives et observationnelles, avec des données limitées chez les enfants et sur les mécanismes de la maladie.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The estimated glomerular filtration rate (eGFR) (Schwartz formula) for this child improved from 81 to 130 ml/min/1.73 m(2) post-treatment.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Median creatinine clearances improved from 29 ml/min/1.73 m(2) (p<0.01) pre-treatment to 62 ml/min/1.73 m(2) (p<0.01) immediately following TPE and 69 ml/min/1.73 m(2) at 2 months post-TPE (p<0.01).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "14.1% of the children presented with nephrotic syndrome, 50% had an eGFR below 90 ml/min/1.73 m In most patients with IgAVN proteinuria decreases slowly and kidney function improves, but full remission is reached only in a minority after 6 months.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "There were 11 patients with an estimated glomerular filtration rate below 90 ml/min/1.73 m A large proportion of patients continued to show signs of CKD at last follow-up while only a small proportion developed stage 5 CKD.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Lower eGFR, higher urinary protein-creatinine ratio (UPCR), and lower serum albumin levels at enrollment were associated with higher risk of first CV and TE event (eGFR per 10 mL/min/1.73 m Age of cohort, duration of follow-up.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Factors associated with having non-DKD on biopsy were having no retinopathy (vs retinopathy) (adjusted odds ratio [aOR], 3.98; 95% CI, 2.69-5.90), lower A1c levels (<7% vs ≥7%) (aOR, 3.08; 95% CI, 2.16-4.39), higher estimated glomerular filtration rate (≥60 vs <60 mL/min/1.73 m Selection bias of clinically indicated biopsies, not protocol biopsies, which likely represent a ceiling (maximum) for non-DKD.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Thirty-two percent of the patients showed renal insufficiency (Creatinine clearance [CrCl] <50 ml/min), usually associated with proteinuria (99%) and/or hematuria (93%).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Regarding renal function, 11% of patients reached end-stage renal failure, 13% exhibited severe renal failure (CrCl <30 ml/min), and 14% moderate renal insufficiency (CrCl <50 ml/min).",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "LN patients had a mean initial estimated glomerular filtration rate (eGFR) of 69 mL/min.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "The mean initial eGFR for 1o FSGS was 33 mL/min, and it did not improve, and only 2 of 5 had partial resolution of proteinuria.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "Eligibility criteria in the study were Lee histological stage I, II or III, albuminuria between 300 and 2,000 mg/day and a glomerular filtration rate > 70 ml/min/1.73 m2.",
      "entity": "GFR (Glomerular Filtration Rate)"
    },
    {
      "sentence": "(1) Complete remission (proteinuria < or = 0.1 g/d or negative by dipstick for 3 consecutive days), partial remission (proteinuria between 0.1 g/d and 50 mg/(kg.d), serum albumin > or = 30 g/L) and resistance to CsA (proteinuria > or = 50 mg/(kg.d), or > or = 3+ by dipstick, after 6 months of CsA treatment over a trough level of 100 microg/L) were observed in 65%, 20% and 15%, respectively.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Clinical, laboratory and renal biopsy data on 50 adult patients investigated in Jamaica because of proteinuria of more than 1 g/day were reviewed.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Proteinuria > 3g/d is diagnostic for a glomerular damage.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "After his admission, he was administered prednisolone (PSL) at 40 mg/day, and a percutaneous renal biopsy was performed.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Due to the occurrence of mild hematuria (5-9/HPF), proteinuria (0.9 g/day) and an increased serum creatinine level (1.31 mg/dL), a renal biopsy was performed.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Four weeks later, her leg edema had increased considerably and urinary protein had increased to 12.4 g/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "We enrolled adult patients with proteinuria > 3.5 g/day despite the use of renin-angiotensin-aldosterone blockade.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "We also explored urinary protein levels in 3 other patients with dysferlinopathy and found microalbuminuria with albumin excretion of 0.14 to 0.18 g/d in 2 patients.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "All patients had active axial disease (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) >/=30/100) and C reactive protein (CRP) >/=10 mg/l, despite adequate treatment.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "A laboratory experiment was performed to examine the individual and combined effects of leachates from the invasive plant European buckthorn (Rhamnus cathartica, L.) and a triclopyr herbicide (Renovate® 3; 0.21 mg/L), which is commonly used to manage R. cathartica, on northern leopard frog (Lithobates pipiens, Schreber) tadpoles at 2 temperature regimes (20 and 25 °C).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Multivariate analysis revealed that serum immunoglobulin A >3.45 g/L and immunoglobulin G >9.06 g/L were risk factors for the occurrence of IgAN.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The random urine protein/creatinine ratio was 10 mg/mg.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "DIAGNOSTIC, TREATMENT AND COURSE: The blood level of albumin was very low, urine analysis showed proteinuria of > 8 g/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "A urine protein concentration of 4.4 g/day was observed, and she was diagnosed with minimal change nephrotic syndrome (MCNS) after kidney biopsy.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "She was prescribed 40 mg/day of prednisolone (PSL) and achieved remission.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "However, MCNS recurred when PSL was tapered to 10 mg/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Her oral PSL dose was increased to 30 mg/day, but she did not achieve remission.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Dose-response analysis indicated that 0.75 mg/day atrasentan is expected to be optimal for renoprotection, with maximal albuminuria reduction and minimal fluid retention events.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Compared with other types and doses, atrasentan 0.75 mg/day is the most promising, with maximal albuminuria reduction and minimal fluid retention.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Her proteinuria was 0.693 g/day on day 350 and she achieved incomplete remission type I.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "TAC was initiated with a dose of 0.10 mg/kg/day, and the dose was increased to attain a trough level of 5.0-10.0 g/l.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The mean urine spot protein/creatinine ratios were significantly lower (0.33 +/- 0.58 vs. 13.5 +/- 21.9 mg/mg, p = 0.002) and the mean serum albumin levels were significantly higher (3.92 +/- 0.35 g/dl vs. 2.39 +/- 0.56 g/dl, p = 0.00005), as compared to those prior to starting TAC.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "They have defined the minimum change criteria of ≧25% with an absolute change of no <5g/L for either minimal response or progression.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "CVa of low (5.6g/L) and high (32.2g/L) concentration monoclonal proteins were 3.1% and 22.2%, respectively.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Mean urinary protein excretion was 9.32 g/day and mean serum albumin was 1.8 g/dL.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The median concentration of serum CRP was significantly higher in the CAN versus the control patients (13.1 +/- 3.9 mg/L versus 3.5 +/- 2.5 mg/L; P = 0.01).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Her serum creatinine was 46 µmol/L (0.48 mg/dL), serum albumin 14 g/L (1.4 g/dL) and 24-h urinary protein 9.79 g/day with no haematuria.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Treatment with prednisone (20 mg/day), cyclosporine (50 mg/day), and anticoagulant therapy with edoxaban tosylate hydrate led to the complete resolution of nephrotic syndrome after 4 weeks.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Twenty patients were treated orally with 2 mg/d micronized 17 beta-estradiol and 20 patients with placebo for 6 weeks.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "A total of 1059 patients were randomized to sucroferric oxyhydroxide 1.0-3.0 g/day (n = 710) or sevelamer carbonate ('sevelamer') 2.4-14.4 g/day (n = 349) for up to 52 weeks.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "There were small, but significantly greater increases in mean transferrin saturation (TSAT) and haemoglobin levels with sucroferric oxyhydroxide versus sevelamer during the first 24 weeks (change in TSAT: +4.6% versus +0.6%, P = 0.003; change in haemoglobin: +1.6 g/L versus -1.1 g/L, P = 0.037).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Following treatment with prednisolone, the level of proteinuria decreased to 0.29 g/day by day 35.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Participants were randomized 1:1:1 to placebo, inulin 16 g/day, or inulin 32 g/day which were given for seven days.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Primary outcomes were first remission of proteinuria defined by urinary protein (UP) <0.3 g/day, UP/creatinine ratio (UPCR) <0.3, and/or negative/trace by dipstick test and first relapse of proteinuria defined by UP ≥1.0 g/day, UPCR ≥1.0, and/or dipstick test ≥1+ followed by immunosuppressive therapy.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Ten days after starting prednisolone (60 mg/day), proteinuria was negative.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Laboratory findings showed hypoalbuminemia (20 g/L), elevated urine albumin/creatinine ratio (668 mg/mmol), and elevated creatinine of 116 µmol/L from a baseline of 79 µmol/L.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "We observed statistically significant differences in age (43 [27, 59] years vs. 28 [20, 44] years, Z = 5.487, P < 0.001), male (78.0% vs. 51.4%, χ2 = 22.470, P < 0.001), serum albumin (19.9 ± 6.1 g/L vs. 21.5 ± 5.7 g/L, t = 2.376, P = 0.018), serum creatinine (129.5 [105.7, 171.1] μmol/L vs. 69.7 [57.7, 81.9] μmol/L, Z = 14.190, P < 0.001), serum urea (10.1 [6.2, 15.8] mmol/L vs. 4.7 [3.6, 6.4] mmol/L, Z = 10.545, P < 0.001), IgE (266.0 [86.7, 963.0] IU/ml vs. 142.0 [35.3, 516.5] IU/ml, Z = 2.742, P = 0.007), history of diabetes (6.4% vs. 1.2%, P = 0.009), and history of hypertension (23.9% vs. 5.1%, χ2 = 28.238, P < 0.001) between the AKI group and the non-AKI group.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Urinary CD80 was detectable in 30/61 (49.2%) patients, who presented with a higher level of proteinuria (10.7 vs. 5.8 g/24h;  The elevated urinary CD80 is associated with mild pathological change and steroid-dependent cases of primary FSGS adults, which indicates these patients are more similar to minimal change disease (MCD) in clinicopathological features.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In this study, we aimed to investigate the antiproteinuric effect and tolerability of low-dose valsartan (an angiotensin II receptor blocker) therapy in normotensive IgAN patients with minimal proteinuria of less than 0.5 to 1.0 g/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Normotensive IgAN patients, who had persistent proteinuria with a spot urine protein-to-creatinine ratio of 0.3 to 1.0 mg/mg creatinine, were recruited from five hospitals and randomly assigned to either 40 mg of valsartan as the low-dose group or 80 mg of valsartan as the regular-dose group.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Her initial serum albumin level was 12 g/L, and a 24-hour urine protein output was quantified at 8.14 g/day; she was diagnosed as having nephrotic syndrome.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Primary outcomes were defined as complete remission (CR, proteinuria <0.3 g/d) or partial remission (PR, proteinuria <3.5 g/d with a ≥50% reduction).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Then, excluding patients with a 24-h urinary total protein less than 0.5 g/day, incomplete clinical data, or less than the six-month follow-up, we included 184 cases of non-MCD-IgAN and 98 cases of MCD-IgAN.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Mean serum creatinine was 2.0 +/- 0.2 mg/dl and mean protein excretion was 6.1 +/- 1.0 g/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "She achieved complete remission the next day and did not experience a relapse upon receiving the second mRNA-1273 dose 56 days after the first, under treatment with 35 mg/day of oral prednisolone.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "To assess the association between steroid dose used for relapse and subsequent outcomes, data of patients with tapered prednisolone (PSL) dosage to <10 mg/day before the first relapse in whom the dose was subsequently increased to ≥10 mg/day were extracted and assigned to the High-PSL or Low-PSL groups, based on the median dose of 20 mg/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "A multivariate Cox proportional hazard model revealed that the hazard ratios adjusted with propensity score for the second relapse were 0.94 (High-PSL vs. Low-PSL; 95% confidence interval, 0.42-2.10; P = 0.88) and 0.82 (PSL dose per 10 mg/day; 95% confidence interval, 0.58-1.16; P = 0.25).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Among patients in CR with PSL dose <10 mg/day, higher steroid dose (PSL >20 mg/day) was not associated with favorable outcomes after the first relapse as compared to lower dose (10-20 mg/day).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Twenty-six patients, 17 males (before study start Hb 113+/-6 g/l) and nine females (Hb 111+/-8 g/l), with end-stage renal disease were included.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "After 3 months of rHuEpo therapy Hb levels reached 136+/-14 g/l for males and 128+/-13 g/l for females, and after 1 year 142+/-11 g/l and 126+/-14 g/l respectively.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Inflammatory markers also showed favorable outcomes in Group A, with a decrease of 1.2 mg/L in CRP levels and 20% reduction in IL-6 levels.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Combined MMF and prednisone therapy was used for 6 months with an initial MMF dose of 1.0-2.0 g/day and a prednisone dose of 20-60 mg/day; both drugs were tapered gradually.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The introduction of mycophenolate mofetil (500-15,000 mg/day) was followed by a sustained complete remission in both cases, without secondary effects.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "A third trial has demonstrated that the combined use of cyclophosphamide (100 mg/day) and prednisone (30 mg/day) over several months was superior to the use of prednisone alone (40 mg/day) in improving the long-term prognosis of diffuse-proliferative lupus nephritis (type IV, WHO).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Twelve patients were treated with corticosteroids (CS) at a dose ranging from 40 to 90 mg/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Laboratory findings revealed proteinuria (over 10 g/day), hypoalbuminemia, hyperlipidemia and renal dysfunction.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Three weeks after the initiation of steroid therapy, the proteinuria was improved to less than 1.0 g/day and renal function returned to within the normal range.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In early December 2005, the patient developed edema of the right leg, was admitted to a local general hospital, and was diagnosed as having a relapse of MCNS based on massive proteinuria (urine protein 6.1 g/day).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "With recombinant activated FVII, hemostasis was obtained and prednisolone administration 60 mg/day (1 mg/kg) was started.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "After informed consent, all patients received enalapril starting with 5 mg/day, progressively increased to 20 mg/day, if necessary, in order to maintain the hematocrit below 45%.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The patient had no proteinuria before the anti-tuberculosis agents were started, but urine tests upon admission showed heavy proteinuria with a 24-h urinary protein of 9.2 g/day, and serum creatinine, albumin, and total cholesterol levels were 1.36 mg/dL, 2.40 g/dL, and 283 mg/dL, respectively.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The initial dose of LEF was 10 - 20 mg/day combined with prednisone 0.25 - 1.0 mg/kg/day, gradually tapering after 8 weeks.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Compared LEF therapy with PRED monotherapy (n = 16), the dose of prednisone to maintain remission was reduced (from median 22.5 mg/day to median 7.5 mg/day, p = 0.041); relapse rate during the follow-up decreased from 100% to 31.3% (p = 0.002); the median time before relapse increased from 20.3 weeks to 32.5 weeks.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Compared LEF therapy with CTX therapy (n = 12), the dose of prednisone to maintain remission was reduced significantly (from median 22.5 mg/day to median 5.0 mg/day, p = 0.003); relapse rate during the follow-up decreased from 100% to 31.3% (p = 0.001); the median time before relapse increased from 11.7 weeks to 32.5 weeks.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Experiment 2 involved 4 multiparous mid-lactation Holstein-Friesian cows in a 4 × 4 Latin square design experiment, with 28-d periods, to investigate the effect of incremental dietary inclusion (0, 271, 617, and 814 g/d supplemental oil) of WPG on milk production, composition, and FA concentration in the last week of each period.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "This study was conducted to investigate the possibility of categorizing NERD patients according to symptom types and response to acid-suppressive drug rabeprazole (RPZ) 10 mg/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "On admission, the patient had normal serum creatinine with 24-h urinary protein excretion of 4.1 g/day and severe hypoalbuminemia.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Nephrotic syndrom is an association of proteinuria>3g/d or 50mg/kg/d, an hypoalbuminemia<30g/L and a hypoproteinemia<60g/L.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In every case, anticoagulation course must be completed and maintained in case of patent nephrotic syndrom with an albuminemia under 20g/L.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Starting doses of MF were 2000 mg/day for mofetil MF (1500 mg/day in one patient) or 1440 mg/day for sodium MF.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The initial prednisone (PDN) dose was 10 mg/day in 14 patients, 5 mg/day in two patients and no steroids in one patient.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In the remaining 12 patients, moderate initial doses of PDN were administered (mean: 23.7 mg/day, range: 15-40), tapering to 10 mg/day after 1 month.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In this open-label study, 100 patients with AD and MRI confirmed svCVD received 9.5mg/24 hours Rivastigmine transdermal treatment for 24 weeks.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The patient was started on high-dose prednisone at 60 mg/day, with subsequent addition of mycophenolate mofetil and ACEI, while prednisone was gradually tapered.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Proteinuria response was assessed as percent reduction from baseline and percent of patients meeting complete remission (final proteinuria <500 mg/d), partial remission (≥50 % reduction in proteinuria from baseline and final proteinuria 500-3500 mg/d), clinical response (≥30 % reduction in proteinuria from baseline that did not meet criteria for complete or partial remission), and no response (failed to meet remission or clinical response criteria) following Acthar gel therapy.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Secondary outcome measures included relapse rates (>1+ albuminuria on dipstick urinalysis on 3 consecutive days), alanine aminotransferase (ALT) elevations (>50 U/L), use of lamivudine 100 mg/d (added if HBV DNA titers reached >or=10(5) copies/mL), and adverse effects.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Because of the participation of iron in biological systems to generate hydroxyl radical, we also examined the effect of deferoxamine (DFO, 30 mg/day), an iron chelator, on the PAN-induced proteinuria.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "C4a mean levels were merely lower in patients (153.67 ± 18.69 mg/L) than that in the controls (157.25 ± 11.40 mg/L) with no statistical significance (P = 0.378).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "When comparing significant fibrosis (Ishak score ≥ 3) vs other stages, C4a was significantly lower in F3 compared to other fibrosis scores (143.55 ± 2.33 mg/L vs 155.26 ± 19.64 mg/L; P = 0.047) and at a cutoff value of less than 144.01 mg/L, C4a could discriminate F3 with 76.9% sensitivity and 75% specificity from other stages of fibrosis.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Data from 3 similarly designed, 3-month placebo-controlled, clinical treatment trials of pregabalin 300, 450, and 600 mg/day in patients with FM were modeled to estimate the change in the mean FIQ total and stiffness items corresponding to each category on the Patient Global Impression of Change.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Oral corticosteroid therapy could be discontinued in 81.3% of cases of the childhood-onset group (26/32 cases) and in 70.6% of cases of the adult-onset group (12/17 cases); the oral corticosteroid dose was reduced significantly to 0.9 ± 2.5 mg/day in the childhood-onset group and to 0.8 ± 1.6 mg/day in the adult-onset group (P < .001).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Cyclosporin treatment was also discontinued in 87.5% of cases in the childhood-onset group (21/24 cases) and in 80.0% of cases of the adult-onset group (15/21 cases); the oral cyclosporin dose was reduced significantly to 8.6 ± 27.4 mg/day and 9.2 ± 22.0 mg/day, respectively (P < .001).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Her myasthenic symptoms improved with immunosuppressive treatment using corticosteroid(100 mg/day) and azathioprine(100 mg/day).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "However she presented edema with massive proteinuria(7.54 g/day) and was admitted to our hospital on July 1997.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "After pulse therapy with methylprednisolone(1 g/day x 3 days) following oral administration of prednisolone(60 mg/day), proteinuria disappeared after one month.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Five groups were studied: (a) preproteinuric PAN, 4 days after PA (mean 4.5 +/- 1.5 mg of urinary protein/24 hours); (b) proteinuric PAN, 10 days after PA (mean 128 +/- 9.6 mg/24 hours); (c) recovery from PAN (mean 12.5 +/- 1.5 mg/24 hours); (d) protein-overload proteinuria, induced by injecting albumin intraperitoneally (mean 211 +/- 15.9 mg/24 hours); and (e) saline-injected controls (mean 1.2 +/- 0.2 mg/24 hours).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Patients (N = 206) were randomly assigned to receive either placebo or fixed-dose olanzapine (5, 10, or 15 mg/day) for up to 6 weeks.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The risk for a child to carry penicillin-resistant S. pneumoniae (MIC > or = 0.125 mg/l) did not increase after antibiotic treatment: 84 of 364 (23.1%) before, 70 of 364 (19.2%) after.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Enoxaparin (40 mg/d SC for 1 month) following successful angioplasty did not reduce the incidence of angiographic restenosis or the occurrence of clinical events over 6 months.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The study comprised 106 patients with advanced carcinoma of the prostate (89 with T3/4 M1 and 17 with T3/4 N0/1 M0) who were treated with 1 mg/day of DES.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In a few patients it was possible to reduce the dose to 0.5 mg/day DES; in others, the initial response was not sustained and they were treated with an increased dose of DES or bilateral orchidectomy.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Seventy patients (Group 1) showed a sustained response to 1 mg/day of DES (0.5 mg/day in three) and 50 remained in remission at a mean of 21 months of treatment.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Low-dose oestrogen therapy (1 mg/day of DES) is cheap, effective and caused few side-effects, none of which was life-threatening.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "New relapses have been prevented with cyclosporine therapy in a dose of 3,8 mg/kg bw/day associated to prednisone 10 mg/day during eighteen months.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "methylprednisolone pulses (1.0 g per single dose, average total 1.0 g/20 kg given alternate days) followed by oral prednisone 20 to 25 mg/day and six monthly i.v.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "cyclophosphamide 0.6 g/l m2/month.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Combined treatment with prednisone (1 mg/kg), rifampicin (600 mg/day), and doxycycline (200 mg/day) was initiated.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Two weeks after complete remission, we tapered the steroid to a maintenance dose of 5-7.5 mg/d in both groups until 24 weeks after study drug initiation.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The primary end point was complete remission within 8 weeks (urine protein: creatinine ratio <0.2 g/g).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Secondary end points included time until remission and relapse rates (proteinuria and urine protein: creatinine ratio >3.0 g/g) after complete remission to within 24 weeks of study drug initiation.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Optimized supportive care aiming to maintain proteinuria <1 g/day is preferred in the typical patient presenting with microhematuria, significant but nonnephrotic proteinuria, hypertension, and variable degrees of renal failure.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Compared with normal controls (n = 20), mean +/- SD of urinary OPN in IgAN patients was decreased significantly (21.4 +/- 6.2 versus 11.6 +/- 9.6 mg/g creatinine, P: < 0.001).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "For example older age at onset, male sex, very heavy proteinuria (greater than 10 g/d), sustained hypertension, impaired renal function, and significant chronic tubulointerstitial lesions in the initial renal biopsy all portend an unfavorable outcome.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "We retrospectively analyzed 265 patients with proteinuria > 0.15 g/g·Cr who visited Ehime University Hospital between January 2014 and April 2024.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Diagnostic performance for minimal change disease (MCD) in patients with nephrotic-range proteinuria (≥ 3.5 g/g·Cr) was evaluated using ROC curves, and AUCs were compared using DeLong's test.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "SI (Alb) strongly correlated with SI (Tf) in patients with proteinuria ≥ 3.5 and < 3.5 g/g·Cr.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In this single-center, double-blind trial, patients with CM received either onabotulinumtoxinA, maximum 200 units (U) at baseline and month 3 (100 U fixed-site and 100 U follow-the-pain), plus an oral placebo, or topiramate, 4-week titration to 100 mg/day with option for additional 4-week titration to 200 mg/day, plus placebo saline injections.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The probands were either heterozygous or compound heterozygous for SGLT2 mutations, and had glucosuria quantified at 6-27 g/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "5-ASA was discontinued, AZA was reduced and a rapid remission of the nephrotic syndrome was observed after 6 weeks of steroid therapy (1 mg/kg/day per os) associated with ramipril 5 mg/day, with a follow-up of 9 months.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In 1979, she was admitted to Kanazawa University Hospital due to MCNS verified by renal biopsy and was treated with oral prednisolone(initially 40 mg/day) for two years.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "She was treated with the combination of methylprednisolone pulse therapy(500 mg, 3 days), oral prednisolone(20 mg/day) and cyclosporin(CyA, 3 mg/kg/day), which could induce earlier complete remission.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Hypoalbuminemia combined with nephrotic-range proteinuria (serum albumin ≤2.5 g/dl and urinary protein-creatinine ratio >3.5 mg/mg), compared with serum albumin >2.5 g/dl and urinary protein-creatinine ratio ≤3.5 mg/mg, was associated with higher risk of time to first infection (adjusted hazard ratio, 2.49; 95% CI, 1.51 to 4.12).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Patients were randomly assigned at a 1:1 ratio to degarelix (240-80-80 mg) + apalutamide (240 mg/d) versus degarelix + matching placebo for 3 mo followed by RP.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Nephrotic range proteinuria (3-76 g/d) developed immediately or shortly after transplantation (within 4 months for all reported cases, except for one at 24 months).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "After admission, the proteinuria decreased to 0.06 g/gCr with rest and sodium restriction (6 g/day) alone; a complete remission from nephrotic syndrome was observed at approximately 2 weeks after the onset of symptoms.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In patients with mild IgA glomerulonephritis, OPN mRNA expression in proximal tubules increased exponentially in response to a small amount of urinary protein (<1.2 g/d).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Corticosteroid therapy can be discussed in patients with proteinuria greater than 1 g/day without renal failure.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The intervention group was administrated 40 mg/day of FHP for 8 weeks.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "A total of 120 chronic kidney disease (CKD) stage 5 patients on HD and with the serum phosphorus level >2.1 mmol/l were randomized to receive double-blind treatment with either 3, 6 and 9 g/day MCI-196 or placebo for 3 weeks.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Serum phosphorous decreased in all three treatment groups (-0.038, -0.268 and -0.257 mmol/l in the 3, 6 and 9 g/day groups, respectively).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The difference between treatment and placebo groups was significant for the 6 and 9 g/day groups (P < 0.05 in both cases).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "However, calcium-phosphorus product (Ca x P) was significantly reduced in the 6 and 9 g/day groups P < 0.05).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "MCI-196 at all doses decreased serum intact PTH between baseline and endpoint, and differences between treatment groups and placebo were statistically significant for the 3 and 9 g/day groups (P < 0.02 in both cases).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "When massive proteinuria (10.4 g/day) was found, she was admitted to our ward.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The PAs were significantly correlated with nephrotic syndrome (NS) (P = 0.000) and with the degree of proteinuria, ranging from 8% in patients with proteinuria less than 0.5 g/d to 58% in patients with proteinuria > or = 15.0 g/d (P = 0.001), but 40% of the nephrotic syndrome patients were PA-negative despite values of proteinuria comparable to those of PA-positive patients, suggesting that the presence of PAs is not simply related to protein loss, but probably to some other unidentified factor or lesion.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Patients presented either nephrotic syndrome (n=25) or mild proteinuria (<1g/24h, n=12).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Lp(a) in MCD patients did not differ from that controls (101 +/- 102 and 90 +/- 115 mg/L) and correlated positively with total daily urinary protein loss (r = 0.7962, P less than 0.05).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In contrast, the patients with membranoproliferative glomerulonephritis had significantly higher Lp(a) values than the controls (219 +/- 222 mg/L), and Lp(a) concentrations correlated negatively with the daily protein loss in urine (r = -0.6545, P less than 0.05).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Patients with relapsing-remitting multiple sclerosis commercially prescribed alemtuzumab 12 mg/day on 5 consecutive days (initial course) were enrolled in this prospective, observational study.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In all of the patients studied, depletion of CD19 and CD20 cells was noted, with significant reduction in the degree of proteinuria from 3.7 ± 3.4 g/day at baseline to 1.3 ± 2.0 g/day at 6 months after the drug administration (p = 0.002).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The laboratory findings were as follows: proteinuria 23 g/day, serum albumin 1.9 g/dl, total cholesterol 629 mg/dl, LDL-Cho 1,930 mg/dl.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "He was also given fluvastatin (40 mg/day) for hyperlipidemia after the renal biopsy.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Prednisolone therapy, 60 mg/day, was started and resulted in a full remission within a week and the prednisolone dose was subsequently tapered.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Seven months later, when 10 mg/day of prednisolone was being administered, she developed erythematous rash with photosensitivity and polyarthralgia without exacerbation of the nephrotic syndrome, and fulfilled four of the American College of Rheumatology criteria for classification of systemic lupus erythematosus (SLE).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "To provide further insight into the effect of tamoxifen at low doses on the IGF system, we have correlated the drug serum levels attained after 2 months of either placebo (n = 32), tamoxifen 20 mg/day (n = 26), 10 mg/day (n = 23) or 10 mg/every other day (n = 29) with the changes in IGF-I, Insulin-like Growth Factor-II (IGF-II), Insulin-like Growth Factor Binding Protein-1 (IGFBP-1), Insulin-like Growth Factor Binding Protein-3 (IGFBP-3), and IGF-I/IGFBP-3 ratio.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Compared to placebo or no treatment, it is uncertain whether prebiotics improves indoxyl sulfate at eight weeks (2 studies, 75 participants: SMD -0.14 mg/L, 95% CI -0.60 to 0.31; very low certainty evidence) or microbiota composition because the certainty of the evidence is very low.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Nephrotic syndrome is defined by a triad of clinical features: oedema, substantial proteinuria (> 3.5 g/24 hours) and hypoalbuminaemia (< 30 g/L).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Intravenous steroid therapy of 500 mg/day for 3 days, following oral administration of 15 mg/day prednisolone and 75 mg cyclosporine twice a day was taken from July 2004.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "On July 2005, he went into remission of NS with 0.6 g/day proteinuria.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Sixty Gray radiotherapy diminished the pleural metastatic lesion and also improved proteinuria from 6.6 g/day to 0.4 g/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Cy A in a dose of 3-5 mg/kg/day, reduced proteinuria from 16.85 +/- 6.67 to 3.37 +/- 1.48 g/24 hours (P = 0.008), with an associated increase in serum albumin from 15.2 +/- 2.6 to 34.3 +/- 2.5 g/l (P < 0.001).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The average daily dose of steroid was reduced from 12.5 mg/day pre MMF to 2 mg/day post MMF with a p-value of 0.00229.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The chance of a patient with minimal-change disease, mesangial proliferative glomerulonephritis, or focal-segmental glomerulosclerosis and a pretreatment urRBP level equal to or >1.0 mg/l being resistant to steroid treatment is 30 times that of a patient with a urRBP level <1.0 mg/l and even higher, if we consider the levels obtained during treatment.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Nephrotic syndrome is a known clinical syndrome in which there is increased permeability in the glomerular basement membrane leading to proteinuria, >3.5g/24h, and hypoalbuminemia.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "He received oseltamivir (150 mg/day) for 5 days.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Proteinuria of the patients ranged from 448 to 11725 mg/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "However, once the antidepressant-associated manias (28 of the sample, of 97 subjects) were excluded from the controlled study, the post-hoc analyses indicated the higher dose (512 mg/day) topiramate treatment group showed a statistically significant reduction in endpoint Y-MRS change scores as compared to placebo (p < 0.03).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "20 relapsed/refractory multiple myeloma patients received thalidomide (200 mg/d), cyclophosphamide (300 mg.m(-2).d(-1), d1-4, every 4 weeks) and pulsed dexamethasone (20-40 mg/d, d1-4, every 4 weeks).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Group 1 (n = 17) was treated with intravenous MPT (0.5 or 1.0 g/day for 3 days) followed by oral cyclosporine (2-3 mg/kg/day) and prednisolone (30 mg/day).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The mean duration to achieve <20 mg/day of prednisolone was also the shortest in Group 1 (P < 0.05).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Proteinuria significantly decreased, from its median value of 4.9 g/day (IQR 2.9-8.4) to 1.28 g/day (IQR 0.5-2.9), p < 0.001.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Oral tacrolimus (TAC) was started at 1 mg/day (target trough levels of 3-6 ng/mL) before serum creatinine (SCr) decreased to ≤133 μmol/L, and then increased doses were given (target trough level of 5-10 ng/mL) when SCr decreased to ≤133 μmol/L.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Remission defined as urinary protein < 0.3 g/day (or g/gCr) was observed in 104 (96.3%) patients.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Of 97 patients with remission within 6 month of IST, 42 (43.3%) developed relapse defined as ≥ 1.0 g/day (or g/gCr) or dipstick urinary protein of ≥ 2+.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The patients presented with gross anasarca and very low serum albumin, which was less than 15 g/l in 30 patients.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Up to 300 mg/d proteinuria is known to occur in pregnancy due to physiological changes.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Proteinuria of greater than 3 g/d is categorized as being within the nephrotic range, and the most common cause of nephrotic range proteinuria in the later stages of pregnancy is preeclampsia.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Of the remaining 28 patients, mean baseline proteinuria was 3.31 +/- 3.09 g/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "At the end of six months of treatment, mean proteinuria was 1.02 +/- 0.85 g/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Mean plasma albumin was 3.69 +/- 0.78 g/day, and mean serum creatinine was 0.85 +/- 0.26 mg/dl.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The 3-month efficacy and safety of a once-daily controlled formulation of diltiazem (180 to 360 mg/day) were assessed in a study of 54 patients with angina pectoris.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Rats given S alpha L before the induction of AMN nephrosis (S alpha L-AMN) developed significantly greater proteinuria on day 10 than rats given AMN alone (372 versus 274 mg/24 hours, p less than 0.05) and on day 12 (603 versus 453 mg/24 hours, p less than 0.05).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Initial examinations revealed massive urinary protein and decreased serum albumin, at 13.9 g/g Cr and 1.5 g/dL, respectively.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Prednisolone 60 mg/day was promptly started on the 5th day of hospitalisation, and complete remission was achieved on the 12th day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "NS (minimal change disease) was characterized by frequent remissions and relapses as prednisone was lowered under 30 mg/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "We randomly assigned 41 patients with lesions suitable for directional coronary atherectomy to the cilostazol group (200 mg/day) or the aspirin (250 mg/day) group.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "A 82-year old Caucasian female presented with pronounced nephrotic syndrome (proteinuria of 7.1 g/d, hypoproteinemia of 47 g/l).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The patient was started on prednisolone 40 mg/day, achieving remission with normalized proteinuria, but relapsed with edema and proteinuria (7.74 g/L) during tapering.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Prednisone was re-initiated at 30 mg/day, tapered to 2.5 mg every other day, and she remains in clinical and biochemical remission while continuing this low dose, with plans to discontinue after one month if remission persists.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Repeated measure of estimated glomerular filtration rate (eGFR); recurrent time-to-event outcome of GN disease worsening as defined by doubling of the urinary protein-creatinine ratio (UPCR) to at least 1.5g/g or increase in dipstick urine protein by 2 ordinal levels to 3+(300mg/dL) or above.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "We detected proteinuria, serum cholesterol of 269 mg/dl, AST of 50 U/L, ALT of 41 U/L, serum total protein of 3.4 g/dl, serum albumin of 1.2 g/dl, positive cryoglobulin, and urine protein of 9.84 g/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "RTX significantly reduced PSL and CyA doses during the final observation in each subject (median dose: PSL 15→0 mg/day, p = 0.0002; CyA 80→0 mg/day, p = 0.0005).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Periods with urinary protein excretion more than 1.0 g/day was slightly shorter in Group A (12.9+/-8.4 days) than Group B (23.7+/-18.3 days) (p= 0.0963).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The MN and MCD patients were stratified into two layers according to serum albumin (SALB) levels (<20g/l or 20-30g/l).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "reported about the beneficial effects of ginkgo biloba special extract EGb 761 (240 mg/day) in outpatients with pre-senile and senile primary degenerative dementia of the Alzheimer type (DAT) and multi-infarct dementia (MID) of mild to moderate severity.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The study was performed on the forearm skin of 7 healthy volunteers using an 8-MOP psoralen concentration of 2.6 mg/l.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Nephrotic Syndrome (NS) is a rare diseases (around 2-7 cases per 100.000 children per year) characterized by proteinuria ≥50 mg/kg/day (or ≥40 mg/m2/h) or a proteinuria/creatininuria ratio >2 (mg/mg); hypoalbuminaemia less than 25 g/l and edema.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "After a 6-week washout period, CyA 5 mg/kg/day and prednisolone 10 mg/day were administered for up to 8 months, depending on responses to CyA.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Our results suggest that infliximab adds minimal potential benefit to corticosteroids for pulmonary sarcoidosis at doses above 15-20 mg/day of prednisone.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In addition, mRNA levels in T cells obtained from patients with more than 1.0 g/day proteinuria were markedly higher than those with less than 1.0 g/day proteinuria.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "At the onset the mean values of serum creatinine was 2.9 +/- 1.8 mg/dL and proteinuria 4.5 +/- 0.8 g/d.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "We defined complete remission as stable renal function with proteinuria falling to <500 mg/day, and partial remission as stable renal function with >50% reduction in proteinuria from 500 to 3500 mg/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Most patients (97%) were treated initially with a single dose of 50 mg/day and 79% never used more than 50 mg/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The mean serum albumin at presentation was 15.6 +/- 7.1 g/L and all of them had 4+ proteinuria on urinalysis.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In Stage 1, 10 patients received escalating single doses from 25 to 200 mg/day or maximum tolerated dose (MTD).",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In Stage 2, 34 patients received daily doses escalating from 75 to a maximum of 250 mg/day, a dose that induced change in bowel function or MTD, followed by a fixed dose for 7 days, and a 2-week washout.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Nine months before admission, she was diagnosed as having ocular and pulmonary sarcoidosis, for which prednisolone at an initial dose of 40 mg/day was started.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "When the dose of prednisolone was tapered to 20 mg/day, she noticed swelling of the lower extremities.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "We used intravenous methylprednisolone pulse therapy followed by 40 mg/day oral prednisolone.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Laboratory tests showed 6.62 g/day of proteinuria.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Although allograft function was excellent immediately after surgery, massive proteinuria (35 g/d) appeared on post-transplantation day 5.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Pre-treatment urine protein varied from 2.9 g/d to 4.3 g/d.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "All three had resolution in proteinuria to less than 1 g/d and maintained their GFR to baseline values.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The patient had edema, dyspnea, hypertension, and 12 g/day proteinuria at admission.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Hydroxychloroquine with methylprednisolone 1 mg/kg (64 mg/day) was started, and methylprednisolone was slowly tapered.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "His proteinuria regressed to 79.2 mg/day, creatinine level was 0.83 mg/dL, and serum albumin level increased to 3.88 g/dL on the second week of the glucocorticoid treatment.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "outcome variables included complete remission (decrease in daily proteinuria to protein < or = 0.3 g/d), partial remission (decrease in daily proteinuria to protein < 3.5 g/d but > 0.3 g/d), relapse (increase in daily proteinuria to protein > or = 3.5 g/d in patients who had partial or complete remission), change in kidney function, and tacrolimus dosing and serum levels.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "In presence of a generalized oedema, a biological assessment was performed yielding intense nephrotic syndrome with urine protein excretion 22g/day.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "The diagnosis of MCNS was made and administration of steroid(40 mg/day) was started.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "Urinalysis showed heavy albuminuria (10.4g/day), but urinary sediment showed no abnormality.",
      "entity": "Proteinuria"
    },
    {
      "sentence": "At a previous outpatient clinic visit, her baseline serum creatinine was noted to be 87 μmol/L; on admission, serum creatinine was 1377 μmol/L.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "An accelerated, more rapid than expected, worsening of maternal renal function was observed in five GN patients of whom four (two IgA, two MPGN) had serum creatinine (Scr) levels greater than 160 mumol/L (1.8 mg/dL) early in gestation, and in five patients with reflux nephropathy whose Scr at conception ranged from 180 to 490 mumol/L (2.0 to 5.5 mg/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "However, that with serum creatinine between 1.3 to 3 mg/dl, MsePGN was found to be more common.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Laboratory examination revealed amylase 551 U/L, lipase 1073 U/L, blood sugar 873 g/dl, triglyceride 1298 mg/dl and cholesterol 1044 mg/dl.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In the fully adjusted model, the risk of MCD progression increased by 29% for every 1 mg/dL increase in the baseline serum uric acid level (hazard ratio [HR], 1.29; 95% confidence interval [CI], 1.09-1.54; p = 0.004).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Falling into the high uric acid group (serum uric acid level > 7 mg/dL in men and > 6 mg/dL in women) was also a risk factor for progression of MCD to ESRD (HR, 3.40; 95% CI, 1.59-7.31; p < 0.001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Plasma homocysteine in the lab chow group was 5.4 +/- 0.5 micromol/L and did not change with the addition of folate.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The Acute Kidney Injury Network (AKIN) definition was based on the RIFLE system but added an absolute change in SCr of ≥ 0.3 mg/dL, omitted eGFR criteria and included a time constraint of 48 hours.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The concentrations of IgE (250 IE/ml) and IgA (745 mg/dl) were raised, and there was eosinophilia of 14%.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Mean serum creatinine (SCr) of the patients was 2.36 ± 2.07 mg/dL.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In patients with SCr 1.4 mg/dL or less (n = 131), FSGS was the most common histology (17.26%) followed by MGN (23.66%) and minimal change disease (7.63%).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Whereas, in patients with SCr more than 1.4 mg/dL (n = 139), DPGN was the most common diagnosis (23.74%) followed by FSGS (17.26%) and IgAN (12.23%).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Among adults, hypertension was present in 45.2%, mild renal insufficiency in 23% (sCr 111-200 micromol/l) and advanced renal insufficiency in 13.7% (sCr 201-400), while 11.5% of patients had sCr >400 micromol/l.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Baseline mean serum urate level was 8.9 mg/dl and mean number of flares was 4.7 over last year.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Her serum creatinine on admission was 1,057 µmol/L with a premorbid serum creatinine of 78 µmol/L.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "She had 5 sessions of hemodialysis and her serum creatinine gradually reduced to 106 µmol/L, and she is being followed up on an outpatient basis.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Sa créatinine sérique à l’admission était de 1 057 µmol/L avec une créatinine sérique prémorbide de 78 µmol/L.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Elle a subi 5 sessions d’hémodialyse et son taux de créatinine sérique a progressivement à 106 µmol/L, et elle est suivie en ambulatoire.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "On admission, serum creatinine was 1.3 mg/dL and 24-hour urinary protein excretion was 4 grams with fluid overload.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The change in creatinine level remained stable after CAS and did not differ between the 2 groups (.02 versus .03 mg/dL, P = .96).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The subjects included normal control (Nor), minimal change nephrotic syndrome (MCNS), IgA nephropathy (IgA), membranous nephropathy (MN), membranoproliferative glomerulonephritis (MPGN), and chronic renal failure (CRF) (s-Cr greater than 2 mg/dl).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In the CRF group, B1-Ag in urine showed a significant increase in the progressive CRF group with delta s-Cr greater than 1.0 mg/dl/month as compared to the stationary CRF group with delta s-Cr less than 1.0 mg/dl/month.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Mean serum creatinine at the time of biopsy was 3.3 mg/dl.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "It was not included patients with acute glomerulonephritis, minimal change disease, crescentic glomerulonephritis, connective tissue diseases or patients with serum creatinine level greater than or equal to 4.0 mg/dl.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "During the 5-month postsurgical period, the serum urea nitrogen concentration averaged 18.41 +/- 1.59 mg/dl (mean +/- SE) for the microsphere-injected dogs vs 9.31 +/- 0.38 for the control dogs (P less than 0.001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Similarly, the mean serum creatinine value was significantly higher (P = 0.020) for the microsphere-injected dogs, compared with the controls (1.23 +/- 0.12 mg/dl vs 0.94 +/- 0.03).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In adjusted analysis, extended hours were associated with lower phosphate (- 0.219 mmol/L [- 0.314, - 0.124; P < 0.001]), higher calcium (0.046 mmol/L [0.007, 0.086; P = 0.021]) and no change in PTH (0.025 pmol/L [- 0.107, 0.157; P = 0.713]).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Two patients presented with acute renal insufficiency (serum creatinine greater than or equal to 1.3 mg/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Median baseline pNa was similar in the 2 groups [127 mmol/L (interquartile range [IQR] 126-129) FR and 128 mmol/L (IQR 126-129) NoTx, P = 0.36].",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "PNa rose by 3 mmol/L (IQR 2-4) after 3 days FR, compared with 1 mmol/L (IQR 0-3) NoTx, P = 0.005.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "There was minimal additional rise in pNa by day 30; median pNa increased from baseline by 4 mmol/L (IQR 2-6) in FR, compared with 1 mmol/L (IQR 0-1) NoTx, P = 0.04.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "After 3 days, 17% of FR had a rise in pNa of ≥5 mmol/L, compared with 4% NoTx, RR 4.0 (95% CI 0.66-25.69), P = 0.35.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "After 3 days, 61% of FR corrected pNa to ≥130 mmol/L, compared with 39% of NoTx, RR 1.56 (95% CI 0.87-2.94), P = 0.24.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "More than one-third of patients fail to reach a pNa ≥130 mmol/L after 3 days of FR, emphasizing the clinical need for additional therapies for SIAD in some patients.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Biologic-naïve adults with active PsA (≥5 swollen joints /≥5 tender joints ; C reactive protein ≥0.6 mg/dL) were randomised to guselkumab 100 mg every 4 weeks (Q4W); guselkumab 100 mg at week 0, week 4, then every 8 weeks (Q8W); or placebo→guselkumab 100 mg Q4W (week 24).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Pre-treatment laboratory tests showed a mean 24-hr proteinuria of 4372 +/- 2686 mg/dL.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Serum phosphorus increased from baseline (0.52 mmol/L) and was maintained after dose titration from week 22 (0.91 mmol/L) to week 144 (0.82 mmol/L, p < 0.0001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Further laboratory investigation revealed elevated serum lithium (2.17 mmol/L), potassium (6.0 mmol/L), and creatinine levels (2.92 mg/dL), nephrotic range proteinuria, and hypoalbuminemia.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Serum creatinine values ranged from 0.3 to 1.2 mg/dl at the start of treatment and were stable in 17 of 18 patients during CsA therapy.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "GN, 5 cases of membranoproliferative GN, 3 cases of focal glomerulosclerosis and 12 cases of chronic renal failure who had creatinine levels of more than 2 mg/dl resulting from chronic GN.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "One week later she was referred and admitted to our hospital, wherein laboratory tests revealed that her serum creatinine level, serum albumin level, and urine protein-creatinine ratio were respectively 0.79 mg/dL, 2.5 g/dL, and 7.0 g/gCr.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Overall, participants (n = 27) showed substantial improvement during the Intensive Phase, including InsAUC (-59 ± 18.2 µU/ml × 120 min, P = 0.004), total cholesterol (-9.9 ± 3.6 mg/dl, P = 0.01), weight (-2.7 ± 0.5 kg, P < 0.001), waist circumference (-3.1 ± 0.8 cm, P < 0.001), HOMA-IR (-1.7 ± 0.4, P < 0.001), systolic blood pressure (-5 ± 1.4 mm Hg, P = 0.002), and CRP (-0.1 ± 0.1 mg/dl, P = 0.04).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "No difference was found between groups 1 and 2 in relation to fasting blood glucose (207.1 +/- 71.7 vs 187.6 +/- 84.6 mg/dl), HbA1 (8.1 +/- 0.9 vs 8.6 +/- 1.1%) or urinary volume [202 (48.3-435) vs 246 (77.3-683.3) ml].",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "This study described LLT utilization patterns and LDL-C goal achievement (to <70 mg/dL) among patients with ASCVD in the United States.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Laboratory data confirmed severe renal failure, his blood urea nitrogen level was 107.3 mg/dL, and his serum creatinine 16.5 mg/dL.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Follow-up data showed a rise in serum creatinine (>50%) in five patients, +1.42 +/- 0.79 mg/dL (P = 0.016), of whom four were African American.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Logistic regression analysis showed a significant increase in the risk of developing MCD as the number of Ig risk factors, namely, IgG < 450 mg/dl and IgE > 110 mg/dl, increased.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "One week later, severe anemia (hemoglobin 4.4 g/dl) and acute renal failure (creatinine 2.0 mg/dl) developed, and a CT scan of the abdomen revealed a hematoma in the left iliopsoas muscle.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Patients with MGN presented with the highest proteinuria (protein excretion, 8.3g) whereas patients with FSGS had the highest creatinine levels (2.6mg/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Patients with serum creatinine levels >1.5 mg/dl (132.6 micromol/l) were excluded.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The combined mean serum total calcium (11.9 ± 1.4 mg/dL), serum PTH (668.6 ± 539 pg/mL), serum alkaline phoshpatase (619 ± 826.9 IU/L) and weight of excised parathyroid glands (4.4 ± 3.8 grams) are much higher than those reported from the western studies.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Compared with 42 patients with non-CG FSGS, the CG cohort showed a greater percentage of black patients (86% v 38%), significantly higher mean levels of serum creatinine (3.8 +/- 2.7 mg/dL v 1.9 +/- 1.5 mg/dL) and urinary protein (14.3 +/- 9.6 g/24 hr v 7.7 +/- 5.8 g/24 hr) at the time of renal biopsy, and a greater likelihood of and more rapid progression to end-stage renal failure.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "To look for clinical and pathologic factors that increase the risk for developing acute renal failure, 21 adults with minimal change glomerulopathy and a serum creatinine greater than 177 mumol/L (mean, 486 mumol/L; range, 194 to 1,344 mumol/L) (greater than 2.0 mg/dL [mean, 5.5 mg/dL; range, 2.2 to 15.2 mg/dL]) were compared with 50 adults with minimal change glomerulopathy and a serum creatinine less than 133 mumol/L (mean, 88 mumol/L; range, 53 to 124 mumol/L) (less than 1.5 mg/dL [mean, 1.0 mg/dL; range, 0.6 to 1.4 mg/dL]).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Tubular epithelial simplification identical to that observed with ischemic acute renal failure (acute tubular necrosis) was observed in 71% of the patients with serum creatinine greater than 177 mumol/L (greater than 2.0 mg/dL) and 0% of those with less than 133 mumol/L (less than 1.5 mg/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "All 18 patients with renal failure for whom follow-up data were available had recovery of function (mean creatinine, 539 +/- 301 mumol/L [6.1 +/- 3.4 mg/dL] at the time of biopsy and 106 +/- 27 mumol/L [1.2 +/- 0.3 mg/dL] at last follow-up), but sometimes only after weeks of dialysis support.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "One of them died due to cardiac infarction, one became dialysis-dependent, there of them (treated also with plasma exchange) responded favorably to this treatment and after 3 to 12 months had life-sustaining renal function (s-creatinine < 265 umol/L; < 3 mg%).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Probucol, a well-tolerated new drug with moderate hypocholesterolemic effect in the general population, was evaluated in hypercholesterolemic (greater than 300 mg/dl) cardiac transplant recipients.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "When clinical and histological features at presentation have been evaluated by multivariate analysis, serum creatinine concentrations (>1.5 mg/dl) and the presence of tubulo-interstitial lesions (>20%) are significant positive predictors of progression to ESRD.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The maximal change in glucose from baseline was 140 +/- 10 mg/dL (a 2.1-fold rise) for the OGTT compared to 86.3 +/- 6.1 mg/dL (a 1.7-fold rise) for the MTT (P <.05).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The average serum creatinine was 2.9 mg/dl, with values > 3.5 mg/dl in 25% of cases.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The investigation showed 9.5 g of 24 hr urine protein, hypoalbuminemia (2.6 gm/dL), and hypercholesterolemia (320 mg/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Pertinent laboratories were a creatinine of 0.5 mg/dL (0.4-1.1 mg/dL) and an albumin 2.3 g/dL (3.5-5.0 g/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Hyperhomocysteinemia (Hhcy) is a biochemical alteration with plasma levels of homocysteine higher than 15 µmol/L, associated with atherosclerosis, and with vascular thrombosis by disrupting endothelial cells.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Mean calcium, creatinine, and blood urea nitrogen levels were 8.97 ± 1.19 mg/dL, 1.41 ± 1.37 mg/dL, and 16.83 ± 14.50 mg/dL, respectively.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Mean sodium, potassium, and uric acid levels were 135.49 ± 6.79 mEq/L, 4.157 ± 0.65 mEq/L, and 5.81 ± 2.82 mg/dL, respectively.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Serum bile acids (sBA) decreased (CFB: 29 μmol/L; p = 0.03), persisting throughout the study.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "One had a large decrease in sBA (CFB: -112 μmol/L), and two had small increases (CFB: 8, 11 μmol/L).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Mean levels of Lp(a) (98 +/- 92 mg/dL [mean +/- SD]) were markedly elevated in the nephrotic patients as compared with the controls (14 +/- 13 mg/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Mean low-density lipoprotein cholesterol level was 2.4 mmol/L, and 88% of patients received statins.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "12 weeks after LT, the patient was found to have low apolipoprotein B (65 mg/dL), high-density lipoprotein (HDL) (<10 mg/dL), low-density lipoproteins (LDL) (9 mg/dL), and total cholesterol (<50 mg/dL) levels.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Liver enzymes normalized after 3 months and her lipid profile improved markedly (HDL 27 mg/dL, total cholesterol 128 mg/dL), with progressive decrease in liver size and resolution of ascites after 5 months of therapy.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "There were no differences in hs-CRP levels between controls (median 0.08 mg/dl; range 0.03-1.87 mg/dl) and patients with IgAN (0.08 mg/dl; 0.03-3.13 mg/dl), MN (0.07 mg/dl; 0.03-0.99 mg/dl) or MCD (0.08 mg/dl; 0.03-1.75 mg/dl).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "RLP cholesterol (0.277 +/- 0.254 mmol/L) and triglyceride (0.386 +/- 0.552 mmol/L) levels corresponded approximately to the 90th percentile in women in the Framingham study.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The mean duration of symptoms was 46 weeks (range 6-119), the mean CRP was 5.1 mg/dl, and the majority were HLA-B27 negative and showed good clinical response for gut disease.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The mean difference of these variables was -10.07 mg/dl [95 %CI:30.84; 10.70], -8.93 mg/dl [95 %CI:27.07; 9.21], and -10.37 mg/dl [95 %CI:32.26; 11.52] for TC, LDL-c, and non-HDL-c, respectively.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Hypertension, renal insufficiency (serum creatinine (Scr) > 1.24 mg/dL), and microhematuria occurred in 4 (13.8%), 11 (37.9%), and 13 (44.8%) cases, respectively.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Repeat serum protein electrophoresis as well as serum immunoelectrophoresis revealed no paraproteins, urine analysis was negative for protein or blood by dipstick and spot urine protein was 9 mg/dL with creatinine of 101 mg/dL at time of last office visit.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Both serum total and LDL cholesterol decreased significantly in all treatment groups compared to placebo (by 0.71-1.05 mmol/l, for total cholesterol and 0.68-0.94 mmol/l for LDL cholesterol P < 0.001 in all cases).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Polyclonal hyperimmunoglobulinemia (IgG 6,620 mg/dl) and mild plasma cell proliferation (6.4%) in a bone marrow specimen were found, but a lymph node aspiration biopsy showed no specific findings.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Low-density lipid (LDL) was 216 mg/dL, 201 mg/dL, and 178 mg/dL in FSGS, MCD, and MN, respectively; the difference was only in FSGS vs MN group (p=0.04).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Initial HDL was 58 mg/dL, 77 mg/dL, and 50 mg/dL in FSGS, MCD, and MN respectively (p=<0.001), differences were in MCD vs FSGS, and MCD vs MN groups (p=0.001, and p=<0.001 respectively).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "At presentation, he had a serum creatinine of 2.3 mg/dl, blood urea nitrogen (BUN) of 69 mg/dl, urinary protein excretion of 10.5 g/24 h, serum albumin of 1.3 g/dl, and a urine output < 400 cc/24 h. A renal biopsy was done and the renal pathology was compatible with early diabetic nephropathy.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "After 8 months of dialysis therapy, the patient's renal parameters and urinary output spontaneously restored to normal limits (serum creatinine was 1.1 mg/dl, urinary albumin excretion was 411 mg/24 h, serum albumin was 4.3 g/dl, and normal urine output) and dialysis was discontinued.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "He was managed conservatively initially, but over the next year the serum creatinine concentration increased from 18 to 32 µmol/L (0.2 to 0.36 mg/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Ezetimibe significantly decreased low-density lipoprotein cholesterol (LDL-C; 129 mg/dL vs 94 mg/dL, P < .0001), non-high-density lipoprotein cholesterol (non-HDL-C; 170 mg/dL vs 127.5 mg/dL, P = .0058), and total cholesterol (236 mg/dL vs 200 mg/dL, P < .0001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The proportion of patients achieving goal LDL-C < 100 mg/dL significantly increased from 11.5% at baseline to 60.5% after the addition of ezetimibe (P < .0001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "For 72 patients (43 with NS) (22 FSGS, 36 MGN, and 14 MPGN patients) with normal renal function at entry (serum creatinine, 1.02 +/- 0.23 mg/dL) and a mean follow-up duration of 52 +/- 27 months, for whom PAs were determined and urinary protein characterized by sodium-dodecyl-sulphate polyacrylamide gel electrophoresis (SDS-PAGE) at the beginning of the follow-up period, the functional outcome was correlated with the patterns of proteinuria.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The daily excretion of proteinuria was not decreased after pravastatin treatment, but, the serum albumin rose from 3.1 +/- 1.1 to 3.4 +/- 1.0 mg/dl.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The serum total cholesterol level was significantly reduced from 401 +/- 174 mg/dl to 331 +/- 103 mg/dl in spite of an absence of marked change in the control group.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Participants in the ROSE-AHF trial with baseline to 72-hour serum creatinine; net fluid output; and urinary KIM-1, NGAL, and NAG were included ( When considering only change in VD, the median diuresis to elicit a ≥0.3 mg/dl rise in creatinine was -7526 ml (IQR, -5932 to -9149).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "After accounting for stable creatinine filtration during diuresis, a change in VD alone was insufficient to elicit a ≥0.3 mg/dl rise in creatinine.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In vitro, human podocytes were respectively stimulated with oxLDL (80 µg/ml), A438079 (10 µmol/L), or the compound oxLDL and A438079 together.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Radial EUS included scoring for nine criteria (normal<4 criteria) with endoscopic collection of duodenal samples at 15, 30, and 45 min after secretin stimulation (normal peak bicarbonate>or=80 mmol/l).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Metformin DR 1200 and 1500 mg significantly reduced HbA1c (-0.49±0.13% and -0.62±0.12%, respectively, vs. PBO -0.06±0.13%; p<0.05) and FPG (Caverage Weeks 4-16: -22.3±4.2 mg/dL and -25.1±4.1 mg/dL, respectively vs. -2.5±4.2 mg/dL p<0.05).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The mean daily proteinuria was 10.2 g, and serum albumin was 1.8 mg/dl.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "At T1, TC significantly decreased in DOR2 (-15 mg/dL) and DOR3 (-23 mg/dL), and significantly more in DOR3 than in DOR1 (-6 mg/dL) (p = 0.016).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "HDL-C declined in DOR2 (-2 mg/dL) whereas it increased in DOR1 (+ 3 mg/dL) (p = 0.042) and remained stable in DOR3.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "LDL-C significantly decreased from baseline in DOR2 (-12 mg/dL) and DOR3 (-22 mg/dL) and was different between DOR1 (-8 mg/dL) and DOR3 (p = 0.022).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The test indicators are as follows: total bilirubin: 100.1 μmol/L, direct bilirubin: 65.0 μmol/L.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The blood concentration of tacrolimus (FK506) was 6.3 ng/mL total bilirubin 19.6 μmol/L before discharge.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Mean baseline plasma albumin was 2.84 +/- 1.002 g/dl and mean baseline serum creatinine was 0.87 +/- 0.42 mg/dl.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Under wheat bran there was only a slight decrease of carotene concentrations by 13.5 mg/dl (p less than 0.05) and a minimal increase of alkaline phosphatase activity by 14.5 U/l (p less than 0.1).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "A significant decrease in the concentration of ammonium ion was observed after 5 months of treatment (135.53 and 82.9 μmol/L, p=0.002) and maintained throughout the study.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "We assessed the role of alterations in renal perfusion and glomerular permeability by measuring clearances of inulin and para-aminohippurate before and during intravenous administration of a 20% albumin solution in patients with MCNS and oliguric ARF (serum creatinine > 1 mg/dL [88 micromol/L], urine output < 0.5 mL/kg body weight/h).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Anti-β2-GPI antibody-positive MN patients (n = 32) had a lower serum C4 level than anti-β2-GPI antibody-negative MN patients (n = 235; 21.6 ± 7.6 vs. 24.6 ± 7.1 mg/dL, p = 0.030).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The primary endpoint was change in blood glucose levels following 2-hour oral glucose tolerance test (OGTT) from baseline to the average of Week36 and Week48; participants had a mean change of -35.0 mg/dL (95%CI:-49.2,-20.7;P<0.0001) (-1.9 mmol/L [95%CI: 2.7, 1.2]).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "A significant improvement was observed in the mean levels of proteinuria (5.80 vs. 1.70 gm/dL; P < 0.001), total cholesterol (270.00 mg/dL vs. 160.00 mg/dL), serum creatinine (2.18 mg/dL vs. 1.68 mg/dL; P < 0.001), and serum albumin (1.86 gm/dL vs. 3.29 gm/dL; P < 0.001) at baseline to three months.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Kidney function remained stable with a creatinine of 1.2 mg/dL.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The subjects demonstrated an overall improved HbA1c (from 9.4% to 8.5%) and fasting blood glucose level (from 209 to 154 mg/dl).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Mean (+/- SE) levels of serum Lp(a) were elevated in the nephrotic patients compared to controls (76.5 +/- 19.7 vs 18.6 +/- 0.9 mg/dl, p less than 0.001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "After treatment with prednisolone, Lp(a) concentrations were decreased from 85.2 +/- 21.6 to 42.2 +/- 14.0 mg/dl.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Five children had elevated serum creatinine at presentation while the mean serum creatinine was 50.4 +/- 45.6 micromol/L.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "67 free living subjects, total cholesterol 5.5-7.9 mmol/l.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The smoking association with minimal, moderate, and more severe disease was progressive, estimated as equivalent to LDLc effects of 40, 85 and 238 mg/dl respectively.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Baseline average creatinine was 1.5 mg/dL (132.9 mmol/L) and glycated hemoglobin (HbA1c) was 8.2 g/dL at the start of the study, whereas creatinine was 1.6 mg/dL (138.5 mmol/L) and HbA1c was 7.4 g/dL at the end.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Although no correlation was observed with proteinuria, hematuria, serum creatinine, serum beta 2 microglobulin and urinary NAG, urinary G3-Ag showed a significant (p less than 0.05) increase in excretion in the group of progressive CRF patients with s-Cr more than 1.0 mg/dl/month as compared to the stationary CRF group with s-Cr less than 1.0 mg/dl/month.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Patients were candidates if they had at least one graftable obstructed coronary artery and at least one major arterial distribution not amenable to revascularization, a serum creatinine level less than 3 mg/dL, ejection fraction greater than 0.20, and estimated operative mortality of less than 25%.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "All had preoperative serum creatinine levels < or = 1.7 mg/dl (1.29 +/- 0.24 mg/dl) and were receiving either no antihypertensive medication (22%) or only a single agent (78%).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The median decrease in postoperative serum creatinine level (> or = 7 days after operation) was 0.81 +/- 0.05% (mean postoperative serum creatinine level 1.27 +/- 0.07 mg/dl).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "All patients also had LDL-C levels higher than those established by the Spanish Society of Arteriosclerosis (Sociedad Española de Arteriosclerosis [SEA]) according to baseline cardiovascular risk and previous use of lipid-lowering therapy (for patients with low, moderate, or high cardiovascular risk, the recommended LDL-C goals are ≤175 mg/dL, ≤155 mg/dL, and ≤135 mg/dL, respectively; for patients with CVD, the LDL-C goal is ≤100 mg/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In the ALI-EVO group (n = 40), median LDLC fell from 165 mg/dl at entry to 70 mg/dl (median - 59%, p < .0001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In the ALI 75 mg group (n = 29), entry LDLC fell from 115 to 68 mg/dl (median - 39%, p < .0001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In patients with HeFH and/or CVD, LDLC decreased from 115 to 68 mg/dl (39%) on ALI 75 mg with mean follow-up of 49 weeks, and from 165 to 70 mg/dl (59%) on ALI-EVO over 37 weeks, p < .0001 for both.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Optimal low-density lipoprotein cholesterol (LDL-C) was defined as LDL-C <70 mg/dL or ≥50% reduction from the baseline.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The theoretical prediction of [Na] increase by 1.6 mmol/L per 5.6 mmol/L decrease in [Glu] in most clinical settings, except in extreme hyperglycemia or profound hypervolemia, was supported by studies of hyperglycemia in CKD stage 5 treated only with insulin.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Mean corrected [Na] was 139.0 mmol/L in 772 hyperglycemic episodes in CKD stage 5 patients.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In patients with preserved renal function, mean corrected [Na] was within the eunatremic range (141.1 mmol/L) in 7,812 DKA cases, and in the range of severe hypernatremia (160.8 mmol/L) in 755 cases of HHS.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The corrected [Na], computed as [Na] increase by 1.6 mmol/L per 5.6 mmol/L decrease in [Glu], provides a reasonable estimate of the degree of hypertonicity due to losses of hypotonic fluids through osmotic diuresis at presentation of DKH or HHS and should guide the tonicity of replacement solutions.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The maximal serum uric acid and creatinine levels were 4.40+/-2.49 (range 0.4-13.3) and 5.45+/-3.33 mg/dl (range 1.10-17.7), respectively.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The serum uric acid level after recovery was 0.70+/-0.25 mg/dl (range 0.1-1.4).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Mean serum creatinine was 89.28 μmol/L (1.01 mg/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Glomerular tubular connections (GTC) were analyzed in two patients early and late in the disease spectrum (creatinine 0.2 and 2.8 mg/dl, respectively).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The serum IgA concentration was significantly higher in IgA(+) patients than in IgA(-) patients(341 +/- 79 mg/dl vs. 252 +/- 99 mg/dl, p = 0.034).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Serum phosphorus did not change significantly and urinary phosphorus increased from 487 to 1,062 mg/dl (p < 0.05).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Significant decreases in serum ionized calcium (from 1.26 to 1.19 mmol/l) and calcitriol (from 34.5 to 24.9 pg/ml) were observed.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "After the termination of steroid therapy and about 10 months after PBSC transplantation, nephritic syndrome appeared and the patient's serum creatinine value increased to 1.7 mg/dL.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Cerebro-spinal fluid studies showed a protein level of 92 mg/dL and a white cell count of 1 per high-power field.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "To define the long-term outcome of patients with minimal urinary abnormalities (defined by the presence of microscopic hematuria with no or less than 1 gm/day proteinuria), and normal renal function (defined by a serum creatinine < 1.3 mg/dl), we retrospectively studied patients who fulfilled the above criteria and had a kidney biopsy done before the year of 1992 (i.e.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In rats, duodenal abrasion reduced hyperglycemia by 59 mg/dL on average, compared with no change from baseline in the sham treatment arm (P < .05).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Patients with at least two coronary segments visibly involved with atherosclerosis, in whom an angiogram was carried out according to the standards required for quantitative analysis, were selected provided that the serum total cholesterol was between 5.5 and 8.0 mmol/L and fasting triglycerides were lower than 4 mmol/L.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Serum TBA (118.9 ± 39.0 μmol/L) and WBC (11.4 ± 2.7 × 10(9)/L) were significantly increased (p = 0.001) after bile duct ligation as compared with SH rats (38.0 ± 15.0 μmol/L and 5.5 ± 1.0 × 10(9)/L, respectively; p = 0.001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Age-adjusted mean concentrations of total cholesterol were 5.60 mmol/L (216 mg/dl) during 1988-1994 falling to 5.09 mmol/L (197 mg/dl) in 2007-2008 (P<0.001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Third, urinary mCHO, total protein (TP), albumin, and N-acetyl-beta-D-glucosaminidase (NAG) levels were measured longitudinally over 12 months (20.5 +/- 5.8 months) in 68 nondiabetic patients with impaired renal function [serum creatinine (Cr) > or = 1.5 mg/dL].",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The frequency of serum creatinine under 1.5 mg/dl, increased from 42.2% in 1980-1989 to 67.2% in 2000-2003 (p = 0.001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The frequency of serum creatinine over 6.0 mg/dl, decreased from 19.3% in 1990-1994 to 7.2% in 2000-2003.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In patients with renal sufficiency (Cr < 1.3 mg/dl) and reduction of proteinuria > 50% after 1 year of therapy urinary secretion of sTNF RII was higher before treatment than in patients with protein reduction < 50%.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The median non-HDL cholesterol increased by 7.3 mg/dl (IQR: -2.4 to 18.6, p = .021) in the CBCR group, but the increase was not significant in the CTR group (p = .080).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "All cases showed total cholesterol and triglyceride levels above the 95% percentile for both their age and sex (417 +/- 119 mg/dL and 448 +/- 313 mg/dL respectively).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Ninety-two percent of the children showed LBD above the 95 percentile for their and sex (307 +/- 108 mg/dL) and 72% showed LAD in the normal lower limit, under the fifth percentile for their age and sex (26.9 +/- 13.7 mg/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "A important percentage of the patients showed elevated LMBD (90.8 +/- 61.0 mg/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Serum creatinine was 0.9 mg/dL, albumin 1.3 g/dL and urine protein excretion 3.7 g/24 h. Viral markers (hepatitis-B, C, and HIV), complement c3 and c4 levels and auto-immune antibody profile all remained negative or within normal limits.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Forty-eight children with NS and plasma homocysteine >10 μmol/L were randomly assigned to receive either daily supplementation (5 mg folic acid, 50 mg vitamin B6, and 1 mg vitamin B12) or placebo for six months.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "After six months, the intervention group showed a significant reduction in homocysteine levels (12.8 ± 1.4 μmol/L to 6.9 ± 2.1 μmol/L, p < 0.001), while the control group had minimal change (13.3 ± 1.8 μmol/L to 12.9 ± 1.9 μmol/L, p = 1.000).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The intervention group also had greater reductions than the control group in total cholesterol (-13.2 mg/dL vs. -4.9 mg/dL, p < 0.001) and LDL cholesterol (-9.8 mg/dL vs. -3.6 mg/dL, p < 0.001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Adults with active PsA (≥5 swollen and ≥5 tender joints; C-reactive protein level ≥0.6 mg/dl) despite standard nonbiologic treatment were randomized to receive subcutaneous injections of guselkumab 100 mg every 4 weeks, guselkumab 100 mg at week 0, week 4 and every 8 weeks thereafter, or placebo with crossover to guselkumab 100 mg every 4 weeks at week 24.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "One study showed that more intensive insulin therapy resulted in a lower mean HbA1c (10 ± 0.8% versus 13 ± 0.9%) and lower fasting blood glucose (7.22 ± 0.5 mmol/L versus 13.44 ± 1.22 mmol/L) at 13 months compared with standard insulin therapy.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Of 14 patients with follow-up (2-64 months, mean 19 months), 6 had chronic renal insufficiency (serum creatinine >1.5 mg/dl), 2 had end stage renal disease, and 6 had essentially normal renal function.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The coagulation profile showed a fibrinogen level of 879 mg/dl and antithrombin III value of 9.5%.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "His creatinine was 616 µmol/L coming from a normal baseline of 89 µmol/L.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "At 1 year follow-up his creatinine had plateaued at 120 µmol/L with persistent low-grade proteinuria.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "A 19-year old man with no medical history presented to the Emergency Department with a 20-day history of anasarca and frothy urine, BUN 68 mg/dL, Cr 2.3 mg/dL, urinalysis 3+ RBCs, 3+ protein, and urine protein : creatinine ratio 6.4.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "CI-AKI was defined as an increase of 25% or 0.5 mg/dL in SC from the baseline value within 48-72 h of contrast administration.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Mean LDL-cholesterol levels during the trial were 140 +/- 34 mg/dl in the apheresis group and 170 +/- 58 mg/dl (P < 0.05) in the control group.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Ninety smokers with coronary atherosclerosis shown on a recent angiogram and with fasting cholesterol levels between 220 and 300 mg/dL were enrolled in a randomized, double-blind, placebo-controlled trial of cholesterol-lowering therapy, along with 241 nonsmokers and exsmokers.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Conversely, the total serum cholesterol in patients with restenosis (using the categorical definition) was similar to those without restenosis (5.84 +/- 1.24 versus 5.81 +/- 1.22 mmol/L, respectively, P = NS).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The LDL-A group showed 28.4% reduction in total cholesterol (from 275 +/- 27 mg/dl to 197 +/- 19 mg/dl) and 34.3% reduction in LDL cholesterol (from 213 +/- 25 mg/dl to 140 +/- 27 mg/dl) after one-year follow-up, while the medication group showed no changes in cholesterol levels.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "During CSA therapy the mean proteinuria of the study population decreased from 5.14 g/24 h (4.80 g/m2 per 24 h) to 1.23 g/24 h (0.92 g/m2 per 24 h) (P < 0.001), the mean serum albumin increased from 2.13 g/dl to 3.53 g/dl (P < 0.001), the mean serum cholesterol decreased from 364 mg/dl to 223 mg/dl (P < 0.001), and the mean serum creatinine increased from 0.77 mg/dl to 1.2 mg/dl (P < 0.01).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Among adults, mild renal insufficiency [serum creatinine (SCr) 111-200 μmol/l] was present in 24.7%, advanced renal insufficiency (SCr 201-400 μmol/l) in 15.3, and 12.3% of patients had SCr > 400 μmol/l.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Mean net change in HDL-C level was statistically significant but modest (2.53 mg/dL [0.065 mmol/L]; P<.001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Univariate regression analysis indicated that every 10-minute prolongation of exercise per session was associated with an approximately 1.4-mg/dL (0.036-mmol/L) increase in HDL-C level.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Multiple meta-regression analyses demonstrated that subjects with a body mass index (calculated as weight in kilograms divided by height in meters squared) less than 28 and total cholesterol level of 220 mg/dL [5.7 mmol/L] or more experienced an approximately 2.1-mg/dL (0.054-mmol/L) larger increase in HDL-C level than those with a body mass index of 28 or more and total cholesterol level less than 220 mg/dL (5.7 mmol/L).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "There was no significant change in arterial ammonia level after therapy in GpA (-0.52±7.8 μmol/l).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Arterial ammonia level in GpB (-8.47±5.8 μmol/l), GpC (-7.31±7.9 μmol/l), and GpD (-9.61±9.3 μmol/l) were significantly more than GpA (P<0.0001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The decrease in blood cholesterol levels was greater with tacrolimus compared with CsA (difference in mean values, 45.1 mg/dL; 95% CI, 19.1 to 71.2).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Her laboratory results revealed an incidental finding of a positive COVID-19 RT-PCR swab, serum creatinine 1.04 mg/dL, urine RBC 1/HPF, and a 24-hour urine protein of 9.22 grams with hypoalbuminemia and dyslipidemia.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In the remaining 12 patients, while marked proteinuria persisted after therapy, a significant increase in HDL-C (from 1.38 to 1.83 mmol/l) was noted with no significant changes in TC, FC and TG.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Her M-protein decreased from 2.14 to 0.83 g/dL and her IgG levels from 3,330 to 1,210 mg/dL following replacement of her silicone implant with saline.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The initial median serum creatinine was 65 micromol/l (range 44-133 micromol/l).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Proteinuria was present in all but two cases and was associated with progressive renal impairment in four patients (median serum creatinine 85 micromol/L; range 53 to 144 micromol/L).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The functional outcome was evaluated in 60 patients with baseline normal renal function (serum creatinine 0.97 +/- 0.19 mg/dL).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Only 7 patients (18%) presented with a decrease in renal function (serum creatinine greater than 1.3 mg/dl).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Among the patients, 27.07% had serum creatinine ≥1.5 mg/dL and 28.54% had either macroscopic or microscopic hematuria.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "On admission, serum creatinine was 2.31 mg/dL and 24-hour urinary protein excretion was 6.9 grams.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The hypocalcemic effect was consistent, with a median drop in serum calcium of 1.25 mg/dL per course.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The serum creatinine ranged from 1.2 to 12.9 mg/dL.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In the WHS, there was a curvilinear association, with increased CVD risk among those with Lp(a) >50 mg/dl, but only among women with total cholesterol (TC) >220 mg/dl.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "There was a small change in waist circumference (80.9 ± 9.5 vs. 81.5 ± 9.5 cm) in the entire cohort, as well as in total cholesterol (4.6 ± 1.0 vs. 4.7 ± 1.0 mmol/L, p < 0.01), triglycerides (TGs) (11.5 ± 6.4 vs. 12.6 ± 8.9 mmol/L, p < 0.01), and systolic (109.2 ± 10.2 vs. 106.1 ± 10.4 mmHg, p < 0.01) and diastolic blood pressure (69.8 ± 8.7 vs. 68.1 ± 9.7 mmHg, p < 0.01).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "After the intervention, the hypokalemia among males was 2.18 times than that of females, and the pre-operative serum potassium level was 3.5mmol/L≤K Male patients are more likely to suffer from electrolyte disturbance after coronary intervention.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "The area under the curve for serum phosphorus (P = 0.0042) and the number of visits above K/DOQI (≤1.78 mmol/L, P = 0.0198) and Kidney disease: Improving global outcomes (KDIGO) targets (≤1.45 mmol/L, P = 0.0067) were significantly lower with CaMg.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Ionized serum calcium did not differ between groups; total serum calcium increased in the CaMg group (treatment difference 0.0477 mmol/L; P = 0.0032) but was not associated with a higher risk of hypercalcaemia.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "An asymptomatic increase in serum magnesium occurred in CaMg-treated patients (treatment difference 0.2597 mmol/L, P < 0.0001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Majority of IgAN patients (93.52%, 101/108) showed elevated levels of plasma homocysteine (>10 μmol/L).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Plasma homocysteine in IgAN patients was significantly higher than that in MCD patients (median: 18.32 vs. 11.15 μmol/L, Z = -5.29, P < 0.01) and in healthy controls (median: 18.32 vs. 10.00 μmol/L, Z = -8.76, P < 0.01), but comparable with those in LN patients (median: 18.32 L vs. 14.50 μmol/L, Z = -1.32, P = 0.19).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "Significant differences were observed in sub-groups of IgAN patients according to quartiles of plasma homocysteine for male ratio (22.22% vs. 51.85% vs. 70.37% vs. 70.37%, χ = 14.29, P < 0.01), serum creatinine (median: 77.00 vs. 100.00 vs. 129.00 vs. 150.00 μmol/L, χ = 34.06, P < 0.01), estimated glomerular filtration rate (median: 100.52 vs. 74.23 vs. 52.68 vs. 42.67 mL·min·1.73 m, χ = 21.75, P < 0.01), systolic blood pressure (median: 120.00 vs. 120.00 vs. 125.00 vs. 130.00 mmHg, χ = 2.97, P = 0.05), diastolic blood pressure (median 80.00 vs. 75.00 vs. 80.00 vs. 81.00 mmHg, χ = 11.47, P < 0.01), and pathologic tubular atrophy and interstitial fibrosis (T) (T0/T1/T2: 62.96%/33.33%/3.70% vs. 29.63%/40.74%/29.63% vs. 24.00%/48.00%/28.00% vs. 14.81%/37.04%/48.15%, χ = 17.66, P < 0.01).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "However, the Cr level remained at 2.0 mg/dL, indicating nephrotic syndrome.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "We conducted a randomized, double-blind, placebo-controlled study to evaluate the effects of simvastatin on the progression of MCA stenosis among stroke-free individuals who had mild to moderately elevated LDL cholesterol (3.0-5.0 mmol/l).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "At the end of the study, the LDL cholesterol level decreased by 1.43 and 0.12 mmol/l for the active and placebo groups, respectively (p < 0.001).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "After a median and mean [corrected] duration of therapy of 4.0 and 12.6 months, respectively, patients presented with acute renal failure (mean creatinine 3.5 mg/dl) and nephrotic-range proteinuria (mean 24-hour urine protein 9.7 g).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "No significant changes were observed in the eGFR (P = 0.713) or sK⁺ levels (P = 0.400), which remained within a range of 3.5-5.5 mmol/L.",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "In the post-COVID-19 group, these patients had interval between noticing symptoms of INS, such as edema and INS diagnosis was significantly longer (7 days versus 3.5 days; p = 0.0047), and had significantly raised serum LDL cholesterol levels at the time of INS diagnosis than in the pre-COVID-19 group (314 mg/dL versus 260 mg/dL; p = 0.028).",
      "entity": "Creatinine (serum)"
    },
    {
      "sentence": "There was a rise in mean arterial and systemic vascular resistance with insufflation to 10 mm Hg, which was further exaggerated by reverse Trendelenberg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "After NIPPV, daytime arterial PO2 increased (71 +/- 4 to 81 +/- 2 mm Hg; p < 0.05) and arterial PCO2 decreased (46 +/- 3 to 41 +/- 1 mm Hg; p < 0.05).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Vital capacity (50 +/- 6% predicted), total lung capacity (63 +/- 4% predicted), alveolar-arterial oxygen gradient (20 +/- 3 mm Hg), and maximal inspiratory (39 +/- 9% predicted) or expiratory (32 +/- 5% predicted) pressures did not change after NIPPV.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Six control glands were perfused with autologous blood with an arterial Po2 ranging from 250 to 350 mm Hg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Lowering the arterial Po2 (range 30 to 60 mm Hg) in six glands while maintaining the flow at control levels elicited no significant change.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Similarly, decreasing the flow (25% of control) with the arterial Po2 at 250 to 350 mm Hg produced no significant change in gross appearance, weight gain, or mean amylase levels.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "During both rhythms, we shortened the coupling interval until we obtained maximal contractility, designated CP-S. Next, we increased the delay until we started to see a measurable secondary contraction (left ventricular pressure development of approximately 20 mmHg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In Patient 5, a novel change in exon 7, c.588G > C, initially presumed Q196H, was found to cause a leaky splicing mutation, resulting in three distinct transcripts containing 17, 108, and 190 bp of the 5'-terminal of intron 7, which led to truncated peptides consisting of 203 and 211 amino acid residues (or Q196fsX204 and Q196fsX212, respectively).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "At rest, end-tidal carbon dioxide (PETCO2) was 27 mmHg (25-30) for HVS patients vs. 30 mmHg (28-32); in controls (p = 0.05).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "At peak exercise PETCO2 was also significantly lower (27 ± 4 mmHg vs. 35 ± 4 mmHg; p<0.01) and VE/VCO2 higher ((38 (35-43) vs. 31 (27-34); p<0.01)) in patients with HVS.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In contrast to controls, there were minimal changes of PETCO2 (0.50 ± 5.26 mmHg vs. 6.2 ± 4.6 mmHg; p<0.01) and VE/VCO2 ((0.17 (-4.24-6.02) vs. -6.6 (-11.4-(-2.8)); p<0.01)) during exercise in patients with HVS.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "We found very low-certainty evidence about the effects of fludrocortisone versus placebo on drop in BP in people with diabetes (-26 mmHg versus -39 mmHg systolic; -7 mmHg versus -11 mmHg diastolic; 1 cross-over study, 6 participants).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "For people with Parkinson disease, we found very-low certainty evidence about the effects of fludrocortisone on drop in BP compared to pyridostigmine (-14 mmHg versus -22.1 mmHg diastolic; P = 0.036; 1 cross-over study, 9 participants) and domperidone (no change after treatment in either group; 1 cross-over study, 13 participants).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "A rise in pulmonary capillary wedge pressure (PCWP) of only 0.9 kPa during exercise was significant, whereas changes in stroke volume index (SVI) were considered significant only when exceeding 9 ml/m2.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "By 2 h, Part fell and CO did not change so that systemic vascular resistance decreased from 21.5+/-2.9 to 12.7+/-3.1 mmHg x L(-1) x min (P < 0.05) and remained at 11.3+/-1.7 mmHg x L(-1) x min in the animals observed for 4 h. Plasma nitrate/nitrite, expired NO, and NOS activity did not change.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "All patients had two- or three-vessel coronary artery disease that involved the posterior left ventricular wall circulation and had positive pacing stress tests, i.e., development of angina and a postpacing rise in left ventricular end-diastolic pressure (15 +/- 3 to 31 +/- 6 mm Hg, p less than 0.001).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "followed by repetitive injections of 100 microns glass beads (GB) into the right atrium until a mean pulmonary artery pressure of 35-40 mmHg was reached.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "A 3-bp deletion (DeltaF508) in the cftr gene, which accounts for approximately 80% of all CF mutations in the Caucasian population, is normally diagnosed in IVF embryos using fluorescent PCR (FL-PCR) and allelic sizing.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Twelve hypercapnic COPD patients (mean [+/- SD] PaCO(2), 60+/-11 mm Hg; mean FEV(1), 13+/-5% predicted; and mean FEV(1)/FVC, 31 +/- 7%) were enrolled.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Systolic pulmonary pressure decreased significantly (from 55 +/- 13 to 43 +/- 16 mm Hg, P =.001).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Owing to the high incidence of severe fundal lesions in renal hypertension the eyeground of these patients should be examined and the hypertension treated accordingly even when the rise in blood pressure is relatively mild (less than 180/100 mm Hg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "A minimal decrease from rest of oxygen pressure (DROP)<minus 15mmHg defined the presence of exercise-induced ischemia on the area of interest.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The mean pulmonary artery pressure increased during exercise from 22 to 39 mmHg (p less than 0.001) in group 1 and from 14 to 27 mmHg (p less than 0.001) in group 2.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Acute respiratory alkalosis (blood pH, 7.60; arterial PCO2, 15 mmHg (1 mmHg = 133.322 Pa); plasma bicarbonate, 14 mM) was induced in nine anesthetized dogs by increasing their respiratory rate and depth.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "During maximum dilation with adenosine in dogs, the diastolic coronary pressure at which flow ceases (Pzf) has been observed to be up to 27 mm Hg above coronary sinus and right atrial pressures.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The late diastolic Pzf was 7.0 +/- 2.2 mm Hg (mean +/- SD), less than 4 mm Hg above right atrial pressure; the mean Pzf was 12.1 +/- 3.1 mm Hg, less than 9 mm Hg above right atrial pressure.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The Pzf in the LAD did not change significantly (1) during transient simultaneous occlusion of the right coronary artery (RCA) in seven swine (late diastolic Pzf with the RCA open was 6.6 +/- 1.5 mm Hg and with the RCA closed it was 6.0 +/- 1.5 mm Hg), (2) during increased left ventricular systolic pressure (LVSP) in seven swine (late diastolic Pzf with LVSP of 123 mm Hg was 5.5 +/- 2.2 mm Hg and with LVSP of 184 mm Hg it was 7.3 +/- 2.8 mm Hg), or (3) during increased heart rate in eight swine (late diastolic Pzf at heart rate of 107 per minute was 10.8 +/- 2.9 mm Hg and at 180 per minute it was 12.7 +/- 2.1 mm Hg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Results: There was a significant change in MAP from baseline values at 3% hemorrhage with a 6.0 mm Hg decrease (95% confidence interval [CI], 0.2-11.8; P < 0.05) from 93 (3) mm Hg to 87 (4) mm Hg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In this study, we chose mice model by adriamycin to observe the effect of IL-18BP intervention.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Hypertension and LVH were associated with a 46% increase in left ventricular weight/body weight ratio (LVH, 6.73 +/- 0.31; control, 4.62 +/- 0.30), no significant change in LV MCVR/100 g, and a reduction in total LV MCVR (LVH, 0.11 +/- 0.02 mm Hg/ml/min; control, 0.15 +/- 0.02 mm Hg/ml/min).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "On physical examination, his blood pressure was 150/92 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In patients with F0-F2, the proportion of those with LSM >8.6 kPa increased with increasing ALT (P = 0.002).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Systolic and diastolic blood pressures were reduced at 13 to 60 months in those given low sodium advice as compared with controls (systolic by 1.1 mm Hg, 95% CI 1.8 to 0.4, diastolic by 0.6 mm hg, 95% CI 1.5 to -0.3), as was urinary 24 hour sodium excretion (by 35.5 mmol/ 24 hours, 95% CI 47.2 to 23.9).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Coronary distending pressure of the distal vessel segment increased significantly in both groups; however, this increase was significantly greater in group 2 than in group 1 (55 +/- 4 vs. 14 +/- 3 mm Hg, p < 0.0001).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "As compared to controls without retinopathy, he found a retinal end-organ involvement associated with average systolic (S) / diastolic (D) BP-Ms of 124/76 vs. 112/72 mmHg, with corresponding SBP/DBP-As of 12/10 vs. 8/7 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Tension in these stitches was measured at a systolic blood pressure > 80 mmHg using a custom-made sliding caliper with a strain gauge mounted in line.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Mean aortic valve area was 0.68 ± 0.26 cm and mean aortic valve gradient was 43 ± 17.7 mm Hg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "By including only eyes with an IOP increase greater than 15 mmHg, the mean value of cup width (P = 0.001) and cup depth (P = 0.002) increased, whereas the lamina cribrosa (LC) thickness (P = 0.035), temporal minimal rim width (P = 0.001), and nasal minimal rim width (P < 0.001) decreased.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Angle-closure suspect eyes showed a widening and deepening of the optic cup, decrease in neuroretinal rim width, and thinning of the LC after a darkness-induced IOP increase of >15 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In vitro splicing functional assays with minigene constructs revealed that this intronic variant leads to a 2-bp insertion immediately before exon 24 that results in protein truncation.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Hydralazine was administered short-term to 13 patients who had stable interstitial lung disease (ILD), pulmonary arterial hypertension (PAH); mean pulmonary arterial pressure ( [PAP]=26 +/- 9 mm Hg), and cor pulmonale (CP).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "At 10-year follow-up, the other trial reported that no eye showed visual field progression.One trial reported the mean change in intraocular pressure (IOP) in eyes with pigmentary glaucoma: At an average of nine months of follow-up, the mean difference in IOP between groups was 2.69 mmHg less in the laser iridotomy group than in the control group (95% CI -6.05 to 0.67; 14 eyes; very low-quality evidence).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Criteria for entry included a definite neurological diagnosis and a standing systolic blood pressure of 90-180 mm Hg and diastolic blood pressure of 50-110 mm Hg, on treatment if necessary.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In both groups, the following statistically significant haemodynamic changes were observed: a decrease in PCWP from 25.4 +/- 4.6 to 17.2 +/- 4.6 mmHg; an increase in SWI from 19.1 +/- 10 to 23.6 +/- 13.1 gm m-2; a slight increase in cardiac index with no change in arterial pressure and only minimal decrease in vascular resistance.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Blood pressure at 24 months was significantly lower than that at the baseline (120.9/74.4 vs. 111.8/70.3 mm Hg; p < 0.05).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Preischemic and postischemic Emax were the same in the control group (4.1 +/- 0.4 mm Hg/ml before vs 4.1 +/- 0.4 mm Hg/ml after ischemia), but significantly different in the PAB group (4.7 +/- 0.5 mm Hg/ml before vs 2.97 +/- 0.7 mm Hg/ml after ischemia, p less than .05).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Systolic and diastolic blood pressures were reduced at 13 to 60 months in those given low sodium advice as compared with controls (systolic by 1.1 mm Hg, 95% CI 1.8 to 0.4, diastolic by 0.6 mm hg, 95% CI 1.5 to -0.3), as was urinary 24 hour sodium excretion (by 35.5 mmol/ 24 hours, 95% CI 47.2 to 23.9).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Hypertension was defined as a systolic BP at least 140 mmHg and/or a diastolic BP at least 90 mmHg (using the mean of the second and third readings) or taking antihypertensive medication.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Of those on treatment, 53.9% had controlled BP (<140/90 mmHg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "ICH patients with a systolic BP (SBP) >160 mm Hg who present within 6 h (n = 27) or 12 h (n = 10) of symptoms were prospectively enrolled, treated with open-label clevidipine until SBP ≤160 mm Hg was achieved and then titrated to keep target SBP between 140-160 mm Hg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "A total of 35 patients with baseline median Glasgow Coma Scale score of 12, median NIH Stroke Scale score of 14, mean SBP of 186 mm Hg and a mean time from onset of symptoms of 5.5 h received clevidipine.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In the per-protocol analysis, 70% of patients on bim/tim at month 3 had an IOP <14 mm Hg, which declined to 58% (P = 0.0061) at month 6 (ie, after 3 months of dorz/brim/tim treatment).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In patients receiving dorz/brim/tim at month 3, 38% had an IOP <14 mm Hg, which remained comparable after return to bim/tim.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "A reversible pressure increase of 23 Pa and a relatively stable endocochlear potential (EP) were accompanied by a mean decrease in 2f(1)-f(2) DPOAE of only 3.4 dB.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Thirty-one patients who showed an initial increase in Pa(O(2)) of > 20 mm Hg in response to iNO underwent a discontinuation trial at 10 to 30 h after beginning iNO.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Compared with baseline values before treatment, a significant (P < .0001) diurnal reduction in intraocular pressure of 6 to 8 mm Hg was maintained with minimal fluctuation for the duration of treatment.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "When treatment was switched from timolol to latanoprost, intraocular pressure was reduced by 1.5 +/- 0.3 mm Hg (mean +/- SEM; 8% change in intraocular pressure; 31% of the intraocular pressure reduction produced by timolol; P < .001) compared with the change in intraocular pressure in patients remaining on latanoprost therapy.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Patients treated with PTRAS had similar baseline characteristics to those with high-grade RAS with no intervention, with the exception of lower diastolic BP (DBP; 74 +/- 11.2 vs. 80 +/- 14.2 mm Hg, p = 0.04) and a higher proportion of hyperlipidemia (78 vs. 55%, p = 0.05).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "When baseline and postprocedure variables were compared in PTRAS patients with 12-month follow-up, there was a reduction in systolic BP (SBP, 153 +/- 20.8 vs. 136 +/- 27.2 mm Hg, p = 0.01) and mean arterial pressure (MAP, 103 +/- 11.2 vs. 95 +/- 14 mm Hg, p = 0.04).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "We have previously shown that the 1831-bp Ncx1 H1 (1831Ncx1) promoter directs cardiac-specific expression of the exchanger in both development and in the adult, and is sufficient for the up-regulation of Ncx1 in response to pressure overload.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "We demonstrate that the proximal 184 bp of the Ncx1 H1 (184Ncx1) promoter is sufficient for expression of reporter genes in adult cardiomyocytes and for the correct spatiotemporal pattern of Ncx1 expression in development but not for up-regulation in response to pressure overload.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "To evaluate their respective participation in different forms of glomerulonephritis, the plasma values of C3, C4, C3PA, C1q and properdin were determined in 70 patients.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The median LSM change was -0.70 kPa (95% confidence interval, -3.0 to +1.7) and was similar with and without HBV coinfection.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "All such patients should be treated to a blood pressure of 125/75 mm Hg with dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibition and angiotensin receptor blockade.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Compared to breathing room air, capillary O2 pressure increased (from 54.7 +/- 9.4 to 82.8 +/- 21.8 mmHg) whereas Vt (from 458.7 +/- 86.8 to 358.3 +/- 75.1 ml) and MV (from 7.7 +/- 1.5 to 5.5 +/- 1.1 l/ min) decreased significantly (each p < 0.0001) with eITO in all patients.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Peak, minimal and mean atrial pressure increased from 8.57 +/- 2.37 to 18.14 +/- 4.74 mm Hg, 2 +/- 2.23 to 5.14 +/- 2.60 mm Hg (p = 0.0001) and from 4.28 +/- 1.6 mm Hg to 9.77 +/- 2.9 mm Hg (p = 0.001), respectively during AV interval modification.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Ten minutes after disconnecting the ventilator, PaCO2 was increased to 78 +/- 3 mmHg and pH was reduced to 7.17 +/- 0.02.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Cardiac output increased from 4.8 +/- 0.7 to 5.7 +/- 0.8 L.min-1 (P less than 0.05), and mean pulmonary artery pressure increased from 11 +/- 1 to 17 +/- 2 mmHg (P less than 0.01).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In conclusion, the apnoea test did not produce haemodynamic disturbances when respiratory acidosis was limited to a pH 7.17 +/- 0.02 and PaCO2 60-80 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In the 304 patients treated, minimal increases in mean systolic (≤8 mm Hg) and diastolic (≤3 mm Hg) blood pressures from precourse baseline were observed on infusion days 3 to 5.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "During peak dobutamine infusion, P(d) and P(d)/P(a) reached similar levels as during adenosine infusion (60+/-18 versus 59+/-18 mm Hg and 0.68+/-0.18 versus 0.68+/-0.17, respectively; all P=NS).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Results showed that at normocapnia (PaCO(2) 38-39 mmHg) there was little change in cerebral blood flow on ipsilateral carotid ligation, but when both carotid arteries were tied the blood flow to the brain fell significantly.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "At hypercapnia (PaCO(2) 58-60 mmHg) the CBF/CO(2) gradient fell significantly on ipsilateral carotid ligation; on bilateral carotid ligation there was only minimal rise in cerebral blood flow in response to the rise in PaCO(2).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "At hypocapnia (PaCO(2) 20-21 mmHg) the gradients of fall in the CBF were similar before and after ipsilateral carotid ligation; after bilateral carotid ligation there was minimal change in the CBF in response to the fall in the PaCO(2).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Left ventricular dysfunction with left ventricular end-diastolic pressure > or = 15 mm Hg was produced by injection of microspheres into the left coronary artery.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In the children with non-MCD lesions, plasma colloid osmotic pressure was significantly lower in the hypovolemic types (4.2 +/- 0.4 mmHg) than in those with stable edema (13.0 +/- 3.8 mmHg; P < 0.05); in MCD, no such difference existed (respectively, 8.1 +/- 3.0 and 9.9 +/- 2.2 mmHg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The 95% limits of agreement ranged from-150.3 to 133.5 kPa, and the minimal detectable change ranged from 30.8 to 80.6 kPa.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The 95% limits of agreement ranged from -48.5 to 48.8 kPa/sec, and the minimal detectable change ranged from 6.8 to 21.0 kPa/sec.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "We tested the hypothesis that passive constraint at 3 mm Hg reduces wall stress with minimal change in pump function.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "A pressure of 3, 5, 7, and 9 mm Hg was applied to the epicardium.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "A constraining pressure of 2.3 mm Hg was associated with a 10% reduction in stroke volume, and mean end-diastolic fiber stress was reduced by 18.3% (inner wall), 15.3% (mid wall), and 14.2% (outer wall).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "If the reduction in cardiac output is to be less than 10%, passive constraint should not exceed 2.3 mm Hg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "SLD was defined as CAP ≥ 263 dB/m, CSF as LSM of ≥8 kPa, and advanced fibrosis (AF) as LSM ≥ 12 kPa.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "We found a minimal promoter within 177 bp of the transcription start site, and an upstream enhancer region that facilitated expression in leukocyte cell lines.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Black females exhibited greater increases in SBP during exercise [change (d)=75, 95% CI: 64-86 mmHg,",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Diastolic coronary pressures distal to the Cx stenosis (54.5 +/- 11.5 mmHg) and distal to the LAD occlusion (44.5 +/- 5.2 mmHg) did not change significantly with either isoflurane or halothane.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "MN (vs. MCD, AOR: 6.00 [95% CI 2.57-14.0]) and higher baseline systolic blood pressure (SBP) (per 10-mmHg increase, AOR: 1.36 [95% CI 1.09-1.70]) were associated with a higher incidence of ACEI/ARB prescription.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "On average, incidence of ACEI/ARB prescription increased from 19.2% to 40.8% as baseline SBP increased from 100 to 140 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Regarding VC, only BP significantly decreased after 10 U Dysport and 7.5 U Botox compared to V (from 3.7±0.6 to 1.5±0.1 and 1.4±0.3mm Hg, respectively; p<0.01 and p<0.001, respectively).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Dysport (10 U) and Botox (7.5 U) significantly inhibited NVC by decreasing their amplitude (from 7.4±1.1 to 5.8±0.5 and 5.4±0.6mm Hg, respectively; p<0.05); frequency (from 2.2±0.4 to 1.5±0.2 and 1.3±0.3 NVC per minute, respectively; p<0.01); and increasing volume threshold to elicit NVC (from 29.8±3.7 to 47.6±6.9 and 47.7±6.3%, respectively; p<0.05 and p<0.001, respectively).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "We evaluated the hypothesis that BP nondipping would be associated with a blunted night-time reduction in SVR in a biracial sample of 140 (63 African-American and 77 white) men and women with elevated clinic BP (130-159/85-99 mmHg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Earlier we had noted an increase in CO2 pneumoperitoneum volume at repeat insufflation with an intra-abdominal pressure (IAP) of 5 mmHg after previous stepwise insufflation up to an IAP of 15 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In a new group of eight pigs, we also explored this effect at repeat IAPs of 10 and 15 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Previous stepwise insufflation of the abdomen with CO2 up to 15 mmHg significantly (p < 0.01) increased subsequent working-space volume at a repeat IAP of 5 mmHg by 21 %, 7 % at a repeat IAP of 10 mmHg and 3 % at a repeat IAP of 15 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The external anteroposterior diameter significantly (p < 0.01) increased by 0.5 cm (14 %) at repeat 5 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The inter- and intraobserver variations were, respectively, 5.7 and 4.9 mmHg at ankle level and 3.5 and 2.7 mmHg at toe level.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The mean day-to-day variation was 11 mmHg at ankle level and 10 mmHg at toe level, thereby giving a minimal significant difference between two DBP determinations of 22 mmHg at ankle and 20 mmHg at toe level.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "At 10 mg/kg p.o., ABBOTT-81282 lowered blood pressure in the RAL rat (delta MAP 66 +/- 9 mm Hg from control MAP 167 +/- 7 mm Hg, n = 6) to a normotensive level (MAP, 115 +/- 5 mm Hg) for greater than 24 h and did not change heart rate.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "administration of 1 mg/kg of ABBOTT-81282 also produced a sustained, long-lasting decrease (delta MAP 27-52 mm Hg) in blood pressure that was significantly different from the vehicle group at 8 h postdosing (143 +/- 3 mm Hg, n = 4 for ABBOTT-81282 vs. 181 +/- 3 mm Hg, n = 6 for vehicle group, p < 0.01).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "When blood pressure in the renal hypertensive rat was maximally lowered (delta MAP 72 +/- 9 mm Hg, n = 4) following the 1 mg/kg i.v.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "of ABBOTT-81282 had no effect on basal MAP (119 +/- 3 vs. 115 +/- 4 mm Hg, pre- vs. 3.5 h postdosing, n = 4) and heart rate (364 +/- 18 vs. 363 +/- 14 beats/min, pre- vs. 3.5 h postdosing, n = 4) but inhibited the AII (0.1 micrograms/kg i.v.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The pancreatic main ductal pressure was significantly higher in the patients in the early stage of chronic pancreatitis (35.7 +/- 9.1 mm Hg (mean +/- SD) in patients suspected of having chronic pancreatitis and 44.9 +/- 20.4 mm Hg in minimal-change chronic pancreatitis) than in the controls (16.2 +/- 8.7 mm Hg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Vitals-blood pressure (BP)-70/50 mm Hg, in view of shock, patient was started on inotropes at emergency medical department (EMD).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The mean gradient decreased as the valve size increased (21 mm valve gradient = 10.0 +/- 5.6 mmHg; 27 mm valve gradient = 6.2 +/- 2.2 mmHg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The mean increase in gradient at five years was < 7 mmHg, with a trend towards increased gradients at smaller valve sizes.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The quantitative reliability was evaluated in five repeated scans of 10 healthy feet by calculating the intraclass correlation coefficient and minimal detectable change, and the detectability of microvascular changes was tested by imaging 10 healthy feet intentionally occluded with use of a pressure cuff (160 mm Hg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "For the group, forced expiratory volume in one second (FEV1) was 1.04 +/- 0.40 L and arterial oxygen-tension (PaO2) was 77 +/- 11 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Significant systolic (-3.59 mm Hg) and diastolic (-1.73 mm Hg) changes were noted up to 30 months (p less than 0.05) with minimal side effects.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The drug resulted in a significant reduction in heart rate (from 125 +/- 5 to 110 +/- 4/min, p less than 0.001), mean systemic arterial pressure (from 147 +/- 4 to 137 +/- 3 mm Hg, p less than 0.01), and electrocardiographic ST-segment depression (from 1.9 +/- 0.5 to 0.8 +/- 0.3 mm, p less than 0.01) without any change in pulmonary arterial or wedge pressure during submaximal supine leg exercise on a bicycle ergometer.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Minimal distending pressure (MDP) and gastric compliance (Deltav/Deltap) were determined by increasing intrabag pressure in 2-mm Hg increments.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "With the intrabag pressure set at MDP +2 mm Hg, 500 microg sublingual glyceryl trinitrate was administered and the percentage change in intrabag volume from initial volume recorded.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The MDP was significantly greater in patients than controls (7.5 vs. 6.7 mm Hg median; p = 0.02).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "There was no difference between groups in the pressure at first intragastric sensation (11.2 vs. 10.3 mm Hg above MDP; p = 0.5) or in the maximal tolerated pressure (15.8 vs. 14.3 mm Hg above MDP; p = 0.2).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "This indicates that when resting diastolic pressure was more than 6 mm Hg, almost 38% of the pressure was due to external factors.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Mean systolic blood pressure of 123.4 mmHg did not change and diastolic blood pressure decreased insignificantly from 78.0 to 76.7 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Coronary sinus and great vein blood flow (thermodilution) and systemic hemodynamics were measured before, during, and after timed lower extremity compression, augmenting peak diastolic pressure to within 5 mm Hg of systolic pressure.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "External counterpulsation increased mean arterial pressure (108 +/- 11 [1 SD] to 114 +/- 12 mm Hg, p less than 0.01) and the diastolic pressure-time index (440 +/- 51 to 498 +/- 82 units, p less than 0.01), with no change in the systolic pressure-time index, absolute coronary sinus, or great cardiac vein blood flow.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "A corresponding excess of ultrafiltration pressure (versus control), attributable solely to reduced intracapillary oncotic pressure, was by 10.8 and 11.5 mm Hg, respectively.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "No significant correlations were observed between the Fc-receptor blockade and the C3, C3d, C4, C3PA or immune complex-plasma levels.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The action potential duration (APD) was measured from eight sites on the epicardium of the heart at low (50+/-7 mmHg) afterload and high afterload (97+/-12 mmHg) at baseline and during dofetilide perfusion.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "TL increased in neutrophils (+9·6 bp, P = 0·009) and decreased in whole blood, to a trivial extent (-12·1 bp, P = 0·001), and was unchanged in lymphocytes.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "There was no significant change in median lower esophageal sphincter pressure (14.0 to 12.0 mm Hg, p = 0.19), peristaltic amplitude (64 to 66 mm Hg, p = 0.71), or lower esophageal sphincter length (3.0 to 3.0, p = 0.28).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The reliability coefficient and MID were 0.83, 0.87, 0.88 and 1.44, 1.06, 1.12 kPa, respectively.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Individually significant change can be assumed beyond 14 % (RCV) or 1.12 kPa (MID).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "However, there was a small but significant difference in right ventricular end-diastolic pressure (5.3 +/- 2.5 and 8.1 +/- 1.8 mm Hg [p less than 0.05]) for Group I and II, respectively.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Diagnosis of EH (blood pressure > 140/90 mm Hg) was based on three repeated readings of blood pressure (BP).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "After 16 weeks of treatment, BP was reduced significantly (from 172/110 to 137/86 mm Hg, P < 0.001).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "For example, the Coptics of Egypt (1000 BP) and Chinchorro of Chile (5000-800 BP) have diets of similar diversity to those observed in the modern group but were isotopically influenced by local nutritional sources.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "4000 BP), we have observed a much more uniform isotopic signature, indicating a more constant diet.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "We have also recognized a primary vegetarian component in the diet of the Neolithic Ice Man of the Oetztaler Alps (5200 BP).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "At maximum exercise, the systolic blood pressure increased significantly (Δ = +69 ± 18 mm Hg; P< .001), whereas diastolic blood pressure showed minimal change (Δ = +1 ± 7 mm Hg; P= .001).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The upper reference values were 220 mm Hg in male and 200 mm Hg in female athletes for systolic blood pressure, and 85 mm Hg in male and 80 mm Hg in female for diastolic blood pressure.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Recurrent gain of a approximately 400 bp signal was observed in multiple patients.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In COCM diastolic PVR was shifted upwards in 4 cases, while dp/dtmin increased significantly (R = -1107 +/- 327, E = -1508 +/- 626 mm Hg-s-1, p less than 0.05), T on the average was unchanged (R = 53 +/- 10.5, E = 51 +/- 14.2 msec).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In A-St. in 3 of 4 cases diastolic PVR was significantly shifted upwards with E, dp/dtmin increased (R = -1633 +/- 93, E = -2093 +/- 170 mm Hg-s-1, p less than 0.001), T in contrast to N and AI was prolonged (R = 33.8 +/- 4, E = 39.9 +/- 1.9 msec).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In response to 2 x 4 mg p.o., diastolic pulmonary arterial pressure fell from 12.1 to 8.8 mm Hg in patients with filling pressure below 20 mm Hg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Patients with left heart failure and left ventricular filling pressure above 20 mm Hg (Group 2) displayed a decline in filling pressure from 23.8 to 17.4 mm Hg following 12 mg i.v.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Arterial blood pressure was reduced by a mean of only 10 mm Hg at high dosages and remained unchanged at lower dosages.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Systolic and diastolic blood pressures were reduced at 13 to 60 months in those given low sodium advice as compared with controls (systolic by 1.1 mm Hg, 95% CI 1.8 to 0.4, diastolic by 0.6 mm hg, 95% CI 1.5 to -0.3), as was urinary 24 hour sodium excretion (by 35.5 mmol/ 24 hours, 95% CI 47.2 to 23.9).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In Group II (acute respiratory alkalosis), both PaCO2 and cisternal CSF PCO2 decreased by 10 mm Hg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "SpO2 and PaO2 at the time of unilateral lung filling declined following initiation of SHFJV, from 98% and 93 mmHg to 95% and 62 mmHg, respectively.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Mixed-effects models revealed systolic, diastolic, and pulse blood pressure increases of 2.86 (P<0.001), 0.95 (P<0.001), and 1.95 mmHg (P<0.001) per decade for women and 0.91 (P<0.001), 0.93 (P<0.001), and -0.02 mmHg (P=0.93) for men, substantially lower than rates found elsewhere.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "There was no significant difference in change of stasis on the timed barium oesophagogram after 2 min (PD vs sham: median 0.0 cm, p25-p75 range 0.0-4.3 cm vs median 0.0 cm, p25-p75 range 0.0-0.0; p=0.122) or change in lower oesophageal sphincter relaxation pressure (PD vs sham: 10.54±6.25 vs 14.60±6.17 mm Hg; p=0.052).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "After reaching its nadir (18.2 +/- 2.0 mm Hg), the PO2 remained unchanged in five patients but increased in the other five patients despite the further increase in work rate and oxygen uptake.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Mean systolic pressure decrease from baseline values was greater during control than during Fluosol inflations (-9.0 +/- 3.3 mm Hg, p = 0.013), but no significant difference was observed in the change in maximal rate of rise in left ventricular pressure (maximal positive dP/dt).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Peak and minimal atrial pressure increased significantly from 8.5 +/- 2.8 to 20.1 +/- 2.9 mmHg (11.56 +/- 3.8 to 27.3 +/- 3.9 cmH2O) ( P=0.001) and from 2.06 +/- 1.69 to 5.33 +/- 2.9 mmHg (2.8 +/- 2.29 to 7.2 +/- 3.9 cmH2O), respectively (P=0.002) during AV interval modification.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Prior to infarction, all of the patients had a history of exertional angina only, yet following the infarction, episodes of recurrent ischemia occurred at rest in spite of maximal medical management with beta-blockers and/or nitrate preparations, which lowered the heart rate to a mean of 65 beats/min, and the blood pressure to a mean of 109/70 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Ebullism is the pathophysiological process that occurs as a result of exposures to extremely low ambient pressures, traditionally below 47 mmHg (<0.9 psi, ∼63,000 ft/19,202 m equivalent).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "A rodent animal model (N = 20) was exposed to rapid depressurization as low as 0.3 mmHg for up to 2 min; controls were placed in the chamber but not exposed to a pressure change.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The proportion of eyes with intraoperative IOP ≧30 mm Hg were as follows: T3=0%, T4=3.23%, T5=9.68%, T6=6.45%, T7=22.22%, and T8=25%.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Maximum IOP was 36 mm Hg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Each posterior sclera was mounted on a pressurization apparatus, IOP was elevated from 5 to 45 mm Hg while the 3D displacements of the scleral surface were measured by speckle interferometry.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Specifically: (1) Glaucomatous eyes in which the contralateral normal eyes displayed large modulus or thickness were less prone to biomechanical changes; (2) glaucomatous scleral modulus associated with an IOP of 10 mm Hg decreased (when compared with that of the contralateral normal) after minimal chronic IOP elevation; (3) glaucomatous scleral modulus associated with IOPs of 30 and 45 mm Hg increased (when compared with that of the contralateral normal) after moderate IOP elevation; and (4) FE-based estimates of collagen fiber orientation demonstrated no change in the glaucomatous eyes.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Among the 26 patients with head injuries, eight were found to have elevations of ICP above 20 mm Hg and pupillary dynamics in each of these patients remained normal.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In 13 patients with a midline shift greater than 3 mm, elevations of ICP above 20 mm Hg, when present for 15 minutes, were frequently associated with a reduction in constriction velocity on the side of the mass effect to below 0.6 mm/second (51% of 156 paired observations).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In five patients with diffuse brain swelling but no midline shift, a reduction in constriction velocities did not generally occur until the ICP exceeded 30 mm Hg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Changes in the percentage of reduction from the resting state following stimulation were always greater than 10%, even in patients receiving large doses of morphine and propofol in whom the ICP was lower than 20 mm Hg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Asymmetry of pupillary size greater than 0.5 mm was observed infrequently (< 1%) in healthy volunteers and was rarely seen in head-injured patients unless the ICP exceeded 20 mm Hg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "If the systolic pressure is greater than 145 mm Hg proliferative disease is more likely, but if the cholesterol is greater than 530 mgm/100ml, a minimal change lesion is more likely.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Prior to steroid treatment in the edematous phase, hypertension was found in 78% of adults (BP greater than or equal to 140/90 mm Hg or antihypertensive treatment other than diuretics) and 95% of children (BP greater than 95 percentile of age).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The study consisted of 14 patients (10 cases of inferior infarction and 4 cases of anterior infarction) with a mean capillary pressure of less than 20 mmHg and a cardiac index greater than 2 l X min-1 X m-2.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The basal values of the cardiac index (2.7 l X min-1 X m-2 +/- 0.37), the mean capillary pressure (9.4 mmHg +/- 2.7) and the systolic index (38.3 ml/m2 +/- 6.4) did not change significantly during the infusion, in the 14 patients studied.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The combination group had a significantly lower systolic blood pressure (117 vs. 125 mmHg; P=0.02) and a lower plasma aldosterone level (56 vs. 75 pg/ml; P=0.02) at follow-up.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "HMCL and FSI simulations exhibited excellent agreement in trends of ΔP change with CO, with minimal error of 1.6±1.1 mmHg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Systolic and diastolic blood pressures were reduced at 13 to 60 months in those given low sodium advice as compared with controls (systolic by 1.1 mm Hg, 95% CI 1.8 to 0.4, diastolic by 0.6 mm hg, 95% CI 1.5 to -0.3), as was urinary 24 hour sodium excretion (by 35.5 mmol/ 24 hours, 95% CI 47.2 to 23.9).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Seventeen men and two women (mean baseline PaO2, 65 mm Hg; PaCO2, 41 mm Hg; and FEV1/FVC ratio, 48 percent) participated in a double-blind, placebo-controlled, randomized study.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "IOPs were classified into three groups: low (<16 mmHg), normal (16 to 21 mmHg), and elevated (>21 to 30 mmHg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Change in IOP from the operating theater to 1 day after surgery was within +/-5 mmHg in 54 eyes (31.7%), elevated by 6 to 15 mmHg in 22 eyes (12.9%), and elevated more than 15 mmHg in four eyes (2.3%).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "IOP was reduced by 6 mmHg to 15 mmHg in 39 eyes (22.9%) and reduced by more than 15 mmHg in nine eyes (5.3%).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "An increase in positive first derivative of LV pressure (dP/dt) and in the ratio between dP/dt and the pressure developed (dP/dt/P) (1,530 +/- 287) 1,600 +/- 329 mm Hg/s [p less than 0.05], and 30 +/- 6 to 34 +/- 8 s-1 [p less than 0.05], respectively) demonstrated the inotropic effect of k-strophantidin, whereas volumetric parameters of systolic function (end-systolic and stroke volume indexes, and ejection fraction) did not show any significant change.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Lowest LV and end-diastolic pressures increased from 8 +/- 4 to 11 +/- 4 mm Hg (p less than 0.05) and from 17 +/- 6 to 20 +/- 8 mm Hg (p less than 0.05), respectively.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Mean aortic pressure increased from 110 +/- 10 to 120 +/- 12 mm Hg (p less than 0.001).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Systolic BP increased [median +2 mmHg, 95% confidence interval (CI) -16,+23 mmHg], whereas diastolic BP decreased (median -3 mmHg, 95% CI -15,+11 mmHg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "On multivariable analyses, plasma CETP activity was inversely related to change in pulse pressure (PP; beta per SD increment= -0.71 mmHg, P=0.005).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "When dichotomized at the median, plasma CETP activity above the median was associated with a 1 mmHg lower PP on follow-up (P=0.045).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Although peak pulmonary arterial pressure increases in the HBOC-201 group were 10 mm Hg to 15 mm Hg above baseline, cardiac index was unchanged.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Patients underwent HSI at the upper arm, forearm, and palm before and after cuff occlusion (50 mm Hg above systolic) for 5 minutes.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "As expected, the calculated serum oncotic pressure was reduced severely from the remission value of 28.6 +/- 0.9 mm Hg to 15.4 +/- 1.1 (P less than 0.005) during relapse.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The mean PO2 values of the lambs treated with artificial surfactant were 65.7 +/- 11 mm Hg vs. 24.8 +/- 1.6 mm Hg for the untreated lambs (P less than 0.001).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The PO2 values of those lambs previously treated with artificial surfactant remained greater than 100 mm Hg for 2.5 +/- 0.5 h vs. 0.9 +/- 0.3 h for lambs untreated with artificial surfactant (P less than 0.01).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The mutation in exon 7 is a 4-bp deletion in codon 536 leading to premature termination of the encoded polypeptide [HRKS536(4-bp del)].",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "To provide biochemical evidence for pathogenicity of these mutations, wild-type human rhodopsin kinase (HRK) and mutant forms HRKV380D and HRKS536(4-bp del) were expressed in COS7 cells and their activities were compared.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "In contrast, both mutant proteins were markedly deficient in catalytic activity with HRKV380D showing virtually no detectible activity and HRKS536(4-bp del) only minimal light-dependent activity.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Antiproteinuric therapy can be dosed to a prespecified urine protein target rather than a specific BP goal, with the proviso that successful therapy will usually lower the BP below the goal of 130/80 mmHg that is used for other forms of kidney disease.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "During acute ANG II hypertension, the AT1-specific receptor blocker losartan induced a large fall in MAP (64 +/- 4 mmHg) in ganglion-blocked (chlorisondamine) rats, whereas, during chronic ANG II hypertension, losartan had only a small hypotensive effect (11 +/- 3 mmHg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Intracoronary infusions of 80 micrograms/min or more into the left coronary artery (n = 6) also caused maximal hyperemia (4.4 +/- 0.1.resting CBFV), and doses up to 240 micrograms/min caused a minimal decrease in arterial pressure (-6 +/- 2 mm Hg) and no significant change in heart rate or in electrocardiographic variables.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "During the 140-micrograms/kg/min infusion, arterial pressure decreased 6 +/- 7 mm Hg, and heart rate increased 24 +/- 14 beats/min.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Infusion of dobutamine significantly increased femoral vein resting PO(2) (27.4 +/- 4.9 mm Hg vs 32.5 +/- 3.8 mm Hg) and critical PO(2) (20.5 +/- 1.5 mm Hg vs 21.9 +/- 1.7 mm Hg), but not the PO(2) at peak O(2) (22.1 +/- 3.3 mm Hg vs 22.0 +/- 2.9 mm Hg).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Despite a 19 +/- 2 mm Hg rise in mean arterial pressure during handgrip exercise, CFR was unchanged from baseline (3.7 +/- 0.3 vs. 3.7 +/- 0.4, p = NS, n = 7) because rCBFV rose proportionally with hCBFV.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "When pulmonary capillary wedge pressure was increased from 9 +/- 1 to 16 +/- 1 mm Hg after volume expansion, CFR was significantly decreased (from 3.8 +/- 0.2 to 2.9 +/- 0.2, p less than 0.05, n = 9) because rCBFV was increased while hCBFV remained unchanged.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The Pao2 increased from 113 +/- 51 torr (15.06 +/- 6.79 kPa) to 134 +/- 49 torr (17.86 +/- 6.53 kPa) during this period and was associated with a decreasing oxygenation index (from 11.4 +/- 2.0 to 9.3 +/- 1.5).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "MDC for lingual isometric pressure was 5.44 kPa (PD), 2.35 kPa (PSP), and 3.41 kPa (ataxia), whereas swallowing pressure was 5.60 kPa (PD), 2.97 kPa (PSP), and 7.34 kPa (ataxia).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Thus, in our 19 patients, PaO2 fell by an average of 17% (12 mm Hg), mean systemic arterial pressure by 19% (17 mm Hg), pulmonary arterial pressure by 38% (6 mm Hg), pulmonary arterial occlusive pressure by 62% (5.3 mm Hg), and cardiac index by 16% (0.37 liter/min/m2) [P less than 0.001 for each] after nitroglycerin.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Cyclophilin (408 bp) and beta-actin bands (234 bp) were distinct on electrophoresis.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Baseline values included mean office blood pressure of 164/103 ± 14/10 mmHg, mean 3.9 ± 0.6 anti-hypertensive agents, and an estimated glomerular filtration rate of (79 ± 19) ml × min(-1)×1.73 m(-2).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Office blood pressure after the procedure was reduced by -14/-10, -17/-11, -21/-12, and -24/-14 mmHg at 1, 3, 6, and 12 months respectively, and the reduction of the number of antihypertensive agents at the above corresponding time points was -1.3, -1.5, -1.7 and -1.8 respectively (all P < 0.001).",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The major difference in hemodynamics during CAO and CAR was in left ventricular end-diastolic pressure, which rose by 6 +/- 1 mmHg in pigs over the initial 24-h reperfusion period but did not change significantly in baboons.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Postoperative findings were elevated intraocular pressure (28 mmHg) and a significant reduction of vision.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "The SEM for all (proximal and distal) DROP values was 8 [7, 10] mm Hg and the MDC of DROP was 23 mm Hg.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "For an individual, an improvement or deterioration in DROP of ≥ 23 mm Hg after an intervention would be required to be 95% confident that the change is significant.",
      "entity": "BP (Blood Pressure)"
    },
    {
      "sentence": "Both women were diagnosed with HSP, and the results of urinalysis indicated that the HSP had already progressed to renal involvement (3+ proteinuria with 3+ urine occult blood in case 1; 100-120 RBC/HPF with 2+ urine occult blood in Case 2).",
      "entity": "Hematuria"
    },
    {
      "sentence": "In addition, the grade of hematuria significantly reduced after 24 months of steroid therapy (35.6 +/- 36.3 RBC/HPF vs. 13.7 +/- 28.4 RBC/HPF, P = 0.0249) and 24 months of anti-platelet drugs (30.1 +/- 37.1 RBC/HPF vs. 12.4 +/- 20.3 RBC/HPF, P = 0.0465), respectively.",
      "entity": "Hematuria"
    },
    {
      "sentence": "Both women were diagnosed with HSP, and the results of urinalysis indicated that the HSP had already progressed to renal involvement (3+ proteinuria with 3+ urine occult blood in case 1; 100-120 RBC/HPF with 2+ urine occult blood in Case 2).",
      "entity": "Hematuria"
    },
    {
      "sentence": "Urinalysis was positive for 2 + protein and 360 RBCs/HPF.",
      "entity": "Hematuria"
    },
    {
      "sentence": "Both women were diagnosed with HSP, and the results of urinalysis indicated that the HSP had already progressed to renal involvement (3+ proteinuria with 3+ urine occult blood in case 1; 100-120 RBC/HPF with 2+ urine occult blood in Case 2).",
      "entity": "Hematuria"
    },
    {
      "sentence": "Twenty-seven percent (3 of 11) of children with minor injuries and 25% (2 of 8) of those with major injuries had microscopic hematuria of less than 20 RBCs/HPF.",
      "entity": "Hematuria"
    },
    {
      "sentence": "The authors found that (1) a threshold of > or = 20 RBCs/HPF as an indication for radiograph evaluation would have missed 28% of cases with GU tract injuries or occult anomalies, and (2) pelvic fractures and abdominal/chest injuries help to identify patients who require evaluation of the GU tract.",
      "entity": "Hematuria"
    },
    {
      "sentence": "Urinalysis was positive for 2 + protein and 360 RBCs/HPF.",
      "entity": "Hematuria"
    },
    {
      "sentence": "We analyzed the performance of 3 urine dipstick assays to detect proteinuria compared to 24-hour protein/creatinine ratios, using 2224 dipstick measures from 296 patients.",
      "entity": "Hematuria"
    },
    {
      "sentence": "c. Acute hypoxia (defined as PaO Patients in the experimental arm will receive daily 32,4 mg Zilucoplan subcutaneously and a daily IV infusion of 2g of the antibiotic ceftriaxone for 14 days (or until hospital discharge, whichever comes first) in addition to standard of care.",
      "entity": "Weight"
    },
    {
      "sentence": "These patients will receive additional prophylactic antibiotics until 14 days after the last Zilucoplan dose: hospitalized patients will receive a daily IV infusion of 2g of ceftriaxone, discharged patients will switch to daily 500 mg of oral ciprofloxacin.",
      "entity": "Weight"
    },
    {
      "sentence": "The control group will receive standard of care and a daily IV infusion of 2g of ceftriaxone for 1 week (or until hospital discharge, whichever comes first), to control for the effects of antibiotics on the clinical course of COVID-19.",
      "entity": "Weight"
    },
    {
      "sentence": "Based on established global climate-change scenario data, we assess the potential of Aedes aegypti to establish in Europe over the 21st century by estimating the vector population growth rate for five climate models (GCM5).",
      "entity": "Weight"
    },
    {
      "sentence": "In a low carbon emission future (RCP2.6), we find minimal change to the current situation throughout the whole of the 21st century.",
      "entity": "Weight"
    },
    {
      "sentence": "Our results show that successfully enforcing the Paris Agreement by limiting global warming to below 2 °C significantly lowers the risk for infestation of Aedes aegypti and consequently of potential large-scale arboviral disease outbreaks in Europe within the 21st century.",
      "entity": "Weight"
    },
    {
      "sentence": "Clinical and laboratory data from HIV-positive patients who underwent renal biopsy from 1st January 2003 to 31st December 2004 were collected.",
      "entity": "Weight"
    },
    {
      "sentence": "In this region we also found three unreported substitutions in IgAN patients, c.2351C>T (p.Ala784Val), c.2378G>A (p.Cys793Tyr) and c.2393G>A (p.Gly798Asp).",
      "entity": "Weight"
    },
    {
      "sentence": "However, on the first day of admission, his urinary protein decreased from 5.05 g/gCr to 1.85 g/gCr.",
      "entity": "Weight"
    },
    {
      "sentence": "On the fourth day of admission, his urinary protein further decreased to 0.38 g/gCr and the patient developed acute kidney injury (AKI).",
      "entity": "Weight"
    },
    {
      "sentence": "After the renal function improved, the urinary protein worsened again to 5.49 g/gCr.",
      "entity": "Weight"
    },
    {
      "sentence": "The primary outcomes included complete or partial remission [complete remission (CR): proteinuria <0.3 g/24 h, with serum albumin ≥ 3.5 g/dl and stable renal function; partial remission (PR): proteinuria between 0.3 and 3.5 g/24 h and a decrease of at least 50 % from the baseline level, with serum albumin ≥ 3.0 g/dl and stable renal function].",
      "entity": "Weight"
    },
    {
      "sentence": "The daily dosage of MMF was 2 for the first 6 months and 1.5 g for a further 18 months, combined with steroids.",
      "entity": "Weight"
    },
    {
      "sentence": "Immunohistochemical examination of quadriceps muscle showed a deficiency in dysferlin in sarcolemma, and dysferlin gene analysis showed 3370 G missense mutation, leading us to the diagnosis of LGMD2B.",
      "entity": "Weight"
    },
    {
      "sentence": "Both groups showed significant increases in the serum albumin levels and notable decreases in the urinary protein levels in the 1st and 6th months after RTX therapy.",
      "entity": "Weight"
    },
    {
      "sentence": "Investigations revealed that 64% of the children with relapse had serum total protein ≤ 4.2 g/dL (p = 0) and that 59% had serum albumin ≤ 1.8 g/dL (p = 0.004).",
      "entity": "Weight"
    },
    {
      "sentence": "During his hospitalization, his daily opioid requirement exceeded 1 gram of morphine equivalent daily dose (MEDD) with suboptimal pain control.",
      "entity": "Weight"
    },
    {
      "sentence": "Even though hiatal hernia and a body mass index of >24 kg/m(2) was significantly associated with ERD, there was no correlation with Halimeter ppb levels.",
      "entity": "Weight"
    },
    {
      "sentence": "The MT1-MMP promoter contains two SNPs (-378 T/C and -364 G/T) in close vicinity to the RR1.",
      "entity": "Weight"
    },
    {
      "sentence": "Each patient received 4-6 pulses of 1 g/1.73 m2 methylprednisolone.",
      "entity": "Weight"
    },
    {
      "sentence": "He had a mutation, IVS8 + 1G > A, which led to an insertion of intron 8 into the transcripts.",
      "entity": "Weight"
    },
    {
      "sentence": "Because intradialytic intravascular volume changes alter PWV, a subgroup analysis in 11 patients where dialysis fluid removal during both periods was minimal (<1 kg) was performed, and a persistent and significant increase in aortic PWV was detected with the polysulphone kidney being maximal (40%) at 75 min (P<0.01).",
      "entity": "Weight"
    },
    {
      "sentence": "She was given optimal antibiotic treatment with ceftriaxone 2 g (intravenously) every 24 hours plus gentamicin 120 mg (intravenously) every 24 hours (synergy dose) but failed to respond to antimicrobial therapy.",
      "entity": "Weight"
    },
    {
      "sentence": "As part of the Undergraduate Medical Education for the 21st Century (UME-21) initiative, the University of Miami in partnership with AvMed Health Plans, a nonprofit managed care organization (MCO) developed a longitudinal educational program that prepares all students for medical practice in emerging systems of care.",
      "entity": "Weight"
    },
    {
      "sentence": "Recently he developed a nephrotic syndrome with lower-leg oedema and proteinuria (14 g albumin in 24-hour urine).",
      "entity": "Weight"
    },
    {
      "sentence": "After 12 mo of nocturnal feedings, the subjects had a mean weight gain of 11.75 kg and a mean height gain of 6.98 cm.",
      "entity": "Weight"
    },
    {
      "sentence": "Measurements were taken using ultrasound imaging at rest and during muscle contraction at 120° of shoulder flexion with a 1-kg load for upper trapezius (UT), lower trapezius (LT), serratus anterior (SA) and levator scapulae (LS).",
      "entity": "Weight"
    },
    {
      "sentence": "Microhaematuria was present in 65.9%, macrohaematuria in 9.2%, nephrotic proteinuria (> or = 3.5 g/24 h) in 39.3%, and low-grade proteinuria (<3.5 g/24 h) in 41.4%.",
      "entity": "Weight"
    },
    {
      "sentence": "Since 1999, diabetic patients represented 12.2% of adults, with mean proteinuria 8.9 g/24 h; diabetic glomerulosclerosis was found in 42.4% (with microhaematuria present in 66%) and non-diabetic renal diseases in 47.5% (IgAN in 17.5%, MGN and NAS in 11.1% and NV in 9.5%).",
      "entity": "Weight"
    },
    {
      "sentence": "Using multivariate binary logistic regression analysis, high serum level of gamma-glutamyl transpeptidase (GGT) (OR = 5.163; 95%CI, 1.105-24.130; P = 0.037), dyslipidemia (OR = 3.083; 95%CI, 1.029-9.243; P = 0.044), 24-hour urinary protein excretion (UPE) ≥3.5 g/24 hrs (OR = 5.010; 95%CI, 1.316-19.074; P = 0.018), and treatment with glucocorticoids (OR = 2.973; 95%CI, 1.093-8.084; P = 0.033) were independently associated with vitamin D deficiency.",
      "entity": "Weight"
    },
    {
      "sentence": "High serum GGT level, dyslipidemia, 24-hour UPE ≥3.5 g/24 hrs, and treatment with glucocorticoids are independent associated factors of vitamin D deficiency.",
      "entity": "Weight"
    },
    {
      "sentence": "At adulthood, rats were anesthetized [urethane (1g/kg) + isoflurane (0.5%)], and diaphragmatic electromyogram (dEMG) was measured under baseline and hypercapnic conditions (Pa(CO(2)): 10 Torr above baseline).",
      "entity": "Weight"
    },
    {
      "sentence": "There was a proteinuria of 25 g daily.",
      "entity": "Weight"
    },
    {
      "sentence": "The mean serum albumin and daily urinary protein excretion were 1.28+/-0.64 g/dl and 8.75+/-5.16 g, respectively.",
      "entity": "Weight"
    },
    {
      "sentence": "Nephrotic patients with a serum albumin level < 20 g/liter should be routinely anticoagulated.",
      "entity": "Weight"
    },
    {
      "sentence": "We examined the association of AAT V213A, S and Z deficiency alleles, and the functional 3' UTR 11478G>A with change in minimal luminal diameter, a measure of focal disease, in the Lopid Coronary Angiography Trial gemfibrozil study of post-bypass men.",
      "entity": "Weight"
    },
    {
      "sentence": "Rituximab (1 g) was administered at 14",
      "entity": "Weight"
    },
    {
      "sentence": "At study entry, patients with NS had hourly urinary protein losses of 398 ± 313 mg/m(2) and daily peritoneal protein losses of 3.4 ± 1.9 g/m(2), compared with 29.9 ± 31 mg/m(2) and 1.5 ± 1.1 g/m(2) respectively in the control group (p < 0.05).",
      "entity": "Weight"
    },
    {
      "sentence": "Serum T4, free-T4, T3, free-T3, and TSH were measured at 1st, 2nd, 3rd, and 7th P.O.D.",
      "entity": "Weight"
    },
    {
      "sentence": "However, the changes in the median ESS (2.25 pre-pandemic versus 2.5 during the pandemic; p = 0.38) and Hb level (9.5 g/dL pre-pandemic versus 10 g/dL during the pandemic; p = 0.38) for the study population were not statistically significant.",
      "entity": "Weight"
    },
    {
      "sentence": "Due to concern for maternal and fetal well-being, the decision was made to deliver via Caesarean section at 31 weeks, given worsening proteinuria (23.18 g/24 h).",
      "entity": "Weight"
    },
    {
      "sentence": "A live male infant was delivered weighing 1625 g. Renal biopsy at 4 weeks post-partum was consistent with primary FSGS.",
      "entity": "Weight"
    },
    {
      "sentence": "Thirty-one percent of TMA patients had proteinuria up to 1 g/24 h. Half of TMA cases are exclusively renal localized.",
      "entity": "Weight"
    },
    {
      "sentence": "Patients had lost 10.5 +/- 6.4 kg over 461 +/- 304 days.",
      "entity": "Weight"
    },
    {
      "sentence": "Glomerular filtration rate (GFR), effective renal plasma flow (ERPF) and humoral factors were simultaneously examined before and after a 50-gram oral protein load in 12 healthy controls and 12 nephrotic patients.",
      "entity": "Weight"
    },
    {
      "sentence": "CTX was initiated at 1 g/1.73 m(2) for a total dosage of 10 g/1.73 m(2) over 1 year.",
      "entity": "Weight"
    },
    {
      "sentence": "Of 521 children with a previously untreated nephrotic syndrome, as defined by proteinuria greater than or equal to 40 mg/h/m2 and serum albumin less than or equal to 2.5 g/dL, entering the International Study of Kidney Disease in Children between January 1967 and April 1976, 389 showed minimal changes on renal biopsy.",
      "entity": "Weight"
    },
    {
      "sentence": "High school students identified as carrying excess weight [body mass index (BMI) ≥25 kg/m(2), or BMI percentile ≥85 %] were invited to participate in The BODY Project, an intervention that included a medical evaluation and a personalized medical report of the results of that evaluation sent to the parent/guardian at home.",
      "entity": "Weight"
    },
    {
      "sentence": "Women were also given daily 1 g of Calcium and 800 IU of vitamin D (Calcichew D 3 forte Shire, UK).",
      "entity": "Weight"
    },
    {
      "sentence": "Lumbar spine BMD decreased by 0.5% at 12 months compared with baseline (mean difference 0.005 g/cm(2), 95% C.I -0.2287 to 0.03459, P = 0.28).",
      "entity": "Weight"
    },
    {
      "sentence": "The presenting 24-hour urine protein was 11.3 +/- 10.2 (range, 2.1 to 24) g and all patients were hypoalbuminemic (serum albumin less than 3.5 g/dL) with edema.",
      "entity": "Weight"
    },
    {
      "sentence": "Estimates of total left ventricular mass from studies obtained 1 hr after stress (341 +/- 90 g) were comparable to values obtained after 4 hr (336 +/- 89 g), with a correlation of r = 0.97; p < 0.0001.",
      "entity": "Weight"
    },
    {
      "sentence": "The left ventricular defect size 1 hr after exercise or dipyridamole infusion (149 +/- 74 g) was similar to that observed after 4 hr (151 +/- 73 g).",
      "entity": "Weight"
    },
    {
      "sentence": "The two measurements of hypoperfusion with stress were highly correlated (r = 0.91; p < 0.0001) and were significantly larger than the defect size at rest (121 +/- 70 g).",
      "entity": "Weight"
    },
    {
      "sentence": "On the last day of infusion, rats were injected with 35sulfate (1.0 mCi/200 g) intraperitoneally and killed after 8 h. Glomeruli were isolated and GBM obtained.",
      "entity": "Weight"
    },
    {
      "sentence": "Urinary protein excretion is generally less than 1 g/24 h in autosomal dominant polycystic kidney disease (ADPKD), and the association of the nephrotic syndrome with this condition is considered rare.",
      "entity": "Weight"
    },
    {
      "sentence": "Seven months later, galactose was again added for six months, after which proteinuria remained below 2 g/24 h and the plasma albumin and cholesterol concentrations normalized.",
      "entity": "Weight"
    },
    {
      "sentence": "After six months, we added galactose for three months, which reduced proteinuria to 0.76 g/24 h. After the discontinuation of galactose therapy, proteinuria increased to 2.48 g/24 h, despite further treatment with tacrolimus.",
      "entity": "Weight"
    },
    {
      "sentence": "It seems that oral galactose at a dose of 0.2 g/kg twice a day could be a promising new and nontoxic therapy for the treatment of resistant nephrotic syndrome.",
      "entity": "Weight"
    },
    {
      "sentence": "This was an observational, multicenter, prospective, 3-month study in cancer patients with hemoglobin (Hb)≤11 g/dl.",
      "entity": "Weight"
    },
    {
      "sentence": "Of the patients, 65.8 % improved Hb level during follow-up (increase of ≥1 g/dL and/or achieving >11 g/dL), which translated into a significant improvement in the PERFORM score [mean (95 % confidence interval (CI)] change, -1.2 (-0.04 to -2.4), whereas more fatigue was observed in patients without improvement in Hb [change (95 % CI) in PERFORM, +3.3 (1.5 to 5)].",
      "entity": "Weight"
    },
    {
      "sentence": "Minimal increases or decreases in Hb of ≥1 g/dL were associated with meaningful changes in patient-perceived fatigue as measured with the PERFORM questionnaire.",
      "entity": "Weight"
    },
    {
      "sentence": "The development of sudden massive proteinuria (4+; 16.7 g/gCr) with a weight gain of 8 kg within a two-week period was noted, and nephrotic syndrome was suspected.",
      "entity": "Weight"
    },
    {
      "sentence": "Healthy patients requiring orthodontic premolar extractions were randomly assigned to one of the three groups: control (CG) where no OF was applied, 7 and 28 days, where premolars were extracted either 7 or 28 days after the application of a 50-100 g OF.",
      "entity": "Weight"
    },
    {
      "sentence": "The median change in body weight was -1.0 kg (interquartile range: -2.1 to 0.0 kg) at 24 h and -2.3 kg (interquartile range: -5.0 to -0.7 kg) by discharge/day 10.",
      "entity": "Weight"
    },
    {
      "sentence": "After risk adjustment, increasing body weight during hospitalization was associated with a 16% increase per kg in the likelihood of 30-day mortality or HF readmission for patients showing weight loss ≤1 kg or weight gain during hospitalization (odds ratio per kg increase 1.16, 95% confidence interval [CI]: 1.09 to 1.27; p < 0.001).",
      "entity": "Weight"
    },
    {
      "sentence": "Among the subset of patients experiencing >1-kg increase in body weight post-discharge, increasing body weight was associated with higher risk of 180-day mortality (hazard ratio per kg increase 1.16; 95% CI: 1.09 to 1.23; p < 0.001).",
      "entity": "Weight"
    },
    {
      "sentence": "Considering all patients and diagnostic groups together, proteinuria decreased from 9.0 +/- 4.3 to 4.7 +/- 3.8 g/24 h during CsA treatment (mean +/- SD; p less than 0.01).",
      "entity": "Weight"
    },
    {
      "sentence": "Labs revealed hypoalbuminemia, hyperlipidemia and 15 g of proteinuria.",
      "entity": "Weight"
    },
    {
      "sentence": "Patient was treated with oral steroids and had a good response; his edema resolved, serum albumin improved, and proteinuria decreased to 1 g within 2 weeks of treatment.",
      "entity": "Weight"
    },
    {
      "sentence": "While there are many cross-sectional studies of glomerulonephritis (GN) incidence, changes in incidence over time, particularly in the 21st century have received less attention.",
      "entity": "Weight"
    },
    {
      "sentence": "Problems with the prepackaging of ingredients were eliminated through a simple packaging system which involved weighing all 3 salts into 1 polyethylene bag and heat sealing the end, weighing the glucose into another bag and putting the 1st sealed bag into the 2nd, and heat sealing the 2nd bag containing the glucose and the sealed salt packet.",
      "entity": "Weight"
    },
    {
      "sentence": "The median urinary protein level at the first relapse was 3.12 g/gCr or g/day.",
      "entity": "Weight"
    },
    {
      "sentence": "She had gained 27 kg and had developed significant edema.",
      "entity": "Weight"
    },
    {
      "sentence": "Her condition worsened, and a urinary protein measurement was 14.06 g/24 h-diagnostic of nephrotic syndrome.",
      "entity": "Weight"
    },
    {
      "sentence": "Molecular genetic analysis identified a heterozygous change c.653G>A (p.Arg218His) as the disease-causing variant.",
      "entity": "Weight"
    },
    {
      "sentence": "Treatment with MMF 0.75 to 1.0 g twice daily, either as monotherapy or in combination with low-dose steroid treatment, resulted in substantial reductions in proteinuria or stabilization of serum creatinine.",
      "entity": "Weight"
    },
    {
      "sentence": "We identified a novel heterozygous mutation c.490G>C (p.(Ala164Pro) in exon 3 of the INF2 gene in the index patient and 6 additionally examined affected family members.",
      "entity": "Weight"
    },
    {
      "sentence": "The healthy low-carbohydrate diet target is < 40 g of net carbohydrates during the first 3 months and < 40 to 60 net grams for months 3 to 6.",
      "entity": "Weight"
    },
    {
      "sentence": "He had lost 8 kg of body weight.",
      "entity": "Weight"
    },
    {
      "sentence": "BMI at time of biopsy was categorised as ≤25 kg/m We included 560 patients with biopsy-proven primary GN and available BMI data: 66.1% were male with median age 54.8 (IQR 41.1-66.2) years and BMI 28.2 (IQR 24.9-32.1) kg/m BMI was not associated with progression to MARE in this patient cohort with primary GN.",
      "entity": "Weight"
    },
    {
      "sentence": "All had moderate splenomegaly (213-803 g, mean 421 g).",
      "entity": "Weight"
    },
    {
      "sentence": "CsA also decreased the GFR by 40% (from 0.74 +/- 0.11 to 0.41 +/- 0.11 mg/ml/100 g body weight; p = 0.002).",
      "entity": "Weight"
    },
    {
      "sentence": "Inclusion criteria were chronic HD, hemoglobin (Hb) < 10 g/dL without preceding treatment (epoetin or transfusion) for 1 month.",
      "entity": "Weight"
    },
    {
      "sentence": "Echocardiographic baselines were obtained Epoetin-alfa was initially given 4,000 IU subcutaneously twice a week and titrated biweekly to keep the Hb range of 11 to 12 g/dL (titration period 12 weeks).",
      "entity": "Weight"
    },
    {
      "sentence": "After 24-week of epoetin therapy, the predialysis Hb level increased significantly from 8.0 +/- 1.3 g/dL to 11.0 +/- 1.1 g/dL (p < 0.001).",
      "entity": "Weight"
    },
    {
      "sentence": "11 patients out of 12 responded to enalapril with a decrease of Hb (14 +/- 2 g/dl vs 16.8 +/- 1.04 g/dl; p = 0.0006) and Ht (41.9 +/- 6.17% vs 51.14 +/- 2%; p = 0.0002) without a significant decrease of Epo (8.1 +/- 3.87; p = 0.1).",
      "entity": "Weight"
    },
    {
      "sentence": "All studies pertaining to the epidemiology of PHPT published after 1st January 2000 and published in English language were included for analysis.",
      "entity": "Weight"
    },
    {
      "sentence": "The enzymes secreted during the 1st and 3rd days differed significantly in stability (37 degrees C, pH 7.0).",
      "entity": "Weight"
    },
    {
      "sentence": "Total mixed ration diets containing 420 g of RO or WPG providing 420 g of RO were fed and the effects on milk production, composition, and FA concentration were measured.",
      "entity": "Weight"
    },
    {
      "sentence": "Incremental diet inclusion of WPG in experiment 2 resulted in linear increases in milk yield, cis- and trans-MUFA and PUFA, and linear decreases in SFA (from 73 to 58 g/100 g of FA) and milk fat concentration.",
      "entity": "Weight"
    },
    {
      "sentence": "Among the various primary conditions which may be associated with a nephrotic syndrome at birth or within the 1st year of life, the best known is the congenital nephrotic syndrome of finnish type (CNF) characterized by irregular pseudocystic dilatation of proximal tubules.",
      "entity": "Weight"
    },
    {
      "sentence": "Retrospective analysis of prospectively collected data, including all patients with aortovascular conditions admitted for surgical or conservative treatment from the 1st March to the 20th May 2020.",
      "entity": "Weight"
    },
    {
      "sentence": "Membranoproliferative glomerulonephritis (MPGN type I, II and III) was reclassified in 2013 as MPGN and C3 glomerulopathy (C3G) based on the complement system activation mechanism.",
      "entity": "Weight"
    },
    {
      "sentence": "To evaluate whether C4d, a component of the classical pathway, could be a diagnostic tool in differentiating between MPGN and C3G.",
      "entity": "Weight"
    },
    {
      "sentence": "Using the 2013 C3G consensus classification, the 15 MPGN types I, II and III biopsies were re-classified as MPGN (8) and C3G (7).",
      "entity": "Weight"
    },
    {
      "sentence": "Following C4d staining, of the 8 biopsies diagnosed as MPGN, 4 had classical pathway involvement [C1q (+), C3 (+), C4d (+)]; two had lectin pathway involvement [C1q (-), C3 (+), C4d (+)]; and, two were reclassified as C3G because the absence of C4d and C1q suggested the presence of the alternative pathway [C1q (-), C3 (+), C4d (-)].",
      "entity": "Weight"
    },
    {
      "sentence": "Three of the seven C3G biopsies presented classical pathway involvement and were reclassified as MPGN.",
      "entity": "Weight"
    },
    {
      "sentence": "The alternative pathway was present in one of the other 4 biopsies considered to be C3G.",
      "entity": "Weight"
    },
    {
      "sentence": "Two C3G biopsies involved the lectin pathway and the one case of dense deposit disease had lectin pathway involvement.",
      "entity": "Weight"
    },
    {
      "sentence": "C4d staining may help to differentiate between MPGN and C3G.",
      "entity": "Weight"
    },
    {
      "sentence": "Patients were self-assigned to 1 of 2 treatment groups: the standard prednisone regimen of 1 mg/kg daily or oral MMF 0.5 to 1.0 g BID combined with the lower prednisone dose of 0.5 mg/kg daily.",
      "entity": "Weight"
    },
    {
      "sentence": "The primary outcome measures were rates of complete remission of idiopathic nephrotic syndrome (a decrease in daily proteinuria to within the normal range [<0.3 g]) and rates of HBV reactivation (detectable serum HBV DNA).",
      "entity": "Weight"
    },
    {
      "sentence": "PAN in a dose of 5 mg/100 g body wt significantly increased urinary protein by day 5 (saline: 15 +/- 2, N = 24: PAN: 63 +/- 17, N = 23, P less than 0.001); the proteinuria rapidly increased thereafter, reaching 216 +/- 34, N = 23 by day 7.",
      "entity": "Weight"
    },
    {
      "sentence": "Compared to minimal (< ± 1 kg) weight change over 6 months, those with 3 kg- < 5 kg and ≥ 5 kg weight loss had death HRs of 1.31 (1.14-1.52) and 1.51 (1.30-1.75), respectively.",
      "entity": "Weight"
    },
    {
      "sentence": "Registered 1st March 2018.",
      "entity": "Weight"
    },
    {
      "sentence": "Control Groups 1 to 3 received: BTX-A 10 units + saline instillation; hyaluronan-phosphatidylethanolamine (HA-PE) 0.5 g + saline instillation; and BTX-A 5 Uintra-detrusor injections, respectively.",
      "entity": "Weight"
    },
    {
      "sentence": "These improvements were of value to the patient and persisted beyond the 1st year.",
      "entity": "Weight"
    },
    {
      "sentence": "Regarding the plasma fatty acid composition, alpha-linolenic acid levels in the MCNS group were significantly higher than those in the control group (1.06 +/- 0.08 wt% vs. 0.77 +/- 0.16 wt%, p = 0.008) and docosahexaenoic acid levels in the MN group were significantly higher than those in the control group (5.51 +/- 1.17 wt% vs. 3.96 +/- 1.07 wt%, p = 0.005).",
      "entity": "Weight"
    },
    {
      "sentence": "Proteinuria was present at a rate of ≥3 g/24 h in 46.6% of them.",
      "entity": "Weight"
    },
    {
      "sentence": "All kidney biopsies were performed with real-time ultrasound guidance, using an automatic gun fitted with a 16G needle.",
      "entity": "Weight"
    },
    {
      "sentence": "All patients fulfilled at least four criteria (renal abnormalities excluded) of the American Rheumatologic Association for the diagnosis of SLE, and all had severe nephrotic syndrome (mean proteinuria, 9.23 +/- 6 g of protein/24 h; serum albumin concentration, 1.48 +/- 0.6 g/dL).",
      "entity": "Weight"
    },
    {
      "sentence": "Compressive stiffness (62%), torsional stiffness (60%), and early damping stiffness (84%) decreased immediately after injury with the large needle (26G).",
      "entity": "Weight"
    },
    {
      "sentence": "Patients with serum albumin<2.0 g/dl received prophylactic-dose low-molecular-weight heparin or low-dose warfarin; patients with albumin levels of 2.0-3.0 g/dl received aspirin, 75 mg once daily.",
      "entity": "Weight"
    },
    {
      "sentence": "The cohort had features associated with a high risk of developing VTE; 40% of the cohort had an underlying diagnosis of membranous nephropathy, and the initial median serum albumin was 1.5 g/dl (range, 0.5-2.9 g/dl).",
      "entity": "Weight"
    },
    {
      "sentence": "The OGTT contained a final amount of carbohydrate (CHO) of 1.2 g/kg body weight (BW).",
      "entity": "Weight"
    },
    {
      "sentence": "No maximally tolerated dose of rapamycin was attained through escalation to the maximal planned dose of 0.08 mg/kg (2.5 mg/30 kg dog).",
      "entity": "Weight"
    },
    {
      "sentence": "Thirteen men (age = 66 +/- 9; weight = 81 +/- 13kg) and two women (age = 58 +/- 21; weight = 70 +/- 3kg) with coronary heart disease (CHD) trained for 12 weeks to determine the effect of an exercise regimen composed of three- to six-minute intervals of alternating arm and leg cycling (cross-training) on AT.",
      "entity": "Weight"
    },
    {
      "sentence": "The patients were stratified into the non-obese group and obese group if their BMI was <27 or > or =27 kg/m2 respectively.",
      "entity": "Weight"
    },
    {
      "sentence": "At 12 months post cessation, the mean weight gain was (1.81 kg ± 6.83,  Veterans appeared to have minimal weight gain despite statistical significance and no statistical change with BMI after 12 months of being tobacco-free.",
      "entity": "Weight"
    },
    {
      "sentence": "After receiving the 1st vaccine dose, she presented with nephrotic syndrome, with complete remission 5 days later.",
      "entity": "Weight"
    },
    {
      "sentence": "For Fabry's disease, the mean cost per patient (50 kg) treated is around pounds sterling 85,000 per annum in England and Wales.",
      "entity": "Weight"
    },
    {
      "sentence": "For MPS1, the mean cost per child patient (20 kg) treated is approximately pounds sterling 95,000 and an adult (70 kg) around pounds sterling 335,000 per annum in England and Wales.",
      "entity": "Weight"
    },
    {
      "sentence": "Sequencing of the SGLT2 coding region, intronic segments and cDNA revealed three missense mutations (294C>A: F98L; 1388T>G: L463R; 1435C>G: R479G) and two splice mutations (IVS 1-16 C>A: Del exon3; IVS 11+1 G>C: Del exon11).",
      "entity": "Weight"
    },
    {
      "sentence": "High-calorie-expenditure exercise resulted in double the weight loss (8.2+/-4 versus 3.7+/-5 kg; P<0.001) and fat mass loss (5.9+/-4 versus 2.8+/-3 kg; P<0.001) and a greater waist reduction (-7+/-5 versus -5+/-5 cm; P=0.02) than standard CR exercise at 5 months.",
      "entity": "Weight"
    },
    {
      "sentence": "The patient developed sudden onset edema and 10 kg weight gain.",
      "entity": "Weight"
    },
    {
      "sentence": "Eleven patients with 16 infections due to Enterobacteriaceae or Pseudomonas that were in most cases refractory to treatment with cephalosporins, kanamycin, gentamicin, tobramycin, carbenicillin, or ampicillin (administered singly or in combinations) received 1 g of amikacin daily by the intramuscular route (10 patients) or 0.4 g daily (one patient with renal insufficiency).",
      "entity": "Weight"
    },
    {
      "sentence": "On admission, her proteinuria level was 20.88 g/gCr and her selectivity index value was 0.13.",
      "entity": "Weight"
    },
    {
      "sentence": "If dosages are calculated according to body weight, infants < 3 months (or < 5 kg) need approximately 50% more LMWH than older children or adults to reach prophylactic or therapeutic anti-factor Xa levels.",
      "entity": "Weight"
    },
    {
      "sentence": "B2 was added to our experimental RB (0.1 - 10 wt%).",
      "entity": "Weight"
    },
    {
      "sentence": "Upon investigating the degree of conversion and specimen integrity of the RB as a function of B2 concentration, it was determined that loading should be restricted to 0.1, 1.0, and 1.5 wt%.",
      "entity": "Weight"
    },
    {
      "sentence": "Lastly, the antimicrobial response of Streptococcus mutans (S. mutans) biofilm following 6 h growth and 60 s of blue LED light (1.3 J/cm Adding up to 1.5 wt% B2 had minimal impact on the FS or SBS of the RB.",
      "entity": "Weight"
    },
    {
      "sentence": "However, aging for 28-days notably increased the FS by as much as 50% for the 1.5 wt% B2-loaded RB.",
      "entity": "Weight"
    },
    {
      "sentence": "In addition, adding 1.5 wt% B2 resulted in a significant reduction in WS/SL of the RB.",
      "entity": "Weight"
    },
    {
      "sentence": "A total of 1 month after discharge, her 24-h urine protein content was < 1 g, with normal liver function and improved kidney disease.",
      "entity": "Weight"
    },
    {
      "sentence": "Patients with recurrent macroscopic hematuria or isolated microscopic hematuria and proteinuria <1 g/24 h require no specific treatment.",
      "entity": "Weight"
    },
    {
      "sentence": "Patients at greatest risk of progressive renal impairment are those with hypertension, proteinuria >1 g/24 h, and reduced glomerular filtration rate at diagnosis.",
      "entity": "Weight"
    },
    {
      "sentence": "27 exhibited proteinuria ranging from 0.730 to 14.1 g/24 h (5.98 ± 3.40 g/24 h).",
      "entity": "Weight"
    },
    {
      "sentence": "130-150 adults with new or relapsing MCD/FSGS, from UK Renal Units, are being randomised to receive either rituximab (two 1 g infusions two weeks apart) or placebo.",
      "entity": "Weight"
    },
    {
      "sentence": "In one-year follow-up the 24-h urine protein excretion decreased from 30 γ to 0.186 g, and the renal function remain normal.",
      "entity": "Weight"
    },
    {
      "sentence": "The patient presented with over 12 grams of proteinuria and was successfully treated with oral prednisone over the course of 4 weeks.",
      "entity": "Weight"
    },
    {
      "sentence": "In all, intention-to-treat analyses revealed that 69% (10.4/15) of the participants lost 5% of their weight (mean -5.89, SE 0.68 kg).",
      "entity": "Weight"
    },
    {
      "sentence": "Starting dose of Epirubicin was 100 mg/m2 IV bolus on day 1 combined with Ifosfamide, 2.5 g/m2, as a 6-hr IV infusion on day 1 and day 2 with uroprotection with Uromitexan, 1.6 g/m2, on day 1 and day 2.",
      "entity": "Weight"
    },
    {
      "sentence": "The MMP-14 +6767 G>A polymorphism was found to have a hazard ratio of 2.09 (CI 1.00-4.35, p 0.046) for recurrence-free survival in advanced-stage patients.",
      "entity": "Weight"
    },
    {
      "sentence": "In ovarian cancer, the MMP-14 +6767 G>A polymorphism in the coding region seems to improve recurrence-free survival with a hazard ratio of 2.09 (CI 1.00-4.35, p 0.046).",
      "entity": "Weight"
    },
    {
      "sentence": "Eventually, her renal function improved and nephrotic syndrome was resolved, while microscopic hematuria and proteinuria at ~ 1 g/gCr remained at 6 months post-vaccination.",
      "entity": "Weight"
    },
    {
      "sentence": "Thirty-eight of them (44%) impaired splicing, four of which (c.883G>A, c.883G>T, c.884A>T, and c.1080G>T) induced negligible amounts (<5%) of the minigene full-length transcript.",
      "entity": "Weight"
    },
    {
      "sentence": "Another six variants (c.886G>A, c.886G>T, c.1075G>A, c.1075G>T, c.1076A>T, and c.1078G>T) showed significantly strong impacts (20-50% of the minigene full-length transcript).",
      "entity": "Weight"
    },
    {
      "sentence": "Moreover, c.883G>A, c.883G>T, and c.884A>T were classified as pathogenic/likely pathogenic variants according to ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology)-based criteria.",
      "entity": "Weight"
    },
    {
      "sentence": "To investigate: (1) the interrater, and test-retest reliability of the figure-of-eight walk test (F8WT) in people with Parkinson's disease (PwPD); (2) the minimum detectable change in the F8WT times; (3) the concurrent and known-groups validity of the F8WT times; and (4) the cut-off times that best discriminate PwPD from healthy people and fallers from non-fallers with PD.",
      "entity": "Weight"
    },
    {
      "sentence": "The F8WT was performed along with the timed up and go test, 10 m walk test, Berg Balance Scale, Activities-Specific Balance Confidence Scale, Unified Parkinson's disease Rating Scale, and Hoehn and Yahr Scale.",
      "entity": "Weight"
    },
    {
      "sentence": "The F8WT showed good interrater and test-retest reliability (ICC = 0.964-0.978 and ICC = 0.905-0.920, respectively).",
      "entity": "Weight"
    },
    {
      "sentence": "The MDC was 2.77 s. The F8WT was correlated with other outcome measures.",
      "entity": "Weight"
    },
    {
      "sentence": "Significant differences in the F8WT times were found between PwPD and healthy people and between fallers and non-fallers with PD ( The F8WT is a reliable, valid, and easy-to-administer tool in assessing the walking skill of PwPD.Implications for rehabilitationThe figure-of-eight walk test (F8WT) is a reliable, valid, and clinically available tool for assessing walking skill in Parkinson's disease (PD).The minimal detectable change of the F8WT is 2.77 s, which may help to determine any real change in walking skill after any intervention.The F8WT correlated with functional mobility, gait speed, balance, balance confidence, and severity and stage of PD.The F8WT times may detect impaired walking skill between people with PD and healthy people, and between fallers and non-fallers with PD.",
      "entity": "Weight"
    },
    {
      "sentence": "Peripheral mononuclear blood cells isolated from nephrotic subjects with minimal-change nephrotic syndrome (selective proteinuria greater than 3.5 g/24 h) or various other forms of glomerulonephritis (non-selective proteinuria greater than 3.5 g/24 h) were stimulated with concanavalin A and cultured for 20 h in the presence of kidney tissue under standard conditions.",
      "entity": "Weight"
    },
    {
      "sentence": "We performed a post-hoc analysis of 132 non-diabetic women who underwent 75-g oral glucose tolerance testing.",
      "entity": "Weight"
    },
    {
      "sentence": "Participants were randomly assigned to receive 10 g of Chinese herbal medicine (according to the type of Traditional Chinese medicine syndrome: Sanhanhuayin, Qingrehuatan, or Zaoshihuatan granules) or placebo, two times per day, for 14 days, in addition to conventional medicine.",
      "entity": "Weight"
    },
    {
      "sentence": "Thirty-six patients with ALS will be randomly assigned to one of three groups, each receiving the standard treatment with 100 mg of riluzole in addition to one of 1.6 g of Mecasin, 2.4 g of Mecasin, or a placebo.",
      "entity": "Weight"
    },
    {
      "sentence": "Probiotics may have little or no effect on albuminuria at 12 or 24 weeks compared to placebo or no treatment (4 studies, 193 participants: MD 0.02 g/dL, 95% CI -0.08 to 0.13; I² = 0%; low certainty evidence).",
      "entity": "Weight"
    },
    {
      "sentence": "The hydrogels remained transparent even at very high polymer concentrations (20 wt%) and are demonstrated to facilitate controlled release of a model drug (doxorubicin).",
      "entity": "Weight"
    },
    {
      "sentence": "The mean birth weight of each group was 777 g (629-1000), 3110 g (2888-3358), and 3120 g (2748-3398), respectively (median [25th-75th percentile]).",
      "entity": "Weight"
    },
    {
      "sentence": "Adults at risk for cardiovascular disease (CVD) who lost at least 4 kilograms in an initial 20-week group-based, behavioral weight-loss program were trained to use an interactive website for weight loss maintenance.",
      "entity": "Weight"
    },
    {
      "sentence": "Mean weight loss was 8.6 kilograms.",
      "entity": "Weight"
    },
    {
      "sentence": "It was a cross-sectional study carried out from 1st January 2012 to 30th December 2016 in Histopathology department, Shifa International Hospital.",
      "entity": "Weight"
    },
    {
      "sentence": "We tried to assess the influence of the -2578 C/A and -1154 G/A polymorphisms in the regulatory region of the vascular endothelial growth factor gene upon progression of three primary chronic glomerulonephritides (minimal change disease/focal and segmental glomerulosclerosis, membranous nephropathy, immunoglobulin A nephropathy).",
      "entity": "Weight"
    },
    {
      "sentence": "A balanced distribution of G and A alleles among the respective types of chronic glomerulonephritides was shown in the analysis of -1154 G/A polymorphism.",
      "entity": "Weight"
    },
    {
      "sentence": "Finally, we have not proved any significant influence of the polymorphisms at positions -2578 C/A and -1154 G/A of the vascular endothelial growth factor gene promoter on the progression of chronic glomerulonephritides even though our study suggests a negative effect of CC genotype of -2578 C/A polymorphism on the clinical course of minimal change disease/focal segmental glomerulosclerosis.",
      "entity": "Weight"
    },
    {
      "sentence": "In cases of minor proteinuria [< 3,5 g/24 h] immunosuppressive therapy is not superior to symptomatic therapy.",
      "entity": "Weight"
    },
    {
      "sentence": "With tolvaptan treatment, patient urine output increased dramatically to approximately 5.5 L/day and body weight decreased by 9 kg over 5 days.",
      "entity": "Weight"
    },
    {
      "sentence": "We hypothesized that Tai Chi is equivalent (ie, difference less than ±4 St. George's Respiratory Questionnaire [SGRQ] points) to PR.",
      "entity": "Weight"
    },
    {
      "sentence": "There was minimal mean weight change with aripiprazole (+0.71 kg) and haloperidol (+0.56 kg), and a lack of QT(c) prolongation.",
      "entity": "Weight"
    },
    {
      "sentence": "A fall of haemoglobin of more than 2 g/dl was seen in 71%.",
      "entity": "Weight"
    },
    {
      "sentence": "We report a patient who used non-steroidal anti-inflammatory drugs for years without diabetes, chronic kidney disease, or proteinuria; he then developed severe nephrotic range proteinuria with 7 g of daily urinary protein excretion.",
      "entity": "Weight"
    },
    {
      "sentence": "Subxiphoid minimally invasive pacemaker lead placement was performed in 8 animals (median 4.9 kg) with 100% acute success.",
      "entity": "Weight"
    },
    {
      "sentence": "Comparative responsiveness was determined in a randomized trial of AS patients receiving etanercept (ETN) 50 mg weekly or SSZ 3 g daily.",
      "entity": "Weight"
    },
    {
      "sentence": "Expressed as SDD, a BMD change of at least +/-0.04 g/cm2 at L1-L4 and +/-0.02 g/cm2 at the total hip should be considered significant.",
      "entity": "Weight"
    },
    {
      "sentence": "Median 4-year weight gain was greater for recent quitters without diabetes (2.7 kg [interquartile range {IQR}, -0.5 to 6.4]) and with diabetes (3.6 kg [IQR, -1.4 to 8.2]) than for long-term quitters (0.9 kg [IQR, -1.4 to 3.2] and 0.0 kg [IQR, -3.2 to 3.2], respectively, P < .001).",
      "entity": "Weight"
    },
    {
      "sentence": "Patients were randomized 1:1 to receive either 2 g/kg of IVIg or placebo, administered every 4 weeks until week 16 (First Period).",
      "entity": "Weight"
    },
    {
      "sentence": "After response assessment at week 16, all patients on placebo and those without deterioration on IVIg entered the open-label Extension Period, receiving 2 g/kg IVIg every 4 weeks for 24 weeks.",
      "entity": "Weight"
    },
    {
      "sentence": "In 22 infants and children aged 6 to 62 months (mean = 23 months) with severe constipation a commercially produced solid food containing 4.2 g wheat bran was used for 41 days.",
      "entity": "Weight"
    },
    {
      "sentence": "Variation in proteinuria (2.88+/-2.1 g/24 h vs. 3.45+/-1.7 g/24 h; p=0.4) did not reach statistical significance (Wilcoxon-Mann-Whitney).",
      "entity": "Weight"
    },
    {
      "sentence": "Intermittent treatment with LOLA was given to the study group at 15 g once daily in the morning for 2 months with 2-month off-treatment intervals, with the total treatment duration of 12 months.",
      "entity": "Weight"
    },
    {
      "sentence": "The results of the CFF test significantly improved by the end of the 1st month of LOLA treatment (p=0.008), remaining at the achieved level for 9 months.",
      "entity": "Weight"
    },
    {
      "sentence": "Gallbladder emptying was evaluated for 90 min after ingestion of a solid-liquid meal (14 g fat, 425 kcal), by assessing minimal residual volume, gallbladder ejection fraction, and area under emptying curve at 15-min intervals.",
      "entity": "Weight"
    },
    {
      "sentence": "The aim of the present study was to investigate whether the four guanosines (4G)/five guanosines (5G) polymorphism in the gene coding for plasminogen activator inhibitor-1 (PAI-1) affects the clinical features of primary nephrotic syndrome (PNS).",
      "entity": "Weight"
    },
    {
      "sentence": "Associations between the PAI-1 4G/5G polymorphism and clinical features and pathological types of PNS were analyzed.",
      "entity": "Weight"
    },
    {
      "sentence": "The results indicated that the PAI-1 genotype distribution is significantly different between patients with PNS and healthy controls, with significantly higher numbers of the 4G/4G genotype and lower numbers of the 5G5G genotype detected in PNS patients compared to controls (both P<0.05).",
      "entity": "Weight"
    },
    {
      "sentence": "The frequency of the 4G allele was also significantly higher in PNS patients compared to healthy controls (P<0.01).",
      "entity": "Weight"
    },
    {
      "sentence": "Among the different pathological types of PNS, IgA nephropathy (IgAN) and membranous nephropathy (MN) were associated with significantly increased frequencies of the 4G/4G and 4G/5G genotypes, as well as of the 4G allele.",
      "entity": "Weight"
    },
    {
      "sentence": "The increased 4G frequency was also detected in patients with minimal change disease (MCD).",
      "entity": "Weight"
    },
    {
      "sentence": "Significantly increased international normalized ratio (INR) and prolonged activated partial thromboplastin time (APTT) were observed in 4G/4G compared to 5G/5G PNS subjects.",
      "entity": "Weight"
    },
    {
      "sentence": "In conclusion, the 4G allele of the PAI-1 gene appears to be associated with PNS, especially in MN and IgAN patients.",
      "entity": "Weight"
    },
    {
      "sentence": "These findings suggest that specific targeting may be required for the treatment of PNS patients with the 4G/4G genotype.",
      "entity": "Weight"
    },
    {
      "sentence": "Patients treated with erythropoiesis-stimulating agents (ESAs) to a hemoglobin (Hb) level >12.0 g/dl have increased risk of multiple complications, including death.",
      "entity": "Weight"
    },
    {
      "sentence": "We hypothesized that reducing the target Hb would prevent levels >12 g/dl and lead to significant cost savings.",
      "entity": "Weight"
    },
    {
      "sentence": "Our target Hb range was reduced to 9-11 g/dl from 10-12 g/dl.",
      "entity": "Weight"
    },
    {
      "sentence": "The mean monthly Hb level changed from 11.2 to 10.6 g/dl.",
      "entity": "Weight"
    },
    {
      "sentence": "The percentages of patients with mean Hb >10.0, 12.0 and 13.0 g/dl were 82 ± 6.5, 10 ± 5.6 and 1.8 ± 1.9%, respectively.",
      "entity": "Weight"
    },
    {
      "sentence": "Lowering the target Hb range to 9-11 g/dl in HD patients achieved quality anemia management, avoided values >12.0 g/dl and resulted in cost savings.",
      "entity": "Weight"
    },
    {
      "sentence": "During the 5-year time period, the majority of women (9,251, 55.7%) gained weight (mean 4.43 kg, +/-5.95 kg), and the overall rate of prolapse (WHI Prolapse Classification System: grades 1-3) increased from 40.9% at baseline to 43.8% at year 5 of evaluation.",
      "entity": "Weight"
    },
    {
      "sentence": "Statistical analysis showed a significantly increased chance of TR in children carrying 3435TC genotype (OR=5.13, 95% CI=1.18-22.25; overdominant model).",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "Resistant variants of human immunodeficiency virus type 1 (HIV-1) have been selected by limited passage in MT4 cells of both wild-type and 3'-azido-3'-deoxythymidine (AZT, zidovudine)-resistant strains with the nucleoside analogues (-)-2'-deoxy-3'-thiacytidine (3TC) and (-)-2'-deoxy-5-fluoro-3'-thiacytidine (FTC).",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "When the mutation Met184-->Val was introduced into the infectious clone HXB2, this change alone accounted for the resistance (> 1000-fold) seen with both 3TC and FTC, and for a 5- to 15-fold reduction in sensitivity to their (+) enantiomers.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "All mutants with Met184-->Val were cross-resistant to 3TC and FTC.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "The Fc-receptor function of SM was ascertained by measuring the spleen to liver uptake ratio 40 min after IV injection of heat-damaged autologous erythrocytes labeled with 99Tc, whereas the Fc-receptor function of CM was determined by a \"rosetting\" test.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "An isotopic study with 99Tc may avoid a surgical procedure quite often unnecessary.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "RANTES/CCL5 -403 TC and TT genotype were significantly associated with renal manifestations with an OR (95% CI) of 4.33 (1.44-12.99), adjusted for sex and age and the other two SNP genotypes.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "Highly active anti-retroviral therapy (HAART) consisting of efavirenz, 3TC, and d4T was started.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "The effect of therapy on clinical end points (death, cardiac and cerebrovascular event, renal failure), cardiac and renal function monitored by Doppler echocardiography, 99Tc-GFR, and proteinuria was investigated.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "Dynamic The mIF 1-TC model detected perfusion deficits and  Pharmacokinetic (1-TC) modelling using a 30 min PET-MR time frame detected impaired haemodynamics and increased amyloid load in probable CAA.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "A two-tissue-compartment (2TC) kinetic model was fitted to time-activity curves (TAC) obtained from left ventricle wall and left atrium cavity ROIs to estimate kinetic micro- and macro-parameters.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "Pharmacokinetic analysis based on a 2TC model allows cardiac amyloidosis characterization from dynamic [18F]Florbetaben PET images.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "TTR cardiac amyloidosis was diagnosed according to accepted criteria, which include positive cardiac 99-Tc-DPD scintigraphy in the absence of monoclonal protein expansion in blood.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "The purpose of this study was to describe the ultrasonographic (US) and computed tomographic (CT) appearance of autosomal dominant polycystic kidney disease (ADPKD) in cats; to compare renal volume in cats with ADPKD (n = 5; mean age 59 +/- 10 months)) and normal cats (n = 5; mean age 66 +/- 10 months) using 2 imaging modalities, US and CT; and to calculate cyst volume using CT. Glomerular filtration rate (GFR) was determined by 2 methods: 99mTc-diethylene-triaminepentaacetic acid (99mTc-DPTA) scintigraphic uptake and 99-Tc-DTPA plasma clearance.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "The purpose of this study was to describe the ultrasonographic (US) and computed tomographic (CT) appearance of autosomal dominant polycystic kidney disease (ADPKD) in cats; to compare renal volume in cats with ADPKD (n = 5; mean age 59 +/- 10 months)) and normal cats (n = 5; mean age 66 +/- 10 months) using 2 imaging modalities, US and CT; and to calculate cyst volume using CT. Glomerular filtration rate (GFR) was determined by 2 methods: 99mTc-diethylene-triaminepentaacetic acid (99mTc-DPTA) scintigraphic uptake and 99-Tc-DTPA plasma clearance.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "Statistical analysis showed a significantly increased chance of TR in children carrying 3435TC genotype (OR=5.13, 95% CI=1.18-22.25; overdominant model).",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "In group 1 total cholesterol in blood lowered to normal values, LDLP cholesterol fell by 35.2%, VLDLP cholesterol rose by 17.7%.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "APN was diagnosed by urine culture and typical findings on 99Tc-DMSA scans.",
      "entity": "Cholesterol (total)"
    },
    {
      "sentence": "99Tc-DMSA scans diagnosed 86 children with APN.",
      "entity": "Cholesterol (total)"
    }
  ],
  "negatives": [
    "Apolipoprotein-L1 (APOL1) G1 and G2 risk variants, found in people of recent west sub-Saharan African ancestry, dramatically increase the likelihood of kidney disease, yet the incomplete penetrance an diverse clinical manifestations underscore the need to understand the molecular and environmental factors that modulate APOL1-mediated toxicity.",
    "Recent studies confirm that risk variants exert a toxic gain-of-function effect, exacerbated by inflammatory triggers such as HIV infection and COVID-19.",
    "Epigenetic mechanisms and microRNA pathways further modulate APOL1 expression, influencing disease penetrance.",
    "Multiple models have clarified how subcellular localization, signal peptide processing, and interactions with the endoplasmic reticulum may contribute to pathogenesis.",
    "Therapeutic advances include inhibitors targeting APOL1 ion channel activity and strategies that block key inflammatory signaling pathways.",
    "These findings highlight a multifaceted disease process driven by both the intrinsic toxic potential of APOL1 variants and numerous extrinsic triggers.",
    "Understanding this complex interplay will be pivotal for risk stratification and the development of precision therapies, potentially improving outcomes for populations disproportionately affected by APOL1-associated kidney disease.",
    "HIV-associated nephropathy (HIVAN) is an important cause of secondary focal glomerulosclerosis that occurs primarily in persons of African ancestry with advanced HIV disease.",
    "Although HIVAN is characterized by severe proteinuria and rapid progression to end stage renal disease without treatment, the phenotype is markedly attenuated by treatment with antiretroviral medications.",
    "HIV infection of glomerular and tubular epithelial cells and subsequent viral gene expression is a key contributor to HIVAN pathogenesis and the kidney can serve as reservoir for HIV strains that differ those in blood.",
    "HIV gene expression in renal epithelial cells leads to dysregulation of cellular pathways including cell cycle, inflammation, cell death, and cytoskeletal homeostasis.",
    "Polymorphisms in the APOL1 gene explain the marked predilection of HIVAN to occur in persons of African descent and HIVAN.",
    "Since HIVAN has the strongest association with APOL1 genotype of any of the APOL1-associated nephropathies, studies to determine the mechanisms by which HIV and APOL1 risk variants together promote kidney injury hold great promise to improve our understanding of the pathogenesis of APOL1-mediated kidney diseases.",
    "Risk variants of the apolipoprotein-L1 (APOL1) gene are associated with severe kidney disease, putting homozygous carriers at risk.",
    "Since APOL1 lacks orthologs in all major model organisms, a wide range of mechanisms frequently in conflict have been described for APOL1-associated nephropathies.",
    "The genetic toolkit in Drosophila allows unique in vivo insights into disrupted cellular homeostasis.",
    "To perform a mechanistic analysis, we expressed human APOL1 control and gain-of-function kidney risk variants in the podocyte-like garland cells of Drosophila nephrocytes and a wing precursor tissue.",
    "Expression of APOL1 risk variants was found to elevate endocytic function of garland cell nephrocytes that simultaneously showed early signs of cell death.",
    "Wild-type APOL1 had a significantly milder effect, while a control transgene with deletion of the short BH3 domain showed no overt phenotype.",
    "Nephrocyte endo-lysosomal function and slit diaphragm architecture remained unaffected by APOL1 risk variants, but endoplasmic reticulum (ER) swelling, chaperone induction, and expression of the reporter Xbp1-EGFP suggested an ER stress response.",
    "Pharmacological inhibition of ER stress diminished APOL1-mediated cell death and direct ER stress induction enhanced nephrocyte endocytic function similar to expression of APOL1 risk variants.",
    "We confirmed APOL1-dependent ER stress in the Drosophila wing precursor where silencing the IRE1-dependent branch of ER stress signaling by inhibition with Xbp1-RNAi abrogated cell death, representing the first rescue of APOL1-associated cytotoxicity in vivo.",
    "Thus, we uncovered ER stress as an essential consequence of APOL1 risk variant expression in vivo in Drosophila, suggesting a central role of this pathway in the pathogenesis of APOL1-associated nephropathies.",
    "SARS-CoV-2 infection increases systemic inflammatory cytokines which act as a second-hit driver of Apolipoprotein L1 (APOL1)-mediated collapsing glomerulopathy.",
    "SARS-CoV-2 vaccination also increases cytokines.",
    "Recent reports of new glomerular disease in individuals with  We screened 1507 adults in the Duke's Measurement to Understand Reclassification of Disease of Cabarrus and Kannapolis (MURDOCK) registry and enrolled 105 eligible participants with available SARS-CoV-2 vaccination data, prevaccination and postvaccination serum creatinine, and urine protein measurements.",
    "Paired data were stratified by number of APOL1 risk alleles (RAs) and compared within groups using Wilcoxon signed rank test and across groups by analysis of variance.",
    "Among 105 participants, 30 (28.6%) had 2, 39 (37.1%) had 1, and 36 (34.3%) had 0 APOL1 RA.",
    "Most of the participants (94%) received at least 2 doses of vaccine.",
    "Most (98%) received the BNT162B2 (Pfizer) or mRNA-1273 (Moderna) vaccine.",
    "On average, the prevaccine and postvaccine laboratory samples were drawn 648 days apart.",
    "There were no detectable differences between pre- and post-serum creatinine or pre- and post-urine albumin creatinine ratio irrespective of the participants' APOL1 genotype.",
    "Finally, most participants with APOL1 RA had the most common haplotype (E150, I228, and K255) and lacked the recently described protective N264K haplotype.",
    "In this observational study,",
    "Two coding variants of apolipoprotein L1 (APOL1), called G1 and G2, explain much of the excess risk of kidney disease in African Americans.",
    "While various cytotoxic phenotypes have been reported in experimental models, the proximal mechanism by which G1 and G2 cause kidney disease is poorly understood.",
    "Here, we leveraged 3 experimental models and a recently reported small molecule blocker of APOL1 protein, VX-147, to identify the upstream mechanism of G1-induced cytotoxicity.",
    "In HEK293 cells, we demonstrated that G1-mediated Na+ import/K+ efflux triggered activation of GPCR/IP3-mediated calcium release from the ER, impaired mitochondrial ATP production, and impaired translation, which were all reversed by VX-147.",
    "In human urine-derived podocyte-like epithelial cells (HUPECs), we demonstrated that G1 caused cytotoxicity that was again reversible by VX-147.",
    "Finally, in podocytes isolated from APOL1 G1 transgenic mice, we showed that IFN-γ-mediated induction of G1 caused K+ efflux, activation of GPCR/IP3 signaling, and inhibition of translation, podocyte injury, and proteinuria, all reversed by VX-147.",
    "Together, these results establish APOL1-mediated Na+/K+ transport as the proximal driver of APOL1-mediated kidney disease.",
    "Elevated interferon (IFN) signaling is associated with kidney diseases including COVID-19, HIV, and apolipoprotein-L1 (APOL1) nephropathy, but whether IFNs directly contribute to nephrotoxicity remains unclear.",
    "Using human kidney organoids, primary endothelial cells, and patient samples, we demonstrate that IFN-γ induces pyroptotic angiopathy in combination with APOL1 expression.",
    "Single-cell RNA sequencing, immunoblotting, and quantitative fluorescence-based assays reveal that IFN-γ-mediated expression of APOL1 is accompanied by pyroptotic endothelial network degradation in organoids.",
    "Pharmacological blockade of IFN-γ signaling inhibits APOL1 expression, prevents upregulation of pyroptosis-associated genes, and rescues vascular networks.",
    "Multiomic analyses in patients with COVID-19, proteinuric kidney disease, and collapsing glomerulopathy similarly demonstrate increased IFN signaling and pyroptosis-associated gene expression correlating with accelerated renal disease progression.",
    "Our results reveal that IFN-γ signaling simultaneously induces endothelial injury and primes renal cells for pyroptosis, suggesting a combinatorial mechanism for APOL1-mediated collapsing glomerulopathy, which can be targeted therapeutically.",
    "Studies have documented AKI with high-grade proteinuria in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.",
    "In some patients, biopsies have revealed collapsing glomerulopathy, a distinct form of glomerular injury that has been associated with other viruses, including HIV.",
    "Previous patient reports have described patients of African ancestry who developed nephrotic-range proteinuria and AKI early in the course of disease.",
    "In this patient series, we identified six patients with coronavirus disease 2019 (COVID-19), AKI, and nephrotic-range proteinuria.",
    "COVID-19 was diagnosed by a positive nasopharyngeal swab RT-PCR for SARS-CoV-2 infection.",
    "We examined biopsy specimens from one transplanted kidney and five native kidneys.",
    "Three of the six patients underwent genetic analysis of  All six patients were of recent African ancestry.",
    "They developed COVID-19-associated AKI with podocytopathy, collapsing glomerulopathy, or both.",
    "Patients exhibited generally mild respiratory symptoms, and no patient required ventilator support.",
    "Genetic testing performed in three patients confirmed high-risk  Glomerular disease presenting as proteinuria with or without AKI is an important presentation of COVID-19 infection and may be associated with a high-risk",
    "People of recent African ancestry develop kidney disease at much higher rates than most other groups.",
    "Two specific coding variants in the Apolipoprotein-L1 gene",
    "The genetic variations of the apolipoprotein L1 (APOL1) gene are associated with non-diabetic kidney diseases.",
    "However, very little is known about the role of ApoL1 in glomerular damage.",
    "Here, we aimed to identify the function and mechanism of ApoL1 in glomerular damage.",
    "The mice were randomly divided into two groups: one group was intraperitoneally injected with phosphate buffer saline (PBS), while the other group was intraperitoneally injected with recombinant ApoL1 every other day for 3 months.",
    "Hematoxylin and eosin (HE) and periodic acid Schiff (PAS) staining were used to demonstrate the effects of ApoL1 on kidney inflammation and injury.",
    "Furthermore, quantitative real-time polymerase chain reaction (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA) analyses revealed that ApoL1-treated mice exhibited enhanced expression of various inflammation markers in the kidney and serum compared to the PBS-treated mice.",
    "Immunofluorescence staining revealed that ApoL1 accumulated in kidney podocytes.",
    "Treatment with ApoL1 dose-dependently increased the expression of inflammation markers and apoptotic markers.",
    "The abnormal gene expression associated with ApoL1-mediated podocyte inflammation was evaluated using microarray analysis.",
    "Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses revealed that the upregulated genes were enriched in the inflammation-related processes, such as the RIG-I/NF-κB signaling pathway.",
    "Consistently, the knockdown of RIG-I significantly mitigated the ApoL1-induced upregulation of inflammatory and apoptotic markers in the human podocytes.",
    "Additionally, the ApoL1-induced glomerular damage was attenuated in AAV-shRIG-I mice.",
    "Therefore, the effects of ApoL1 on glomerular damage may be, at least partially, through inducing abnormal expression of inflammatory molecules, which may have important implications for treatment of kidney diseases.",
    "The spectrum of kidney diseases caused by variation in the apolipoprotein L1 (APOL1) gene was identified in 2010 among patients with recent African ancestry.",
    "In the United States, inheriting two APOL1 risk variants (high-risk genotypes) markedly increases risk for solidified glomerulosclerosis, focal segmental glomerulosclerosis, collapsing glomerulopathy, lupus nephritis, and sickle cell nephropathy.",
    "Kidneys from African American deceased donors with APOL1 high-risk genotypes also fail more rapidly after transplant.",
    "One risk variant increases nephropathy risk in Africa.",
    "This review focuses on novel therapies targeting APOL1 and the changing landscape of APOL1 genotyping in patients at risk for APOL1-mediated kidney disease (AMKD).",
    "Renin-angiotensin-aldosterone system blockade and sodium-glucose cotransporter 2 inhibitors slow nephropathy progression but are not curative.",
    "Medications directly targeting APOL1 mRNA and blocking APOL1 protein effects are undergoing clinical trials in AMKD, including APOL1 small molecule inhibitors, an APOL1 antisense oligonucleotide, and a Janus kinase (JAK) signaling inhibitor to reduce APOL1 expression.",
    "Early results are promising and provide hope for well tolerated and effective therapies.",
    "If successful, more patients will need to be considered for APOL1 genotyping, and our approach to diagnosing and treating chronic kidney disease in populations with recent African ancestry will change dramatically.",
    "Mechanisms of APOL1 risk variant nephrotoxicity remain unclear; nonetheless, specific therapies for AMKD show great promise and may improve understanding of disease processes.",
    "With ongoing clinical trials and the potential for effective AMKD treatments, more widespread APOL1 genotyping will likely be needed.",
    "Toxic gain-of-function  We conducted two phase 1 studies evaluating the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of inaxaplin in healthy participants.",
    "In the SAD cohorts, participants were randomized to receive inaxaplin as a single dose (range, 7.5 mg to 165 mg) or placebo.",
    "In the MAD cohorts, participants were randomized to receive multiple doses of inaxaplin (range, 15 to 120 mg daily) or placebo for 14 days.",
    "We assessed safety and tolerability based on adverse events (AEs), clinical laboratory values, electrocardiograms (ECGs), and vital signs.",
    "The proportion of participants with any AEs was similar in the inaxaplin (24.6%) and placebo (22.7%) groups.",
    "All AEs were mild or moderate in severity; there were no serious AEs.",
    "Headache was the most common AE: 10.4% and 2.3% in the inaxaplin and placebo groups, respectively.",
    "There were no drug-related treatment discontinuations and no clinically relevant trends in laboratory values, ECGs, or vital signs.",
    "Inaxaplin is safe and well tolerated at single doses up to 165 mg and multiple doses up to 120 mg daily for 14 days.",
    "These results are consistent with the favorable safety profile of inaxaplin in a completed phase 2a proof-of-concept study.",
    "Together, these findings support continued evaluation of inaxaplin in an ongoing phase 2/3 pivotal trial as a potential precision medicine for patients with AMKD.",
    "In people of African ancestry, apolipoprotein L1 gene (APOL1) variants have been identified as causing increased risk of progressive chronic kidney disease (CKD).",
    "In April of 2024, Kidney Disease: Improving Global Outcomes (KDIGO) convened a Controversies Conference on APOL1 Kidney Disease in Accra, Ghana.",
    "The goals of the conference were to review and discuss current evidence and controversies on APOL1 kidney disease, including naming, epidemiology, pathophysiology, APOL1 testing, treatment, and future research needs.",
    "Participants considered various terminologies for diseases related to APOL1 risk variants (such as APOL1-mediated or -induced kidney disease) and had highest support for using APOL1 kidney disease to describe kidney pathologies associated with the APOL1 G1 and G2 risk variants.",
    "Clinically, the term APOL1 kidney disease can be used on its own or as an overall category of kidney disease, with further specification added as needed (for example, APOL1 kidney disease, focal segmental glomerulosclerosis).",
    "Given that there are currently no established treatments for APOL1 kidney disease, and APOL1 genotype results are not by themselves actionable, there is insufficient evidence to guide recommendations for APOL1 population screening or routine testing.",
    "However, genotyping can be an important clinical consideration for individuals to inform risk stratification, frequency of follow-up, living kidney donation, as well as clinical trial eligibility.",
    "Key areas of need and strategies for future research were delineated and are reported here.",
    "African Americans are at increased risk of CKD in part due to high-risk (HR) variants in the apolipoprotein L1 ( APOL1 ) gene, termed G1/G2.",
    "A different APOL1 variant, p.N264K , reduced the risk of CKD and ESKD among carriers of APOL1 HR variants to levels comparable with individuals with APOL1 low-risk variants in an analysis of 121,492 participants of African ancestry from the Million Veteran Program (MVP).",
    "Functional genetic studies in cell models showed that APOL1 p.N264K blocked APOL1 pore-forming function and ion channel conduction and reduced toxicity of APOL1 HR mutations.",
    "Pharmacologic inhibitors that mimic this mutation blocking APOL1 -mediated pore formation may be able to prevent and/or treat APOL1 -associated kidney disease.",
    "African Americans are at increased risk for nondiabetic CKD in part due to HR variants in the APOL1 gene.",
    "We tested whether a different APOL1 variant, p.N264K , modified the association between APOL1 HR genotypes (two copies of G1/G2) and CKD in a cross-sectional analysis of 121,492 participants of African ancestry from the MVP.",
    "We replicated our findings in the Vanderbilt University Biobank ( n =14,386) and National Institutes of Health All of Us ( n =14,704).",
    "Primary outcome was CKD and secondary outcome was ESKD among nondiabetic patients.",
    "Primary analysis compared APOL1 HR genotypes with and without p.N264K .",
    "Secondary analyses included APOL1 low-risk genotypes and tested for interaction.",
    "In MVP, we performed sequential logistic regression models adjusting for demographics, comorbidities, medications, and ten principal components of ancestry.",
    "Functional genomic studies expressed APOL1 HR variants with and without APOL1 p.N264K in cell models.",
    "In the MVP cohort, 15,604 (12.8%) had two APOL1 HR variants, of which 582 (0.5%) also had APOL1 p.N264K .",
    "In MVP, 18,831 (15%) had CKD, 4177 (3%) had ESKD, and 34% had diabetes.",
    "MVP APOL1 HR, without p.N264K , was associated with increased odds of CKD (odds ratio [OR], 1.72; 95% confidence interval [CI], 1.60 to 1.85) and ESKD (OR, 3.94; 95% CI, 3.52 to 4.41).",
    "In MVP, APOL1 p.N264K mitigated the renal risk of APOL1 HR, in CKD (OR, 0.43; 95% CI, 0.28 to 0.65) and ESKD (OR, 0.19; CI 0.07 to 0.51).",
    "In the replication cohorts meta-analysis, APOL1 p.N264K mitigated the renal risk of APOL1 HR in CKD (OR, 0.40; 95% CI, 0.18 to 0.92) and ESKD (OR, 0.19; 95% CI, 0.05 to 0.79).",
    "In the mechanistic studies, APOL1 p.N264K blocked APOL1 pore-forming function and ion channel conduction and reduced toxicity of APOL1 HR variants.",
    "APOL1 p.N264K is associated with reduced risk of CKD and ESKD among carriers of APOL1 HR to levels comparable with individuals with APOL1 low-risk genotypes.",
    "Two heterozygous missense variants (G1 and G2) of Apolipoprotein L1 (APOL1) found in individuals of recent African ancestry can attenuate the severity of infection by some forms of Trypanosoma brucei.",
    "However, these two variants within a broader African haplotype also increase the risk of kidney disease in Americans of African descent.",
    "Although overexpression of either variant G1 or G2 causes multiple pathogenic changes in cultured cells and transgenic mouse models, the mechanism(s) promoting kidney disease remain unclear.",
    "Human serum APOL1 kills trypanosomes through its cation channel activity, and cation channel activity of recombinant APOL1 has been reconstituted in lipid bilayers and proteoliposomes.",
    "Although APOL1 overexpression increases whole cell cation currents in HEK-293 cells, the ion channel activity of APOL1 has not been assessed in glomerular podocytes, the major site of APOL1-associated kidney diseases.",
    "We characterize APOL1-associated whole cell and on-cell cation currents in HEK-293 T-Rex cells and demonstrate partial inhibition of currents by anti-APOL antibodies.",
    "We detect in primary human podocytes a similar cation current inducible by interferon-γ (IFNγ) and sensitive to inhibition by anti-APOL antibody as well as by a fragment of T. brucei Serum Resistance-Associated protein (SRA).",
    "CRISPR knockout of APOL1 in human primary podocytes abrogates the IFNγ-induced, antibody-sensitive current.",
    "Our novel characterization in HEK-293 cells of heterologous APOL1-associated cation conductance inhibited by anti-APOL antibody and our documentation in primary human glomerular podocytes of endogenous IFNγ-stimulated, APOL1-mediated, SRA and anti-APOL-sensitive ion channel activity together support APOL1-mediated channel activity as a therapeutic target for treatment of APOL1-associated kidney diseases.",
    "APOL1-mediated kidney diseases have forever changed nephrology and kidney transplantation.",
    "Neves et al.",
    "extend this field with analyses in admixed Brazilians with the most severe type of APOL1-mediated kidney disease, idiopathic collapsing glomerulopathy.",
    "Causative gene variants were detected in 58.6% of patients; 80.5% had APOL1 high-risk genotypes, and 19.5% had causative Mendelian variants.",
    "Their work identifies the cause of previous idiopathic collapsing glomerulopathy and provides opportunities to identify novel modifiers in severe APOL1-mediated kidney diseases that are relevant beyond Brazil.",
    "APOL1 is found in human kidney podocytes and endothelia.",
    "Variants G1 and G2 of the  Immunohistochemistry, confocal and immunoelectron microscopy, and podocyte fractionation localized endogenous and transfected APOL1 using a large panel of novel APOL1-specific mouse and rabbit monoclonal antibodies.",
    "Both endogenous podocyte and transfected APOL1 isoforms vA and vB1 (and a little of isoform vC) localize to the luminal face of the endoplasmic reticulum (ER) and to the cell surface, but not to mitochondria, endosomes, or lipid droplets.",
    "In contrast, APOL2, isoform vB3, and most vC of APOL1 localize to the cytoplasmic face of the ER and are consequently absent from the cell surface.",
    "APOL1 is found in the ER and plasma membrane, consistent with either the ER stress or surface cation channel models of APOL1-mediated cytotoxicity.",
    "The surface localization of APOL1 variants potentially opens new therapeutic targeting avenues.",
    "Understanding the genetic risk of APOL1 in children and young adults is important given the lifetime risk of hypertension and kidney disease among children of African descent.",
    "We review recent epidemiologic and biologic findings on the effects of APOL1 and kidney disease.",
    "APOL1 in children and young adults is associated with hypertension, albuminuria and more rapid decline in kidney function and progression to end-stage kidney disease, especially among those with glomerular causes of kidney disease, and those affected by sickle cell disease or HIV.",
    "There are conflicting data on the APOL1 association with cardiovascular disease in children and young adults.",
    "APOL1 functions as part of the innate immune system.",
    "Podocyte expression of APOL1 likely contributes to the development of kidney disease.",
    "In cell culture and model organisms, APOL1 expression disrupts autophagic and ion flux, leads to defects in mitochondrial respiration and induces cell death.",
    "APOL1 explains almost 70% of the excess risk of kidney disease in those of African descent, and is common in children with glomerular disease.",
    "An evolving understanding of the pathogenesis of APOL1-mediated kidney damage may aid in personalized medicine approaches to APOL1 attributable kidney disease.",
    "This JAMA Insights reviews the origin of APOL1 high-risk genetic variants, defines APOL1-mediated kidney disease, and discusses recommendations for screening and management.",
    "Loss of normal kidney function affects more than 10% of the population and contributes to morbidity and mortality.",
    "Kidney diseases are currently treated with immunosuppressive agents, antihypertensives and diuretics with partial but limited success.",
    "Most kidney disease is characterized by breakdown of the glomerular filtration barrier (GFB).",
    "Specialized podocyte cells maintain the GFB, and structure-function experiments and studies of intercellular communication between the podocytes and other GFB cells, combined with advances from genetics and genomics, have laid the groundwork for a new generation of therapies that directly intervene at the GFB.",
    "These include inhibitors of apolipoprotein L1 (APOL1), short transient receptor potential channels (TRPCs), soluble fms-like tyrosine kinase 1 (sFLT1; also known as soluble vascular endothelial growth factor receptor 1), roundabout homologue 2 (ROBO2), endothelin receptor A, soluble urokinase plasminogen activator surface receptor (suPAR) and substrate intermediates for coenzyme Q10 (CoQ",
    "Homozygous Apolipoprotein L1 (APOL1) variants G1 and G2 cause APOL1-mediated kidney disease, purportedly acting as surface cation channels in podocytes.",
    "APOL1-G0 exhibits various single nucleotide polymorphisms, most commonly haplotype E150K, M228I and R255K (\"KIK\"; the Reference Sequence is \"EMR\"), whereas variants G1 and G2 are mostly found in a single \"African\" haplotype background (\"EIK\").",
    "Several labs reported cytotoxicity with risk variants G1 and G2 in KIK or EIK background haplotypes, but used HEK-293 cells and did not verify equal surface expression.",
    "To see if haplotype matters in a more relevant cell type, we induced APOL1-G0, G1 and G2 EIK, KIK and EMR at comparable surface levels in immortalized podocytes.",
    "G1 and G2 risk variants (but not G0) caused dose-dependent podocyte death within 48h only in their native African EIK haplotype and correlated with K",
    "Two variants in the gene encoding apolipoprotein L1 (APOL1) that are highly associated with African ancestry are major contributors to the large racial disparity in rates of human kidney disease.",
    "We previously demonstrated that recruitment of APOL1 risk variants G1 and G2 from the endoplasmic reticulum to lipid droplets leads to reduced APOL1-mediated cytotoxicity in human podocytes.",
    "We used CRISPR-Cas9 gene editing of induced pluripotent stem cells to develop human-derived APOL1 APOL1 was highly upregulated in response to IFN- Lipogenesis and lipid droplet formation are important modulators of APOL1-associated cytotoxicity.",
    "Inhibition of DGAT2 may offer a potential therapeutic strategy to attenuate cytotoxic effects of APOL1 risk variants.",
    "APOL1 kidney risk variants (RVs) were identified in 2010 as major drivers of glomerular, tubulointerstitial, and renal microvascular disease in individuals with sub-Saharan African ancestry.",
    "In December 2020, the \"APOL1 at Ten\" conference summarized the first decade of progress and discussed controversies and uncertainties that remain to be addressed.",
    "Topics included trypanosome infection and its role in the evolution of APOL1 kidney RVs, clinical phenotypes in APOL1-associated nephropathy, relationships between APOL1 RVs and background haplotypes on cell injury and molecular mechanisms initiating disease, the role of clinical APOL1 genotyping, and development of novel therapies for kidney disease.",
    "Future goals were defined, including improved characterization of various APOL1 RV phenotypes in patients and experimental preclinical models; further dissection of APOL1-mediated pathways to cellular injury and dysfunction in kidney (and other) cells; clarification of gene-gene and gene-environment interactions; and evaluation of the role for existing and novel therapies.",
    "Circulating APOL1 lyses trypanosomes, protecting against human sleeping sickness.",
    "Two common African gene variants of  APOL1 topology in serum (HDL particles) and in kidney podocytes was mapped with flow cytometry, immunoprecipitation, and trypanolysis assays that tracked 170 APOL1 domain-specific monoclonal antibodies.",
    "APOL1 localizes to the surface of podocytes, with most of the pore-forming domain (PFD) and C terminus of the Serum Resistance Associated-interacting domain (SRA-ID), but not the membrane-addressing domain (MAD), being exposed.",
    "In contrast, differential trypanolytic blocking activity reveals that the MAD is exposed in serum APOL1, with less of the PFD accessible.",
    "Low pH did not detectably alter the gross topology of APOL1, as determined by antibody accessibility, in serum or on podocytes.",
    "Our antibodies highlighted different conformations of native APOL1 topology in serum (HDL particles) and at the podocyte surface.",
    "Our findings support the surface ion channel model for APOL1 risk variant-mediated podocyte injury, as well as providing domain accessibility information for designing APOL1-targeted therapeutics.",
    "Parasitic infections like malaria (Plasmodium falciparum) and sleeping sickness (Trypanosoma brucei) have driven genetic selection for resistance.",
    "For instance, the sickle-cell mutation (HBB:c.20A>T) offers malaria protection but causes sickle-cell disease.",
    "Similarly, APOL1 gene variants (G1/G2) protect against sleeping sickness but increase the risk of kidney disease.",
    "While these variants provide survival benefits, they also pose significant health challenges.",
    "This highlights the need for research into their effects on organ systems, epistasis, and potential therapies.",
    "Drugs targeting APOL1 synthesis are being tested to treat APOL1-mediated nephropathy, and exploring African genomes may uncover new parasite-resistant variants, advancing global genomic medicine.",
    "Recently evolved alleles of Apolipoprotein L-1 (",
    "Individuals of recent African ancestry are disproportionately affected by kidney disease.",
    "The discovery of the Apolipoprotein L1 (",
    "More than 5 million African-Americans, and millions more in Africa and worldwide, possess apolipoprotein L1 gene (APOL1) high-risk genotypes with an increased risk for chronic kidney disease.",
    "This manuscript reviews treatment approaches for slowing the progression of APOL1-associated nephropathy.",
    "Since the 2010 discovery of APOL1 as a cause of nondiabetic nephropathy in individuals with sub-Saharan African ancestry, it has become apparent that aggressive hypertension control, renin-angiotensin system blockade, steroids and conventional immunosuppressive agents are suboptimal treatments.",
    "In contrast, APOL1-mediated collapsing glomerulopathy due to interferon treatment and HIV infection, respectively, often resolve with cessation of interferon or antiretroviral therapy.",
    "Targeted therapies, including APOL1 small molecule inhibitors, APOL1 antisense oligonucleotides (ASO) and inhibitors of APOL1-associated inflammatory pathways, hold promise for these diseases.",
    "Evolving therapies and the need for clinical trials support the importance of increased use of APOL1 genotyping and kidney biopsy.",
    "APOL1-associated nephropathy includes a group of related phenotypes that are driven by the same two genetic variants in APOL1.",
    "Clinical trials of small molecule inhibitors, ASO, and inflammatory pathway inhibitors may improve outcomes in patients with primary forms of APOL1-associated nephropathy.",
    "The VHL-HIF pathway and lipid droplet accumulation are the main characteristics of clear cell renal cell carcinoma (ccRCC).",
    "However, the connection between the two features is largely unknown.",
    "We used transcriptional sequencing and TCGA database analysis to identify APOL1 as a novel therapeutic target for ccRCC.",
    "The oncogenic functions of APOL1 were investigated by cell proliferation, colony formation, migration and invasion assays in ccRCC cells in vitro and xenografts derived from ccRCC cells in vivo.",
    "Oil red O staining and quantification were used to detect lipid droplets.",
    "Chromatin immunoprecipitation (ChIP) assays and luciferase reporter assays were carried out to identify HIF-2α bound to the promoter of APOL1 and lncRNA LINC02609.",
    "RNA-FISH and luciferase reporter assays were performed to determine that LncRNA LINC02609 functions as a competing endogenous RNA to regulate APOL1 expression by sponging miR-149-5p."
  ]
}